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Abstract 
Background: Epithelial ovarian cancer (EOC) has the poorest survival outcomes for all 
gynaecological malignancies. Despite emerging knowledge on the heterogeneity of the 
disease the majority of patients are initially treated the same. Biomarkers which could predict 
treatment response would greatly enhance patient care.  
Results: Differential DNA methylation analysis of serous EOC tumours identified 180 loci 
significantly associated with residual disease status (n=297, p<0.05, FDR <5%), with 23 
corresponding genes also significantly associated in gene expression array analysis 
(p<0.05, FDR <10%).   
Differential DNA methylation of 27 loci were significantly associated with overall survival in 
patients receiving optimal debulking (n=78, p<0.05). Patients optimally debulked but with 
poor prognosis markers were found to have the same survival as those suboptimally 
debulked suggesting that supraradical surgery is not beneficial in these patients. 
Hypomethylation at intragenic regions of the homeobox gene MSX1 was associated with 
primary platinum resistance significantly (n=61, p<0.05, FDR<5%) and these findings were 
validated in an independent dataset (n=252, p<0.05). DNA methylation was also significantly 
correlated to gene expression. Platinum resistant ovarian cancer cell lines demonstrated 
significantly lower gene expression of MSX1 compared to sensitive pairs. Proliferation and 
apoptosis cell-line assays demonstrated sensitisation to cisplatin when cisplatin resistant 
A2780/CP70 cells re-expressed MSX1 following gene transfection. An increase in p53 
downstream transcripts, CDKN1A (p21) and BAX was also demonstrated in these MSX1 
transfectants. 
The detection of disease at 5 distinct anatomical sites determined by preoperative computed 
tomography was significantly associated with surgical debulking outcomes in a test (n=111) 
and validation (n=70) cohort of patients with EOC (sensitivity 64.7-69.2%, specificity 67.9-
71.4%, AUC 0.721-0.749). 
Conclusions: DNA methylation is a potential rich source of biomarkers predicting 
cytoreductive outcome and survival. The discovery and validation of a novel DNA 
methylation biomarker of chemotherapy resistance is demonstrated with exciting findings 
related to its biological function in cisplatin sensitive assays.  
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Definitions 
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1.1 General introduction 
Ovarian cancer (OC) is the most lethal of gynaecological malignancies, causing over 
125,000 deaths per year worldwide (Sankaranarayanan & Ferlay, 2006). Overall survival 
(OS) is poor due to late presentation, poor surgical outcomes and the development of 
chemotherapy resistance. The disease is clinically and molecularly heterogeneous but 
despite this all patients are treated the same, with cytoreductive surgery and first line 
platinum-based chemotherapy (NICE, 2011). Furthermore clinical characteristics including 
surgical debulking outcomes, overall and progression-free survival (PFS) and chemotherapy 
response will be dependent on the tumour biology of the cancer, amongst other factors. 
There is therefore an urgent need to further understand the molecular profile of ovarian 
cancers associated with clinical characteristics in a bid to enhance individual patient care 
through the development of personalised stratified medicine (Vaughan et al, 2011). DNA 
methylation has been shown to be an important mechanism in cancer development and 
tumour evolution (Jones & Baylin, 2007). The exploration and validation of differential DNA 
methylation may identify important candidate genes and loci which inform upon the 
understanding of tumour cell biology. When in association with patient characteristics these 
epigenetic changes may identify clinical biomarkers and potential therapeutic targets. 
Identification of these targets would be an initial step to achieving the goal of personalised 
medicine in cancer with the ultimate aim to radically improve morbidity and mortality for 
those that suffer from this aggressive and deadly disease. 
  
1.2 Epidemiology 
OC is the second commonest gynaecological malignancy and the 5th commonest cause of 
cancer in women. In 2010 over 7000 women were diagnosed with the disease in the UK and 
it caused 4,295 deaths in the same year (Cancer Research UK, 2011). The incidence of OC 
increases after the menopause with the peak incidence in those aged 60-64 years of age. 
Unlike other gynaecological cancers, OS is very poor with only 34% of patients surviving 5 
years after their diagnosis (Ries et al, 2007). This poor survival is in stark contrast to the 5 
year survival rates of endometrial (87.9%), cervical (71.5%) and breast (87.1%) cancers 
(Ries et al, 2007).  
OC is broadly classified into three distinct histological categories; epithelial, germ cell and 
sex-cord stromal tumours. Germ cell tumours such as dysgerminoma, immature teratoma, 
and yolk sac tumours are relatively rare. They account for approximately 3% of OC and 
present in a much younger age group to epithelial tumours with a peak age incidence of 15-
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19 years old (Arora et al, 2012). They are generally sensitive to chemotherapy and therefore 
have a good prognosis. Sex-cord stromal tumours such as malignant granulosa cell tumour, 
Sertoli-Leydig cell tumours are also rare and account for 8% of OC (Koonings et al, 1989). 
Median age at presentation is earlier than epithelial ovarian cancer (EOC) at around 50 
years of age and there is a larger proportion of stage 1 tumours at presentation (Thrall et al, 
2011). They often secrete endogenous hormones such as oestrogen and so can present 
with abnormal vaginal bleeding. The majority (90%) of OC are epithelial in origin. They can 
be further categorised in their subtypes; high-grade serous, endometroid, clear-cell, 
mucinous and low grade serous (with occasional cases of mixed histological type) with high-
grade serous being the most common subtype (Clarke & Gilks, 2011; Gurung et al, 2013). 
They have a very different clinical characteristics compared to germ-cell and sex-cord 
stromal tumours as they present in later age group (peak incidence 60-64 years) and have a 
very poor survival rate. This work therefore focuses exclusively on epithelial ovarian 
tumours. 
Increasing age and known genetic mutations are thought to be the most important risk 
factors for developing OC (Cancer Research UK, 2011). Women with BRCA1 and BRCA2 
mutations have a risk of developing OC by the age of 70 of between 40-59% and 16.5-18% 
respectively (Chen & Parmigiani, 2007; Mavaddat et al, 2013). Women with hereditary non-
polyposis colorectal cancer (HNPCC) have a 6.7% lifetime risk of developing OC (Watson et 
al, 2008) compared to approximately 2% in the general population. However only 10% of 
patients with OC have a family history of the disease and in those known genetic mutations 
account for less than 50% (Cancer Research UK, 2011). Reproductive factors are also 
known to affect the risk of developing OC with an increased risk found in those with early 
menarche and late menopause and nulliparity. Conversely pregnancy, breast feeding and 
the combined oral contraceptive pill are found to be protective (Sueblinvong & Carney, 
2009). More recent data however, has highlighted that risk factors are very much dependent 
on histological, and thus molecular subtypes (Yang et al, 2012). 
 
1.3 Primary treatment 
1.3.1 Surgery 
In the UK first line treatment for advanced EOC consists of surgery and chemotherapy. 
Surgery aims to “debulk” the tumour (hence debulking surgery) to provide symptom relief, 
confirm diagnosis, provide histological staging and aim to improve survival. Surgery can be 
performed before chemotherapy (primary debulking), in the middle of chemotherapy regime 
17 
 
(interval debulking) or following chemotherapy or to treat recurrence (secondary debulking). 
Surgery normally comprises of total abdominal hysterectomy (removal of uterus), bilateral 
salpingoophrectomy (removal of fallopian tubes and ovaries), omentectomy (removal of the 
omentum), with or without lymphadenectomy (removal of pelvic and paraaortic lymph 
nodes). Often more extensive surgery is required to remove disease at other sites within the 
abdomen such as diaphragm stripping, splenectomy (removal of the spleen) or bowel 
resection.  
1.3.2 Surgical debulking and survival 
Surgical effort is one of the most important prognostic factors in ovarian cancer. It is widely 
accepted that volume of residual disease following surgery influences overall survival 
following treatment (Pomel et al, 2008; Shih & Chi, 2010). This appears to be true 
independent of the type chemotherapy used. The Gynecologic Oncology Group has 
classified cytoreductive surgery to describe the volume of residual disease left at the end of 
surgery (Hoskins et al, 1994). Optimal debulking refers to a maximal diameter of residual 
tumour less than or equal to 10mm, whereas suboptimal debulk has residual tumour greater 
than 10mm. Meta-analysis of published data in post-platinum era shows a positive 
correlation between surgical debulk status and survival in advanced disease (Bristow et al, 
2002). For every 10% increase in maximal cytoreduction there appears to be a 5.5% 
increase in median survival. There is now growing evidence that in fact total or complete 
macroscopic debulking, defined by an absence of any macroscopic tumour post-operatively, 
is one of the most important factors in survival (Colombo et al, 2009; Eisenhauer et al, 2008; 
Wimberger et al, 2007; Wimberger et al, 2010) with a reported increase in OS of 14-28 
months in patients with total debulking as compared to optimally debulked patients. This 
appears to be true for all histological subtypes including clear cell, a particularly aggressive 
form of EOC (Takano et al, 2006). Analysis from the AGO-OVAR group (Wimberger et al, 
2007) demonstrated in a randomised control trial of chemotherapy agents 
(cisplatin/paclitaxel vs. carboplatin/paclitaxel) complete resection significantly improved OS 
versus optimal debulking and suboptimal debulking (4.7 years vs. 3.5 years vs. 3.0 years 
respectively). The authors state that these results also held true when early stage disease 
was excluded from analysis. In a similar paper, data was combined from 3 separate 
randomised controlled trials and specifically focused on results of 573 patients with stage 4 
disease (Wimberger et al, 2010). Complete resection was associated with a significantly 
improved OS rate in comparison with macroscopic disease. Median OS was 54.6 months in 
those with no macroscopic residual disease vs. 25.8 months in those with 1-10mm residual 
disease and 23.9 months in those with >10mm residual disease (p<0.0001).  
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1.3.3 Chemotherapy 
Adjuvant chemotherapy is recommended for those with stage 1C disease or higher and 
normally comprises of platinum based agent with or without paclitaxel (NICE, 2011). 
Platinum based compounds have been used since the mid-1980’s following an initial 
randomised controlled trial (RCT) demonstrating a significant improvement in response and 
OS compared to cyclophosphamide (Lambert & Berry, 1985). The cytotoxic effects of 
platinum agents are due to the formation of inter- and intrastrand DNA adducts. The DNA 
inter-strand crosslinks prevent DNA replication and subsequently cause DNA damage that 
cannot be repaired causing apoptosis and cell death (Rabik & Dolan, 2007). Since the 
1990’s carboplatin is used preferentially over cisplatin in the UK due to the significant 
reduction in toxicity (Adams et al, 1989) with no difference in efficacy (Aabo et al, 1998). 
Despite the improved side effect profile toxicities still occur such as gastrointestinal 
disturbance (nausea and vomiting) and dose limiting myelosuppression particularly 
thrombocytopenia, with leukopenia and anaemia also occurring less frequently (Wagstaff et 
al, 1989). Paclitaxel was introduced as a combination 1st line agent at the beginning of the 
21st century due to preliminary trials demonstrating benefit over cyclophosphamide (McGuire 
et al, 1996; Piccart et al, 2000). Taxanes act by binding to intracellular β-tubulin, leading to 
microtubule stabilisation, the inability to deconstruct the mitotic spindle during mitosis leads 
to cessation of the cell cycle at the G2-M phase and subsequent apoptosis (Dumontet & 
Sikic, 1999; Marupudi et al, 2007). Data on the benefit of carboplatin alone versus 
carboplatin and paclitaxel is more controversial with a concluding meta-analysis determining 
a trend in favour of combination treatment for PFS (Sandercock et al, 2002). The toxicity of 
combination treatment however is increased with side effects of neutropenia, alopecia and 
peripheral neurotoxicity being statistically significantly higher in those receiving platinum and 
taxol versus platinum alone or platinum and cyclophosphamide. Thus National Institute of 
Clinical Excellence (NICE) guidance recommends treatment of choice to be determined on 
an individual basis by the treating clinician and patient after a full discussion of the risks and 
benefits of the treatment options  (NICE, 2003).    
The majority of patients receiving chemotherapy for the treatment of EOC have adjuvant 
scheduling, referring to chemotherapy given after primary surgery. However if clinical 
judgement dictates that debulking surgery would not be possible due to extensiveness of 
disease or poor health of the patient, then a different treatment approach can be offered 
such as neoadjuvant chemotherapy (NAC). Neoadjuvant chemotherapy is split into two 
phases; 3 cycles prior to interval debulking surgery and then subsequently 3 cycles after 
interval surgery. Several studies have attempted to determine whether NAC and interval 
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debulking is superior treatment to primary surgery followed by adjuvant chemotherapy in 
regards to survival, complications and debulking rates. These results summarised in a 
systematic review (Bristow RE, 2007) and a separate meta-analysis (Kang & Nam, 2009), 
appear to show little difference in survival but a significant improvement in residual disease 
clearance in the NAC group. More recently the largest RCT to date comparing 336 patients 
undergoing PDS to 334 patients undergoing NAC, all of whom had advanced stage EOC, 
found there was no significant difference in OS or PFS in either group (Vergote et al, 2010). 
In keeping with previous studies however there was a larger proportion of patients being 
optimally debulked in the NAC group (86%) compared to the PDS group (41.6%). 
In addition to more “standard” chemotherapy regimens there are on-going debates on the 
potential benefits of intraperitoneal chemotherapy (Armstrong et al, 2006; Singhal & Lele, 
2006) and different dosing regimens (van der Burg et al, 2011). More recently a drive to 
develop targeted therapies such vascular endothelial growth factor (VEGF) inhibitors 
(Gaitskell et al, 2011), epidermal growth factor (EGF) receptor blockers (Haldar et al, 2011) 
and poly ADP ribose polymerase (PARP) inhibitors has been encouraged (Vaughan et al, 
2011) and if effective may become commonplace in the clinic in the near future.  
 
1.4 Clinical challenges 
1.4.1 Early diagnosis 
Prognosis following a diagnosis of EOC is poor with 5 year OS at around 34%. The cause 
for this poor outcome is explained by several factors. The majority of patients present with 
advanced stage disease where metastasis has spread outside of the pelvis to abdominal 
organs (stage 3) and more distant sites (stage 4), in contrast to patients who present with 
early stage disease, where disease is confined to one or both ovaries (stage 1) or the pelvis 
(stage 2). OS is correlated to stage where 5 year overall survival of stage 1 disease 
averages 89.3% compared to 65.5% at stage 2, 33.5% at stage 3 and 17.9% at stage 4 
(Ries et al, 2007). The symptoms of ovarian cancer are often vague with many women 
finding themselves presenting to the general practitioner (GP) many months before the 
diagnosis of OC is confirmed (Hamilton et al, 2009). The symptoms are common in benign 
conditions (albeit at less frequency) and are non-specific in nature and thus patients are 
often investigated for gastrointestinal and urinary tract disease before the differential 
diagnosis of OC is contemplated. Current NICE guidance (NICE, 2011) recommend that 
patients who present to their GP with persistent almost daily symptoms of abdominal or 
pelvic pain, abdominal bloating, difficulty in eating or feel full quickly, increased urinary 
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urgency / frequency which occur on a persistent or frequent basis, unexplained weight loss, 
fatigue or changes in bowel habit should also be investigated for suspected ovarian cancer. 
The investigations recommended consist of a Cancer Antigen 125 (CA125) blood test and if 
this is abnormal a pelvic ultrasound scan. This guidance has come under professional 
scrutiny (Olaitan, 2011) due to the poor sensitivity and specificity of CA125 as a biomarker. It 
is found to be raised in 80% of women with advanced stage ovarian cancer and 50% of 
patients with early stage disease (Jacobs & Bast, 1989), and conversely levels are raised in 
benign processes such as endometriosis, pelvic inflammatory disease and pregnancy 
(Alcázar et al, 2004). The early diagnosis of EOC would thus be greatly improved if a more 
sensitive and specific biomarker was discovered. The history of cervical cancer has changed 
dramatically since the introduction of the national cervical cancer screening programme 
which is estimated to have saved 100,000 lives since introduction in 1988 (Peto et al, 2004). 
An effective screening test for EOC would be greatly beneficial with the aim to increase 
detection of early stage disease where surgery exclusively can cure the disease. Thus the 
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was set up in order to 
determine whether screening was feasible, cost efficient and effective. 202, 638 women 
aged 50-74 years old were recruited in the trial between 2001 and 2005, and randomised 
into a no screening group (control group), annual CA125 with TVUSS if results were 
abnormal (Multimodal screening (MMS) group), or annual TVUSS alone (USS group). Initial 
results published in 2009 (Menon et al, 2009) reported that the multimodal screening group 
had a significantly improved specificity of 99.8% (p<0.0001) and a similar sensitivity of 
89.4% compared to the USS group. There were 2.3 operations per screen positive result in 
the MMS group compared to 18.8 operations per screen positive result in the USS group. 
Almost 50% of invasive malignancy detected was stage 1 and 2 disease (compared to 20-
30% in the general population) which appears particularly encouraging. However as recent 
evidence from breast cancer screening has highlighted (Independent UK Panel on Breast 
Cancer Screening, 2012) the impact of over-diagnosis (breast cancer cases that would not 
become clinically apparent due to their indolent nature), may also be a feature of OC 
screening. Thus there may be little effect on survival despite the increased detection rate of 
early stage disease in the trial. Data on effects on mortality are eagerly awaited and 
expected in 2015. 
1.4.2 Prediction of surgical outcome 
Knowing how best to treat an individual with EOC is one of the largest clinical challenges yet 
to be satisfactorily answered. As survival is directly proportional to residual disease following 
primary surgery, effort is focused on achieving complete macroscopic debulking. There are 
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however some women who have such extensive disease that successful surgery is not 
possible. They therefore undergo a laparotomy for no benefit and chemotherapy regimens 
are delayed due to recovery from the operation. Therefore in the UK all patients with 
suspected EOC undergo preoperative assessment in a bid to plan and predict surgical 
treatment. This includes assessment of tumour load through level of tumour markers, 
ultrasound scans, computed tomography (CT) and magnetic resonance imaging (MRI). 
However, despite this ability to preoperatively assess the involvement of certain organs, true 
extent of disease is often difficult to ascertain. Much emphasis has been placed on 
investigating the use of the tumour marker CA125 as a possible predictive model of surgical 
outcome but with minimal success (Ibeanu & Bristow, 2010). There have been numerous 
studies (Alcázar et al, 2004; Arits et al, 2008; Barlow et al, 2006; Brockbank et al, 2004; Chi 
et al, 2000; Chi et al, 2009b; Cooper et al, 2002; de Jong et al, 2007; Eltabbakh et al, 2004; 
Gemer et al, 2005; Gemer et al, 2001; Memarzadeh et al, 2003; Obeidat et al, 2004; Risum 
et al, 2009; Saygili et al, 2002; Vorgias et al, 2009; Vorgias et al, 2001) investigating CA125 
as a predictor for achieving optimal debulking surgery, the majority of which are 
retrospective in design. Unfortunately these studies are heterogeneous, with different patient 
groups, different stages, different statistical analysis and different CA125 cut-offs making 
comparison of the data difficult. Studies have found that CA125 measurements to predict 
suboptimal debulking ranges from 300 to 912 IU/ml with a sensitivity of 49-80% and 
specificity of 54-89.6%.  Other clinical parameters have also been investigated including 
amount of ascites, albumin, performance status, platelet count and weight loss but without 
any conclusive results (Arits et al, 2008; de Jong et al, 2007; Eltabbakh et al, 2004). 
1.4.2.1 Anatomical location and preoperative imaging may predict surgical debulking 
The site of disease prior to surgery has been shown to be a major predictor for complete 
tumour resection, with patients having disease at surgical locations of umbilical, left flank 
and epigastrium regions having the highest risk of incomplete tumour resection (Fotopoulou 
et al, 2010).  It therefore appears logical that efforts to determine tumour burden 
preoperatively through imaging modalities such as CT, MRI and PET would be beneficial 
and inform the surgeon to the likelihood of optimal versus suboptimal debulking. Previous 
studies have examined the use of CT imaging to predict surgical success (Axtell et al, 2007; 
Bristow et al, 2000; Byrom et al, 2002; Dowdy et al, 2004; Jung et al, 2010a; Meyer et al, 
1995; Nelson et al, 1993; Qayyum et al, 2005; Risum et al, 2008; Salani et al, 2008) 
(summarised in Table 1.1) but these studies relate to small patient numbers, changing 
definitions of optimal debulking and out-of-date debulking rates (reviewed in Ibeanu & 
Bristow, 2010). 
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The largest study to date (Salani et al, 2008) was a retrospective study looking at the 
surgical outcome of 180 patients with stage 3 or 4 disease who were deemed to have 
unresectable disease by imaging criteria. The criteria were defined as ascites ≥1000mls, 
omental extension to the spleen >1cm, liver parenchymal disease >1cm, porta hepatis 
involvement >1cm, diaphragmatic disease >1cm, peritoneal carcinomatosis >1cm, 
suprarenal paraaortic lymphadenopathy >1cm. Rates of optimal debulking in patients that 
had at least one of the above criteria ranged from 75% to 91.4%. When disease was at 5 
sites optimal debulking rates were still high at 80%. Contrary to this, the largest prospective 
trial (Risum et al, 2008) explored both CT and PET images in 54 patients being investigated 
for a pelvic mass, who subsequently had a positive diagnosis of advanced ovarian cancer. 
Univariate analysis found that large bowel mesentery implants (p<0.003), pleural effusion 
(p<0.009), ascites (p<0.009) and peritoneal carcinomatosis (p<0.01) could predict 
incomplete debulking (described as macroscopic residual disease <1cm). Curiously in those 
with more residual disease that were suboptimally debulked (>1cm residual disease) only 
large bowel mesentery implants (p<0.03) and ascites (p<0.05) were found to be significant. 
Probably the most highly cited study (Bristow et al, 2000) retrospectively viewed 41 patients 
who had a preoperative CT scan within 21 days of surgery. A predictive index score was 
calculated from 13 radiographic features (including peritoneal thickening, extension to pelvic 
sidewall, parametria or hydroureter and inguinal lymph nodes) and performance index score.  
A Predictive Index score of ≥4 achieved a sensitivity of 100%, specificity of 85.0% and 
accuracy of 92.7% for predicting suboptimal surgical resection. Since these early 
publications two studies have tried to validate the previous studies but with limited success 
(Axtell et al, 2007; Gemer et al, 2005). One of the main arguments in the failure to validate 
previous findings is that factors which accounted for unresectable disease 10 years ago are 
now irrelevant as surgical paradigms change and debulking rates improve (Aletti et al, 
2006b; Chi et al, 2009a). For example a US based study demonstrated that both debulking 
rates and survival outcomes improved at their centre when extensive upper abdominal 
resections were performed (Chi et al, 2009a). Optimal debulking was significantly improved 
from 46% to 80% with a corresponding improvement in both PFS (5 year PFS from 14% to 
31%, p=0.01) and OS (5 year OS 35% to 47%, p=0.03). 
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Study Year Place Study design Dates N= Mean age 
Advanced 
disease 
Optimal 
debulk 
rate  
Total 
debulk 
rate 
Significant radiology features 
Sensitivity 
% 
Specificity 
% 
PPV 
% 
NPV 
% 
P value AUC 
Nelson 
et al 
1993 US Retrospective 
1985-
1991 
42 61 (26-82) 81% 50%  26.20% Unresectable if these features on CT; 92.3 79.3 66.7 95.8 0.0001 
 
          
Attachment of omentum to spleen 
      
          
Disease >2cm in: 
      
          
Mesentery 
      
          
Liver surface or parenchyma 
      
          
Diaphragm 
      
          
Gallbladder fossa 
      
          
Suprarenal paraaortic lymph nodes 
      
          
Pericardiac lymph nodes 
      
          
Pulmonary or pleural nodules 
      
Meyer et 
al 
1995 US Retrospective 
1989-
1992 
28 61(29-87) 64% 
57.1% 
(<2cm) 
Unknown 
Suboptimal if total score of >=3 (all sites 
score 0, 1 or 2 points dependent on size); 
58 100 
   
0.94 
(0.9,0.98) 
          
Omentum 
      
          
Liver 
      
          
Paraaortic lymphadenopathy 
      
          
Diaphragm and lung base 
      
          
Small bowel mesentery 
      
          
Amount of ascites 
      
Bristow 
et al 
2000 US Retrospective 
1997-
1999 
41 67 (24-81) 100% 48.8% Unknown 
Scores assigned, features most strongly 
associated; 
    
  
          
Peritoneal thickening 71.4 90 88.2 75 
  
          
Peritoneal implants >=2cm 57.1 95 92.3 67.9 
  
          
Sm bowel mesentery >=2cm 33.3 100 100 58.8 
  
          
Lg bowel mesentery >=2cm 38.1 90 80 58.1 
  
          
Suprarenal paraaortic LN >=1cm 23.8 100 100 55.6 
  
          
Pelvic sidewall involvement +/- Hydroureter 42.9 85 75 58.6   
          
Score greater than 4 100 85 87.5 100 <0.001 
0.969 (+/-
0.023) 
Byrom 
et al 
2002 UK Retrospective 
1998-
1999 
51 Unclear Unclear 
51% 
(<2cm) 
Unknown Presence of; 88 92 85 94 <0.05 
0.94 (SD 
0.03) 
          
Ascites 
      
          
Omental cake 
      
          
Mesenteric disease 
      
          
Paracolic gutter deposits 
      
          
Diaphragmatic deposits 
      
          
Pleural effusion 
       
             
 
   
              
              
              
Table 1.1. Summary of all published studies which investigate CT images to predict debulking surgical outcome. 
PPV positive predictive value, NPV negative predictive value, AUC area under the curve, SD standard deviation 
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Study Year Place Study design Dates N= Mean age 
Advanced 
disease 
Optimal 
debulk 
rate  
Total 
debulk 
rate 
Significant radiology features 
Sensitivity 
% 
Specificity 
% 
PPV % NPV % P value AUC 
Dowdy 2004 US Retrospective 
1996-
2001 
87 68 (35-87) 100% 71% 29% Associated with debulking; 
   
 
          
Diffuse peritoneal thickening 
    
0.0159 
 
          
Ascites on most cuts 
    
0.0066 
 
          
Diaphragm or lung metastasis >1cm 
    
0.0149 
 
          
Bowel encasement 
    
0.0160 
 
               
 
   
Prospective  
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To predict suboptimal debulking; 
      
          
Diffuse peritoneal thickening (DPT) 64 81 57 85 0.0001 
 
          
DPT + ascites in most cuts 52 90 68 82 <0.0001 
 
          
DPT + ascites + diaphragmatic disease 4 95 79 81 0.0001 
 
Qayyum 
et al 
2004 US Retrospective - 137 58 (17-83) 76.60% 
75% 
(<2cm) 
Unknown Disease at one or more sites, > 2cm; 76 99 94 96 
  
     
91 (CT) 
   
Gallbladder fossa 
      
     
46 (MRI) 
   
Subphrenic space 
      
          
Gastrohepatic ligament 
      
          
Gastrosplenic ligament 
      
          
Lesser sac 
      
          
Small bowel mesentery 
      
          
Dome of the liver surface 
      
          
Retroperitoneal (above renal hila) 
      
          
Coeliac axis 
      
          
Supradiaphramatic disease 
      
          
Hepatic metastases 
      
          
Abdominal wall invasion 
      
Axtell et 
al 
2007 US Retrospective 
1999-
2005 
65 59 (33-87) 100% 78% Unknown Presence of both; 79 75 
  
<0.02 
 
          Diaphragmatic disease >2cm 
      
          
Large bowel mesentery implants >2cm 
      
                 
                 
                 
                 
                 
                 
                 
                 
                 
                 
  
 
 
              
                 
Table 1.1 (continued) 
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Study Year Place Study design Dates N= Mean age 
Advanced 
disease 
Optimal 
debulk 
rate  
Total 
debulk 
rate 
Significant radiology features 
Sensitivity 
% 
Specificity 
% 
PPV 
% 
NPV 
% 
P value AUC 
Salani et 
al 
2007 US Retrospective 
1997-
2006 
180 59 100% 92.2% 22.2% Ascites >1000mls 91.3* 
     
          
Carcinomatosis >1cm 91* 
     
          
Splenic involvement >1cm 84.9* 
     
Risum et 
al 
2007 Denmark Prospective 
2004-
2007 
54 63 (40-85) 100% 56% 35% Site predictive of residual disease =>1mm;       
          Large bowel mesentery implants     <0.009  
          Pleural effusion     <0.009  
          Peritoneal carcinomatosis     <0.01  
          Ascites     <0.009  
Gemer 
et al 
2009 Israel Retrospective - 123 62 (28-84) 100% 73.2% 52.0% Validation of different studies;       
          Nelson 64 64 40 83   
          Bristow 70 64 42 85   
          Dowdy 33 86 50 79   
          Qayyum 67 57 36 82   
Jung et 
al 
2010 Korea Retrospective 
1999-
2008 
77 54.3 100% 92.2% 39.0% Upper abdominal ascites 70.2 56.7 71.7 54.8 0.02 
 
          
Upper abdominal ascites & nodularity in 
subdiaphragmatic peritoneum 
42.6 80 76.9 47.1 0.04 
 
          
 
      
           
 
     
                 
Table 1.1 (continued) 
*percentage of cases with optimal debulking achieved 
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1.4.3 Systematic literature review to explore biological and molecular targets associated with 
debulking surgery 
In order to establish and summarise the current evidence of biological and molecular targets 
associated with debulking surgery a systematic literature search was conducted covering 
any studies that had associated protein and gene expression or DNA methylation with 
surgical debulking outcomes (see Materials and Methods, section 2.3). From a total of 42 
studies, 2 publications were excluded as they were not written in English, 6 were excluded 
as they included tissue taken at recurrence or after chemotherapy, 2 were excluded as there 
was failure to define debulking surgery or residual disease, 1 was excluded as neither 
debulking nor primary surgery was defined and 1 was excluded as it was unclear whether 
tumours were epithelial ovarian in origin.  The final 30 publications which met inclusion 
criteria are summarised in Tables 1.2, 1.3 and 1.4. 
1.4.3.1 Protein expression associated with surgical outcomes 
Sixteen out of the 30 publications included data on protein expression in relation to clinical 
characteristics and surgical debulking outcomes. Table 1.2 describes the main 
characteristics of each study; all used immunohistochemistry to determine levels of protein 
expression. Eleven of the studies were single studies investigating different proteins. 
Increased expression of Cyclin E (Rosen et al, 2006), c-erbB-2 (Simpson et al, 1995), Twist 
protein (Hosono et al, 2007), p63α (Jewell et al, 2009), ERCC1 (Lin et al, 2010), AEG-1 (Li 
et al, 2011) and P130cas (Nick et al, 2011) have all been shown to be associated with 
suboptimal debulking. The majority of studies included all types of EOC histology and all 
stages of disease in analysis although this could lead to confounding and bias. For example, 
in one study increased expression of COX-2 protein was significantly related to suboptimal 
debulking surgery (defined as residual disease >2cm) in 64 EOC samples (p=0.027) (Seo et 
al, 2004). However in subset analysis, using only serous and endometroid tumours (n=46) 
there was no longer a significant association with debulking surgery (p=0.743). Additionally it 
should be noted that all the studies identified used univariate statistical analysis to find 
associations between protein expression and surgery. As surgical debulking is strongly 
associated with stage these results may indicate an association with stage rather than 
surgical outcome. 
Four publications were identified which explored the relationship of p53 and residual 
disease, of which two found a significant association with p53 protein overexpression and 
suboptimal debulking in univariate analysis (n=82, p=0.01) (Dogan et al, 2005) (n=83, 
p<0.041) (Geisler et al, 1997), one demonstrated a trend to overexpression and suboptimal 
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debulking (n= 136, p=0.07) (Ferrandina et al, 1999) and one did not find a significant 
association (n=79, p=0.36)(Bar et al, 2001). These 4 studies used heterogeneous 
histological samples, variable clinical stages and varying definitions of suboptimal and 
optimal debulking. Results from a meta-analysis has highlighted the association between 
p53 expression and stage in ovarian cancer (de Graeff et al, 2009) and thus again there are 
likely to be important confounding factors. 
1.4.3.2 Gene Expression associated with surgical outcomes 
There were 8 studies out of the 30 identified that investigated the relationship of specific 
gene expression to clinical parameters including debulking outcomes. Seven of these used 
RT-PCR of mRNA to determine gene expression, one used a different method of 
quantification, the RiboQuant Multi-Probe RNAse protection assay system (mRNA 
electrophoresis) (Komiyama et al, 2011). The data is summarised in Table 1.3. Increased 
gene expression of insulin-like growth factor-1 receptor (IGF-1R) (An et al, 2009), insulin-like 
growth factor-2 promoter transcripts (Lu et al, 2006), vascular endothelial growth factor C 
(VEGF-C) (Sinn et al, 2009), SRA1 (Leoutsakou et al, 2006), transforming growth factor-beta 
1(TCGFβ1) (Komiyama et al, 2011), Coxsackie-adenovirus receptor isoforms (CAR3/7 
CAR4/7) (Reimer et al, 2007) and lower gene expression of the RNAse III enzyme Drosha 
(Merritt et al, 2008) have all been found to be associated with suboptimal debulking. It is of 
note that the studies vary in genes investigated, promoter transcripts and definitions of 
optimal and suboptimal debulking. 
The use of microarray platforms has enabled a wider exploration of the potential association 
between gene expression patterns. Of the 30 identified studies, 3 publications have 
specifically explored this relationship with debulking status. The first published work 
(Berchuck et al, 2004) performed in 2004 used Affymetrix U133A GeneChip microarray to 
explore expression patterns in association with optimal (≤1cm residual disease) versus 
suboptimal debulking surgery (>1cm residual disease). Using frozen tissue samples from 44 
patients undergoing primary surgery for stage 3 or 4 serous EOC, 120 genes were 
associated with debulking status with a significance of p<0.01. Seventeen of these exhibited 
more than 2 fold expression between the two groups. A statistical model correlation was 
used to define 32 genes which could be incorporated into a predictive model with an 
accuracy of 72.7%. Genes of interest included mitogen protein kinase (MAP) family; a 
metastasis suppressor gene, retinoic acid receptor- β (RARB) and p53 inducible protein 
P2X6. The authors concluded that the study supports the hypothesis that there are biological 
differences between tumours that are optimally versus suboptimally debulked. This analysis 
however has limitations through the absence of adjusting for multiple comparisons by false 
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discovery rate and a lack of independent dataset validation. A similar study (Levine et al, 
2004) has reported opposing results. Gene expression microarray (on the same U133A 
platform) was performed using 70 fresh frozen tissues from stage 3 and 4, high grade serous 
ovarian cancers. Using a supervised class comparison, they found no differentially 
expressed genes between optimal (≤1cm) and suboptimal (>1cm) debulking groups using a 
false discovery rate of 10%. A follow-on study (Bonome et al, 2008), with a larger sample 
size of 185 serous histology tumours, concluded that expression profiling could not 
distinguish between optimally and suboptimally debulked tumours. Additionally, only 21 
probes out of 22,283 were differentially expressed between the two groups. 
One additional seminal study using expression profiling (Tothill et al, 2008) found 6 
molecular subtypes following microarray gene expression profiling on 285 serous and 
endometroid tumours of the ovary, peritoneum and fallopian tube. Although not identified by 
the systematic literature search, this study found that out of the 4 subtypes which 
represented high grade cancers there was a significant difference of residual disease 
volume between the groups. Approximately 50% of patients in the κ-Means clustering 
subtype group C1 were suboptimally debulked compared to 11-27% of patients in the other 
high grade subtype groups. Interestingly this subtype group showed enhanced expression of 
the ‘stromal gene cluster’ which included pathways of enrichment of extracellular matrix 
production and remodelling, cell adhesion and angiogenesis. This difference in debulking 
surgery may however be attributed to the fact that a larger proportion of patients in the C1 
group had primary peritoneal carcinoma, a disease that presents with a diffuse tumour 
pattern which is often not possible to remove completely at surgery. 
1.4.3.3 Other translational studies 
Other microarray-based technologies, such as comparative genomic hybridization which 
provides a genome-wide survey of copy number changes, have also been utilised to study 
relationships between surgical outcome and biological factors (Table 1.4).  In one such study 
(Tan et al, 2011) investigating 50 ovarian clear cell carcinomas, hierarchical unsupervised 
clustering determined 2 distinct groups based on copy number changes, both of which had 
an equal number of patients with residual disease <2cm and >2cm (p=0.687). The 
immunological response to ovarian cancer has also been studied in relation to debulking 
surgery (Barnett et al, 2010). Fresh-frozen EOC tumours were obtained from 232 women at 
primary debulking surgery, and tumour infiltrating T-cells were determined through 
immunohistochemistry. The mean number of T-regulatory cells (CD4+CD25+ T-cells) were 
observed to be higher in suboptimally (≥1cm) debulked patients compared to those optimally 
debulked (<1cm) (n=145, p=0.04). Epigenetic alterations are being increasingly investigated 
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as potential biomarkers for diagnosis, prognosis and treatment targets. Only one published 
study has described relationship of DNA methylation with surgical debulking outcome 
specifically. This study (Fiegl et al, 2008) using MethyLight assay of fresh-frozen EOC 
tumours demonstrated that HOXA11 methylation levels were found to be significantly 
different between tumours that had <2cm residual disease versus >2cm residual disease, 
with lower methylation being associated with the <2cm group (n=92, p=0.002). Again these 
studies arise from heterogeneous tumour types with early and late stage disease and 
variable histopathological grades (including borderline tumours). 
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Author & Year Protein investigated Sample size Sample type 
Associated with 
cytoreductive 
outcomes? 
Increased protein expression 
associated with; p 
(Simpson et al, 
1995) 
EGF-R, c-erbB-2, c-
erbB-3 46 
FFPE 
EOC 
All stages 
Yes – c-erbB-2 
Early stage 
Optimal debulking (<2cm) 
Low tumour grade 
0.003 
<0.02 
<0.04 
(Geisler et al, 
1997) P53 
83 
 
Fresh frozen tissue 
EOC 
All stages 
Yes 
Decreased survival 
Histology 
Advanced Stage 
Suboptimal debulking (>1cm) 
0.001* 
<0.0037 
0.004 
0.041 
(Ferrandina et 
al, 1999) P53 136 
FFPE 
EOC 
All stages 
No (p=0.065) 
Advanced stage 
Poorly differentiated 
Chemo resistance 
0.0022 
0.0038 
0.012 
(Bar et al, 2001) P53 79 
Cryostat acetone-fixed 
tissue and cyst or 
ascitic fluid malignant 
cells 
EOC 
Stage 2 - 4 
No (p=0.36) 
Non responders to chemotherapy 
Shorter overall survival in p53 
expression >50%  
0.007 
 
0.013 
(Sood et al, 
2002) Maspin 80 
FFPE 
EOC 
All stages 
Yes 
Shorter overall survival 
High tumour grade 
Suboptimal debulking (1cm) 
Presence of ascites 
0.003 
0.004 
0.04 
0.02 
(Seo et al, 2004) Cycloxygenase-2 (COX-2) 64 
FFPE 
EOC 
All stages 
Yes  
 
Histological type 
Advanced stage 
Lower overall survival 
Presence of ascites 
Tumour grade 
Suboptimal debulking (>2cm) 
<0.001 
<0.001 
0.001 
0.006 
0.033 
0.027 
(Thaker et al, 
2004) 
Epithelial cell kinase 
(EphA2) 79 
FFPE 
EOC stages 
All stages 
No (p=0.21) 
Advanced Stage 
Poor survival 
High grade  
0.001 
<0.01* 
0.02 
 
  
 
 
 
 
 
 
      Table 1.2. Summary of published studies investigating the relationship between the expression of various proteins and debulking 
status. (Table continued on next page). 
* multivariate analysis 
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(Dogan et al, 
2005) 
 
P53 
Murine double munite-
2 (mdm2) 
82 
FFPE 
EOC 
All stages 
Yes – p53 
Serous histology 
Peritonitis carcinomatosis 
Presence of ascites 
Suboptimal debulking (≥1cm) 
Positive peritoneal cytology 
Ca125 (mean) 
Shorter overall survival 
<0.001 
<0.001 
<0.001 
<0.01 
<0.05 
<0.05 
<0.05 
(Rosen et al, 
2005) 
Cyclin-dependent 
kinase inhibitor 
(p27kip1) 
421 
FFPE 
EOC 
All stages 
Yes  
Late stage (cytoplasmic staining) 
Optimal debulking (<1cm) (nuclear 
staining) 
Longer overall survival (nuclear 
staining) 
<0.03 
0.03 
 
0.0002 
(Rosen et al, 
2006) Cyclin E 405 
FFPE 
EOC 
All stages 
Yes 
High grade 
Clear cell histology 
Serous histology 
Reduced survival in suboptimal group 
Late stage 
Age >60 
Suboptimal debulking (≥1cm) 
<=0.001 
<=0.001 
<=0.001 
<=0.001 
0.002 
0.04 
0.001 
(Hosono et al, 
2007) Twist 82 
FFPE 
EOC 
All stage 
No (p=0.247) Poor PFS and OS <0.0001* 
(Jewell et al, 
2009) 
N-terminally truncated 
p63α 53 
Fresh frozen tissue 
EOC 
Stage 3 & 4 
Yes Suboptimal debulking (≥1cm) Poor OS 
0.025 
0.021* 
(Lin et al, 2010) 
Excision repair cross-
complementary group 
1 (ERCC1) 
Xeroderma 
pigmentosum D (XPD) 
78 
FFPE 
Serous & clear cell 
histology 
Stage 3 & 4 
 
Yes – ERCC1 Suboptimal debulking (>1cm) <0.001 
(Semaan et al, 
2011) 
GLUT-1 
Ki-67 
CD34 
VEGF 
213 
FFPE 
EOC 
All stages 
 
Yes – GLUT-1 
and KI-67 when 
simultaneously 
overexpressed 
Suboptimal debulking (≥1cm) 0.01 
(Li et al, 2011) 
 AEG-1 157 
FFPE 
EOC 
All stages 
Yes 
High grade 
Suboptimal debulking (≥1cm) 
High stage 
<0.0001 
<0.001 
0.0011 
(Nick et al, 
2011)  
P130cas 
(Crk-associated 
substrate) 
91 
FFPE 
EOC 
All stages 
Yes 
Advanced stage 
Decreased PFS 
Suboptimal debulking (≥1cm) 
<0.001 
0.001* 
0.007 
   
Table 1.2 continued 
*multivariate analysis 
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Author Gene/s investigated Sample size Sample type 
Associated with 
cytoreductive 
outcomes? 
Increased gene expression 
associated with; p 
(Sayer et al, 
2005) 
Insulin-like growth factor- 
2 (IGF-2) 109 
Fresh frozen tissue 
EOC 
All stages 
No (p=0.08) 
Advanced stage 
High Grade 
Shorter OS 
 
<0.001 
<0.001 
<0.001* 
(Leoutsakou 
et al, 2006) SRA1 111 
Fresh frozen tissue 
EOC 
All stages 
Yes 
Suboptimal debulking (>1cm) 
Increased size residual disease 
High stage 
High grade 
Shorter OS 
<0.001 
<0.001 
0.003 
0.006 
0.037* 
(Lu et al, 
2006) 
IGF-2 ( 4 different 
promoter transcripts) 215 
Fresh frozen tissue 
EOC 
All stages 
Yes - for P3 and P4 
transcripts 
 
Serous histology 
Shorter OS 
Advanced stage 
Suboptimal debulk (≥1cm) 
Residual tumour >0cm 
Chemotherapy response 
P3 
0.005 
0.008* 
0.021 
0.031 
0.042 
- 
P4 
0.009 
0.025* 
0.035 
0.024 
0.005 
0.019 
(Reimer et 
al, 2007) 
Coxsackie-adenovirus 
receptor isoforms 
(CAR2/7, CAR3/7 
CAR4/7) 
140 
Fresh frozen tissue 
EOC 
All stages 
Yes - CAR3/7, CAR 
4/7 
 
Residual disease >2cm 
CAR3/7 
0.019 
CAR4/7 
0.034 
(Merritt et al, 
2008)  
Dicer 
Drosha 111 
FFPE 
EOC 
All stages 
Yes -   Drosha  Shorter OS** Suboptimal debulking** >1cm 
0.008 
0.02 
(An et al, 
2009) 
IGF-1 
IGF-1 receptor 
Oestrogen receptor alpha 
132 
Fresh frozen tissue 
EOC 
All stages 
Yes - IGF-1R 
High grade 
Suboptimal debulking >1cm 
Advanced disease 
0.009 
0.034 
0.038 
(Sinn et al, 
2009) 
Vascular endothelial 
growth factor C (VEGF-
C) 
97 
FFPE 
EOC 
All stages 
Yes 
Shorter PFS 
Residual disease >2cm 
Shorter OS  
 
0.0155 
0.0372 
0.039 
 
(Komiyama 
et al, 2011) 
TGFβ1 
TβRI 
TβRII 
24 EOC, PP, FTC All stages Yes – TGFβ1 
Chemotherapy resistance 
Suboptimal surgery ≥1cm 
 
0.0011 
0.029 
 
Table 1.3. Summary of published studies investigating the relationship between individual gene expression to debulking status. 
*multivariate analysis 
**associated with decreased gene expression 
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Table 1.4. Miscellaneous published studies investigating the association of various molecular markers to debulking status. 
 
FFPE; Formalin fixed paraffin embedded 
EOC; Epithelial ovarian cancer 
OS; Overall survival 
PFS; Progression free survival 
FTC; Fallopian tube carcinoma 
PP; Primary peritoneal carcinoma
Author & Year Process investigated Method Sample size Sample type 
Associated with 
cytoreductive outcomes? 
(Berchuck et al, 
2004) 
Gene expression 
profiles Affymetrix U133A 49 
Fresh Frozen serous ovarian cancer 
All stages (but analysis restricted to stage 3 
and 4) 
Yes – 32 gene predictive 
model identified 
(Levine et al, 
2004) 
Gene expression 
profiles Affymetrix U133A 70 
Fresh-frozen serous ovarian cancer 
Stage 3 and 4 
Grade 2 and 3 
No 
(Bonome et al, 
2008) 
Gene expression 
profiles Affymetrix UI33A 185 
Fresh-frozen serous ovarian cancer 
Stage 3 and 4 
Grade 2 and 3  
No 
(Fiegl et al, 
2008) 
Methylation of HOXA10 
and HOXA11 MethyLight assay 92 
Fresh-frozen tissue 
EOC 
All stages 
Yes - HOXA11 (p=0.002) 
(Barnett et al, 
2010) 
Tumour infiltrating T-
regulatory and cytotoxic 
T cells 
Immunohistochemistry 
to determine cell 
populations 
232 
Fresh-frozen tissue 
EOC (including borderline) 
All stages 
Yes - T regulatory cells 
(p<0.04) 
(Tan et al, 2011) Genome-wide survey copy number change 
Microarray-based 
comparative genomic 
hybridization 
50 
FFPE 
Clear cell ovarian carcinoma   
All stages 
No 
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1.4.4 Chemotherapy resistance 
Despite the improvement in survival since the advent of platinum based agents most women 
being treated for EOC eventually develop chemotherapy resistance. Initial chemotherapy 
response rates for standard regimes range from 60-75% (Neijt et al, 2000; Sandercock et al, 
2002), indicating that at least 20% of patients are resistant to first-line chemotherapy from 
the outset. In those that do respond, a proportion of patients will relapse within 6 months and 
are unlikely to respond again with the same treatment regime indicating platinum resistant 
disease. Furthermore, second line agents given to these patients have response rates of 
30% at best (Harries & Kaye, 2001). Those with a treatment free interval of more than 12 
months have a more favourable prognosis however the majority will eventually succumb to 
multi-resistance disease within 5 years. Understanding the mechanism and reversal for this 
resistance, as well as the development of more targeted tumour specific therapies is at the 
forefront of current EOC research strategy (Vaughan et al, 2011). Mechanisms that 
contribute to chemotherapy resistance include decreased delivery of drug to the tumour site 
due to influences in pharmacokinetics, increased renal and hepatic clearance and tumour 
vascularity, decreased delivery of drug to its specific target within the cell through increased 
drug efflux and inactivation and target site mutation and decreased ability of the drug to 
cause cell death through increased repair mechanisms of DNA damage and reduced ability 
to undergo apoptosis (Agarwal & Kaye, 2003; Vasey, 2003). It is likely that multiple 
mechanisms contribute to overall resistance as illustrated by multi-gene expression 
signatures which have been found to be associated with chemotherapy response in EOC in 
gene expression arrays (Ferriss et al, 2012; Gillet et al, 2012) and copy number change 
analysis (Wang et al, 2012b). Epigenetic regulation can occur at any number of these 
mechanistic pathways and are discussed further in the introduction and discussion of 
Chapter 4. Treatment failure in ovarian cancer is probably due to a variety of general 
mechanisms including 1) somatic mutations, DNA methylation changes etc. of pre-existing 
tumour cells which escape initial cytotoxic death, 2) survival of quiescent cells (as cytotoxic 
agents are principally effective against proliferating cells) and 3) intrinsically resistant cells 
which are present in relative small numbers initially and then propagate as sensitive cells are 
destroyed (Agarwal & Kaye, 2003). The stem cell hypothesis also contributes to this theory, 
explained by a small number of side populations (cancer stem cells) which due to their low 
proliferation can avoid chemotherapy agents and are intrinsically resistant (Guddati, 2012). 
Gene expression analysis determined side populations in ascites samples of patients with 
high grade serous EOC and found an enrichment in side populations in patients with tumour 
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relapse <12months following chemotherapy, compared to those with relapse at >12 months 
(Vathipadiekal et al, 2012) supporting this hypothesis.  
 
1.5 Heterogeneity of epithelial ovarian cancer 
Historically both clinical and scientific research grouped EOC into one disease entity. 
However over the past 10 years it has become clear that even within the subtype these 
tumours are particularly heterogeneous with distinct molecular, biological, aetiological and 
clinical profiles. Using immunohistochemistry on 500 EOC samples demonstrates that 
expression of 20 biomarkers such as Ki-67 and p53, previously found to be consistently 
expressed in ovarian cancer in other studies were actually significantly differentially 
expressed between subtypes (Köbel et al, 2008). Additionally within the same histological 
class there are distinct molecular differences within different grades of tumour. Two of the 
first studies to describe this both demonstrated through  gene expression microarray that 
grade 1 serous cancers were molecularly more similar to borderline serous tumours (low 
malignant potential tumours) then grade 2 or 3 serous cancers (Bonome et al, 2005; 
Meinhold-Heerlein et al, 2005). High grade cancers were found to be characterised by genes 
involved in cell-cycle, cell proliferation and chromosomal instability. Low grade cancers and 
borderline tumours were associated with an up regulation of the p53 pathway. Additional 
differences include low grade tumours having a high frequency of RAS mutations, being 
chromosomally stable and having BRCA wild type (Diaz-Padilla et al, 2012) whereas the 
majority of high grade have wild-type RAS, widespread DNA copy number change, p53 
mutations (Ahmed et al, 2010) and BRCA dysfunction (through mutation and epigenetic 
silencing) (Bowtell, 2010). Within high grade serous tumours themselves there has been 
shown to be vast heterogeneity. The Cancer Genome Atlas Research Network characterised 
489 high-grade serous ovarian cancers on numerous molecular platforms (Cancer Genome 
Atlas, 2011). Microarray expression profiling determined 4 gene expression subtypes which 
they termed immunoreactive, differentiated, proliferative and mesenchymal. Consensus 
clustering of variable DNA methylation identified four separate clusters which were 
significantly associated with survival and moderately associated with the gene expression 
clusters. Examination of micro RNA microarray data determined 3 different clustering 
groups, with subtype 1 overlapping with the gene expression proliferative subtype and 
subtype 2 with the mesenchymal gene expression subtype. Molecular heterogeneity has 
also been shown in other histological subtypes of EOC including clear cell (Tan et al, 2011) 
and endometrioid tumours (Tothill et al, 2008).  
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Part of this heterogeneity can be explained by the discovery that histological subtypes of 
EOC originate from different primary sites. Recent evidence supports the view that many 
ovarian cancers do not evolve from the ovary but present with regional dissemination to the 
ovary and adjacent pelvic organs. Clear cell ovarian cancer tumours display markedly 
different clinical characteristics to serous tumour histology, for example clear cell tumours 
are notoriously resistant to chemotherapy yet present at an early stage (Sugiyama et al, 
2000). Molecular profiling identified clear cell tumours to be molecularly indistinct from renal 
and uterine clear cell tumours in both hierarchical clustering and principal component 
analysis (Zorn et al, 2005). Endometrioid cancers may develop from endometriosis following 
retrograde menstruation in the pelvis (Ayhan et al, 2012). Mucinous ovarian tumours are 
extremely difficult to classify histologically separately from mucinous gastrointestinal tumours 
(Lee & Young, 2003) and share very similar molecular profiles (Sugiyama et al, 2000). The 
most consistent evidence demonstrates that high grade serous ovarian cancer actually 
develops in the fallopian tube and then sheds dysplastic cells to the ovary and peritoneum 
(reviewed in (Karst & Drapkin, 2010)). Tubal intraepithelial carcinoma is a precursor lesion 
found at the fimbrial end of the fallopian tube, which is distinguished from normal tubal 
epithelium by positive p53 staining, nuclear enlargement, loss of cell polarity and mitotic 
activity (Kindelberger et al, 2007; Medeiros et al, 2006). Several studies have identified this 
precursor lesion in patients having prophylactic bilateral salpingoophrectomy for BRCA 1 
and 2 mutations (Finch et al, 2006; Medeiros et al, 2006; Powell et al, 2005). Additionally 
p53 mutations in these lesions are identical to the p53 mutations of coexisting high grade 
serous ovarian tumours (Kindelberger et al, 2007) with indistinguishable gene expression 
signatures (Tone et al, 2008).  
 
1.6 The role of aberrant DNA methylation in cancer 
1.6.1 Epigenetic mechanisms 
The term “epigenetics” has been defined as a heritable change in gene expression that is 
not due to an alteration in the DNA sequence (Holliday, 1987), currently this includes various 
epigenetic processes such as histone modification, microRNA regulation and DNA 
methylation. Epigenetic mechanisms are crucial for normal development and maintenance of 
cell-type specific responses. Histones are alkaline proteins that package DNA into structural 
units known as nucleosomes. Post translational modifications such as acetylation, 
methylation and phosphorylation occur on amino-terminal histone tails and are strongly 
associated with active gene transcription or transcriptional repression (Fuks, 2005). 
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Generally acetylation of histones by histone acetyltransferase (HAT) is associated with 
active genes and hypoacetylation (by enzymes called histone deacetylases (HDAC)) with 
inactive regions (Egger et al, 2004). Histone methylation is associated with both active and 
silent genes, where tri-methylation of lysine 9 of histone H3 (H3-K9) is a silencing marker 
and methylation of lysine 4 (H3-K4) is found at the promoters of active genes (Lachner & 
Jenuwein, 2002). DNA methylation is a process of addition of a methyl group to the position 
5-carbon on the cytosine (C) nucleotide when followed by guanine (G) (CpG) in the 
presence of a family of enzymes known as DNA methyltransferase (DNMT). In mammals 
DNMT1 is responsible for copying pre-existing methylation patterns onto newly synthesized 
DNA strands during replication and repair (Mortusewicz et al, 2005) and DNMT3A and 3B 
are responsible for de novo DNA methylation in embryogenesis. Loss of methylation can 
also occur, and does so globally in both maternal and paternal pronucleus shortly after 
fertilisation (Mayer et al, 2000). This loss of methylation and subsequent re-methylation at 
specific regions determines and regulates pluripotency, imprinting and X chromosome 
inactivation in females. Loss of methylation occurs through three possible processes;1) 
passive demethylation due to a lack of DNMT’s through numerous cell divisions, 2) an active 
process involving TET proteins which oxidise methylated cytosines to hydroxymethylated 
cytosines and further downstream oxidation steps and 3) single base excision pathways 
which directly remove methylated or hydroxymethylated cytosines from the DNA sequence 
(Auclair & Weber, 2012). 
1.6.2 DNA methylation and gene silencing 
CpG islands (CGI) are defined as regions of the genome that contain higher than expected 
frequency of CpG sites (normally 500kp-2kb in length) (Rakyan et al, 2011). Approximately 
70% of annotated gene promoters are associated with a CGI (Saxonov et al, 2006) and it 
has long been established that genes that are transcriptionally expressed are classically 
hypomethylated at CGIs and those that are silent are hypermethylated (Bird, 1986). 
Silencing may be caused by direct inhibition of transcription factor binding or mediated by 
methyl-binding domain proteins that associate with histone deacetylases activity and 
establish silent chromatin (Bogdanović & Veenstra, 2009; Deaton & Bird, 2011). Methylation 
at promoters has been shown to directly affect binding of the transcription factor family E2F 
which are involved in the regulation of cell growth and apoptosis (Campanero et al, 2000). 
Other transcription factors thought to have affected binding by DNA methylation include SP1 
(which regulates expression of genes involved in cell growth and apoptosis) and CREB 
(which induces transcription of genes in response to hormonal stimulation of the cAMP 
pathway) (Chen et al, 2011; Iguchi-Ariga & Schaffner, 1989). Gene silencing through an 
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There is clear evidence that histone deacetylation, H3K9 methylation and DNA methylation 
leads to gene silencing however the precise sequence of events remains unclear (Fuks, 
2005). Many studies have shown that histone modification is a prerequisite for DNA 
methylation (Lehnertz et al, 2003; Schlesinger et al, 2007; Tamaru & Selker, 2001). There is 
therefore on-going debate over whether methylation is a cause or consequence of 
transcriptional silenced genes with one proposed mechanism being that CGI methylation is 
not an initiating event but rather serves as a ‘lock’ to reinforce previously silenced genes 
(Baylin & Bestor, 2002; Bird, 2002; Jones, 2012). However against this view is the plethora 
of evidence that shows that demethylating agents reduces methylation at promoter regions 
of transcriptional silent genes and consequently increases gene expression in both cell line 
and in vivo models (Plumb et al, 2000; Zeller & Brown, 2010) and in clinical trials (Matei et 
al, 2012). Proposed explanations to this are that once the gene is silenced the initial 
repressive event is lost and thus DNA methylation serves as a maintenance device 
(Illingworth & Bird, 2009), or that demethylating agents can also rapidly reverse chromatin 
structural changes (Nguyen et al, 2002). 
The full cause or consequence of methylation which is not within the promoter region, 
intragenic methylation (IGM) is yet to be fully understood. Experiments in plant models has 
demonstrated that genes with high IGM are expressed at higher levels and conversely low 
IGM is associated with low gene expression (Zilberman et al, 2007). This has since been 
demonstrated in the human genome confirming that IGM correlated to increased gene 
expression (Aran et al, 2011; Rauch et al, 2009). There are several hypotheses for this 
observed affect (summarised in (Shenker & Flanagan, 2012)). IGM may inhibit the initiation 
of transcription from alternative transcription start sites (Maunakea et al, 2010), or suppress 
the expression of antisense strand mRNA or microRNA which may interfere with 
transcriptional sense RNA and thereby reducing active gene expression (Tufarelli et al, 
2003). Additionally exons have been found to be more highly methylated to introns with 
sharp demarcation of methylation occurring at the boundaries possibly suggesting a role for 
methylation in the regulation of splicing (Laurent et al, 2010). To complicate matters IGM has 
also been associated with decreased gene expression (Lorincz et al, 2004) and thus a 
variety of different mechanisms may be at play dependent on cell type, gene of interest and 
specific CpG site location.    
1.6.3 Aberrant DNA methylation 
The uterine environment during embryogenesis and development is also crucially known to 
affect DNA methylation and can lead to persistent epigenetic changes in mouse 
experimental models (Wolff et al, 1998) and in humans. In humans, adults exposed to 
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prenatal famine in utero demonstrated differential methylation compared to siblings who 
were not exposed to famine in utero (Tobi et al, 2009). Additionally DNA methylation 
changes also occur throughout an individual’s lifetime with global hypomethylation occurring 
in aging (Fuke et al, 2004) and at individual CpG loci in smokers (Shenker et al, 2013). It is 
therefore not surprising that epigenetic aberrations are increasingly being found responsible 
for many human inherited syndromes such as Prader-Willi and Angelman’s syndrome, in 
addition to the development of multifactorial disease such as cancer (Egger et al, 2004). 
Knudson’s 2-hit hypothesis describes the development of cancer through loss of both allelic 
copies of a tumour suppressor gene (TSG) within a cell. This loss of function can be caused 
by germline or somatic mutations, loss of heterozygosity (or homozygous deletion) and 
through epigenetic gene silencing.  CGI hypermethylation at TSG has been found in 
numerous cancer types including APC and MLH1 in colorectal cancer (Esteller et al, 2000b; 
Kane et al, 1997) and BRCA1 in breast and ovarian cancer (Esteller et al, 2000a). 
Additionally and in contrast to hypermethylation at promoter regions, cancer cells also 
demonstrate global hypomethylation in the gene body, which is thought to lead to deletions 
and translocations in the DNA and promote chromosomal rearrangements (Esteller, 2008). 
In order to fully investigate differential methylation in a variety of tissues and species much 
progress has been made in industry to develop technology that allows robust exploration of 
differential methylation at a site specific and genome wide level.  
1.6.4 Differential DNA methylation contributing to chemotherapy resistance mechanisms  
There has been much evidence of the importance of aberrant DNA methylation in relation to 
chemotherapy resistance in numerous cancer types. For example, re-expression of silenced 
APAF-1 (apoptotic peptidase activating factor 1), a downstream p53 effector, has been 
demonstrated using the DNMT1 inhibitor, 5-aza-2’-deoxycytidine (decitabine) in melanoma 
cell lines. Such re-expression causes resensitisation of the cells to chemotherapy suggesting 
epigenetic silencing as a mechanism to chemotherapy resistance (Soengas et al, 2001). The 
pro-apoptotic protein DAPK1 (death associated protein kinase 1) has also been 
demonstrated to be silenced by hypermethylation at the promoter region of the gene in 
Burkitts and B Cell non-Hodgkin’s lymphoma (Katzenellenbogen et al, 1999) and chronic 
lymphocytic leukaemia with a related decrease in gene expression (Raval et al, 2007). 
Furthermore in a haemopoetic cell line the addition of decitabine led to an increase in the 
number of apoptotic cells when exposed to γ interferon (Katzenellenbogen et al, 1999). 
Hypermethylation of DAPK1 has also been shown to be a potential mechanism of targeted 
anti-EGFR resistance, furthermore the use of demethylating agents may be able to 
overcome this resistance (Ogawa et al, 2012).  
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Epigenetic regulation of DNA-repair genes have also been implicated in chemotherapy 
resistance. Hypermethylation at promoter region of hMLH1 (mutL homolog 1, colon cancer, 
nonpolyposis type 2 (E. coli)) has been demonstrated in platinum resistant ovarian cancer 
cell lines, with resensitisation to cisplatin with the addition of decitabine (Strathdee et al, 
1999). Promoter methylation of hMLH1 has also been observed in EOC patients with a 
significant increase in methylation at relapse and after four or more course of platinum based 
chemotherapy (Watanabe et al, 2007). Furthermore this differential methylation which also 
predicts OS, can be detected in cell-free circulating (CFC) DNA from plasma of patients with 
EOC demonstrating its potential as a clinically relevant biomarker (Gifford et al, 2004). 
Hypermethylation of BRCA1 has been shown to be associated with an increase in clinical 
response to chemotherapy in ovarian tumours (Chaudhry et al, 2009; Teodoridis et al, 2005). 
Additionally differential methylation of transforming growth-factor-beta inducible gene-h3 
(TGFBI) (Wang et al, 2012a) and p57Kip2 (Coley et al, 2012), has also been associated with 
platinum resistant cell lines and hypermethylation of methylation controlled DNA J (MCJ) 
gene was associated with poor chemotherapy response and decreased OS in EOC tumours 
(Strathdee et al, 2005). 
More recently the advancement in DNA methylation technology has allowed a genome wide 
analysis in association with chemotherapy resistance. The first such study (Li et al, 2009) 
used a custom differential methylation hybridization (DMH) array and Affymetrix U133 gene 
expression array to compare A2780 sensitive clones to isogenic resistant clones developed 
over a variety of cisplatin exposures to identify chemoresistance-associated loci. There was 
a demonstrated increase in hypermethylated genes dependent on number of treatment 
exposures and a significant correlation between the total number of methylated genes and 
the IC50 of the resistant sub-lines. In keeping with this there was a significant increase in 
expression of DNA methyltransferases DNMT1 and DNMT3B in resistant sub lines. 
Furthermore treating the resistant clone with DNA methyltransferase inhibitors, decitabine 
and zebularine demonstrated a dose dependent decrease in IC50 and increase in cisplatin 
sensitivity. 1176 genes were hypermethylated in the resistant sub line compared to A2780 
and 55 of these were found to be significantly down regulated on the gene expression array. 
In a similar study using the Infinium HumanMethylation27 Beadchip and Affymetrix U133 
gene expression array differential methylation and gene expression was determined 
between A2780 and A2780 resistant clones (Zeller et al, 2012). 4092 genes were 
hypermethylated at more than 1 CpG site in the resistant clones whereas only 1289 genes 
were hypomethylated.   From the 4092 hypermethylated genes, 245 genes were found to be 
down regulated on the gene expression array. Treatment of the resistant clone A2780/cp70 
with decitabine induced re-expression of 41 of the 245 down regulated genes. These 
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findings were also validated by pyrosequencing in cell line models of in vivo cisplatin 
resistance and relapsed tumour samples with three genes ARMCX2, MEST and MLH1 
consistently having higher methylation in resistant samples. One further study investigated 
A2780 versus in vitro derived resistant clones using Methyl-Capture sequencing (MethylCap-
seq) which  identified 1224 hypermethylated and 1216 hypomethylated differentially 
methylated regions (Yu et al, 2011). In contrast to the previous studies the authors found a 
lower global methylation in resistant lines compared to sensitive however the differences 
were mostly found at intragenic regions which are not well represented on DMH and Infinium 
HumanMethylation27 arrays. More recently a DMH array on 36 advanced stage serous 
ovarian cancer samples was performed and demonstrated 749 loci whose methylation was 
significantly different between patients with refractory or resistant disease (PFS through 
treatment or < 6months) versus those termed late sensitive (relapse after 12 months)(Lum et 
al, 2013). Of the differentially methylated loci, approximately 60% of samples were 
methylated in resistant tumours compared to 40% in sensitive tumours. From the 749 
significant loci, 296 genes were found to significantly correlate hypermethylation to 
decreased gene expression. Nineteen genes were further validated using an in vitro 
carboplatin resistance assay shRNA screen, including FZD1 (an important Wnt signalling 
receptor). 
 
1.7 DNA methylation technology 
There are a variety of different technologies for measuring DNA methylation (reviewed in 
(Laird, 2010)) the more commonly used platforms which will be briefly discussed here. Three 
main approaches have been developed 1) enzyme digestion, 2) affinity enrichment and 3) 
sodium bisulphite conversion. 
1.7.1 Enzyme digestion and affinity enrichment approach 
Enzyme digestion relies on methylation-sensitive restriction enzymes which cut either 
methylated or unmethylated DNA sequences dependent on the enzyme used. Fragments 
which have not been cut are then able to be amplified by PCR and/or run by gel 
electrophoresis. This process however is prone to false-positive results due to incomplete 
digestion. Differential Methylation Hybridization (DMH) uses this approach at a genome wide 
level, the process includes DNA fragmentation using restriction enzymes that do not cut at 
CG-rich regions (MseI) and thus preserve CpG islands. Sample aliquots are divided in half 
and with the first aliquot processed for further digestion using BstUI, a methylation sensitive 
endonuclease which cuts unmethylated CpG sites. Methylated fragments therefore remain 
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intact and are subsequently amplified with PCR whereas the unmethylated fragments are 
unable to amplify (Huang et al, 1999). Other restriction enzymes have also been developed 
such as McrBC which cuts methylated sequences instead of unmethylated sequences 
(Nouzova et al, 2004).  The remaining (non-BstUI digested) samples are also amplified 
providing product for unmethylated and methylated sequences. Fluorescent labelling of the 
methylated and unmethylated fragments and subsequent hybridization to a customized CpG 
island microarray enables image quantification. Following quality control a DMH ratio is 
produced which is the ratio of signals from the aliquot not exposed to methylation sensitive 
restriction enzyme  to those which were digested with methylation sensitive restriction 
enzyme (Dai et al, 2011). The advantages of DMH include the ability to customise the array 
and thus target regions of interest and the ability to define the average methylation across an 
entire CGI. The main disadvantages are that as the array is customised there is limited 
ability to compare results across different platforms and that it is unable to determine specific 
methylation at individual CpG sites. 
Affinity enrichment techniques rely on antibodies specific to methylated cytosines or methyl-
binding proteins with a high affinity for methylated DNA. This process then allow for 
chromatin immunoprecipitation (Methylated DNA Immunoprecipitation known as MeDIP), 
followed by array hybridization or sequencing. These methods allow for genome wide 
assessment of DNA methylation but do not allow individual CpG site evaluation and require 
optimisation at different regions of the genome due to varying CpG density (Laird, 2010).  
1.7.2 Bisulphite conversion approach 
The most commonly used approach for DNA methylation investigation involves an initial step 
of bisulphite conversion. Bisulphite conversion relies on sodium bisulphite (NaHSO4) to 
convert cytosine bases to uracil on single stranded DNA through a process of sulphonation, 
hydrolytic deamination and desulphonation. Methylated cytosine remain unaffected by this 
process and remain as cytosines. Through PCR the converted uracil bases are then 
converted to thymine thus generating a stable sequence specific product that can be further 
amplified, sequenced and hybridized. Methylation specific PCR (MSP) relies on bisulphite 
conversion and then amplification through PCR primers which either recognise the 
methylated (and thus unconverted sequence) or unmethylated sequence. The products are 
then run on electrophoresis gel and visualised (Herman et al, 1996). This process allows for 
specific investigation of customised loci at small quantities of DNA which is qualitative and 
semi-quantitative (Herman et al, 1996). MethyLight assay is a more quantitative approach 
that relies on a similar approach to MSP but uses fluorescent based real-time PCR 
technology (Eads et al, 2000). Bisulphite converted DNA can also be sequenced by 
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technology such as pyrosequencing. Pyrosequencing involves biotin labelled PCR product 
that is immobilised to Streptavidin Sepharose HP beads with binding buffer and denatured 
through denaturing solution to provide a single-stranded DNA (ssDNA) template for the 
pyrosequencing assay. The ssDNA released from the Streptavidin Sepharose HP beads is 
added to the pyrosequencing plate containing sequencing primer and annealing buffer. The 
pyrosequencing plate is subsequently placed in the processing chamber of the 
pyrosequencing machine with addition of reagents and deoxyribonucleoside triphosphates 
(dNTPs) necessary for the pyrosequencing reaction. Pyrosequencing software calculates the 
ratio of unmethylated cytosines (thymine base following PCR amplification) to methylated 
cytosines at each individual CpG site to give a sensitive and reliable quantitative output of 
DNA methylation. Both pyrosequencing and MSP are however not suitable for genome wide 
methylation analysis due to the high work load involved, and thus array hybridization 
methods have also been developed. The Illumina 27K platform allows interrogation of 
>27,500 individual CpG sites (and more recently an additional platform for over 450,000 
CpG sites is available) through bisulphite conversion followed by whole genome 
amplification and end-point fragmentation. The whole genome amplified DNA fragments are 
hybridized to bead chips with 12 individual samples per chip. The fragments anneal to allele 
and locus-specific oligonucleotides, with methylated sequences hybridizing to corresponding 
methylated beadchip and unmethylated sequences to unmethylated beadchip. Single-base 
extension with a labelled nucleotide allows detection following fluorescent staining (Figure 
1.2). The chip is scanned and the intensities of the methylated and unmethylated bead types 
measured. Software analysis allows for stringent quality control to ensure efficiency of 
fluorescent staining, base extension, hybridization and bisulphite conversion amongst others 
(Wilhelm-Benartzi et al, 2013).  
The use of this developing technology has enabled an ever increasing understanding to the 
variability and function of differential DNA methylation.  Furthermore the relevance of these 
changes in relation to tumour and patient characteristics enables translational potential in the 
discovery of suitable clinically relevant biomarkers and therapeutic targets. 
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1.8 The translational potential of differential DNA methylation in cancer  
1.8.1 Clinical biomarkers  
A clinical biomarker is a quantifiable measurement of a biological process that can define 
what is normal or abnormal (Dalton & Friend, 2006). Currently used clinical examples 
include prostate-specific antigen (PSA) detection in the blood of males in prostate cancer 
screening and treatment response, and Oncotype DX assay which measures the gene 
expression of 21 genes to give a prediction of recurrence and thus need for adjuvant 
chemotherapy in early stage breast cancer (Paik et al, 2004). There is a huge clinical need 
for further biomarkers to be developed to aid clinicians in all aspects of patient cancer care, 
from pre-invasive screening, early detection and diagnosis, to treatment stratification and 
prognostic indicators. There has been recent emphasis on the need “to perform complete 
and transparent reporting of biomarker studies…to ensure that there is a comprehensive 
body of unbiased evidence” (McShane & Hayes, 2012). Many biomarker studies in the past 
have suffered from incomplete reporting, poor study design and lack of reproducibility 
leading to the actual number of biomarkers in clinical use being incredibly small (Harris et al, 
2007). These problems led to recommendations for reporting of tumour marker prognostic 
studies (REMARK guidelines) that have been globally accepted by the scientific community 
(McShane et al, 2005). The guidelines recommend that studies should report clear study 
objectives, patient characteristics and treatments received, clear specimen description and 
detailed and reproducible assay methods and techniques. The data analysis should be well 
described with clear statistical methods and the relationship of the biomarker in question to 
standard prognostic variables should be determined (REMARK criteria fully explained in 
(Altman et al, 2012)). With the increase in data generated from microarray platforms 
stringent statistical methods are also required to ensure that the screening of hundreds or 
thousands of markers do not lead to spurious results (Laird, 2003). Previous studies lack in 
the quality of statistical analysis; ignoring potential confounders and not adjusting for 
important covariates. The need to include adjustment for multiple comparisons by false 
discovery rate is also very important in array datasets since multiple comparisons will lead to 
a greater number of incorrect null hypothesis rejections (p values found to be <0.05 which 
are not in fact significant). Additionally validation of findings in independent datasets is 
crucial to avoid false associations and ensure reproducibility across populations which thus 
lead to the discovery of highly sensitive and specific tests.  
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1.8.1.1 Advantages of DNA methylation biomarkers 
The use of DNA methylation as a biomarker has several advantages over other molecular 
gene expression and proteomic processes. These include the ability to amplify the sequence 
to detectable levels and it being very stable compared to messenger RNA (Laird, 2003). 
DNA methylation measurements can be compared to absolute reference points (completely 
methylated or completely unmethylated DNA) which affirms reliable accurate assays (Laird, 
2003). Additionally tumour DNA methylation can be detected in plasma and serum leading to 
development of non-invasive screening, diagnostic and prognostic tests as compared to 
biopsy-driven gene expression analysis (Gifford et al, 2004; Laird, 2003). These factors have 
led to DNA methylation being used as a potential tool for determining cancer risk, such as 
ATM in bilateral breast cancer cases (Flanagan et al, 2009) and MLH1 in colorectal cancer 
(Hitchins et al, 2007) and diagnosis between benign and malignant disease (Liggett et al; 
Teschendorff et al, 2009). As yet these findings are still several years away from real clinical 
application. Further validation in independent datasets and a high sensitivity and specificity 
of each test is required before they can truly be useful to the clinician.  
One of the most exciting and potentially clinically relevant epigenetic biomarkers currently in 
use is the assessment of MGMT (O-6-methylguanine-DNA methyltransferase) methylation 
status in the treatment of patients with malignant glioblastoma. Randomised controlled trials 
(Hegi et al, 2005; Malmström et al, 2012) clearly show the survival benefit obtained in 
patients whose tumours contain a methylated MGMT promoter. Additionally, patients with 
the methylated promoter show improved OS with a 49% risk reduction with the addition of 
radiotherapy plus temozolomide (an alkylating chemotherapy agent) compared to those 
receiving radiotherapy alone (n=92, p=0.007, HR 0.51, 95% CI 0.31, 0.84) (Hegi et al, 2005). 
Crucially there appears to be no benefit in survival with the addition of temozolomide in 
patients without the methylated MGMT promoter. This demonstrates a DNA methylation 
biomarker that identifies patients who could be stratified into treatment groups dependent on 
their methylation status.  Since these landmark results there has been much debate over the 
optimal technical assay to be used in clinical trials and clinical applications, including the 
exact region to be assayed, the number of CpG sites needed to be determined and the 
definition of hyper or hypomethylated regions (von Deimling et al, 2011). Furthermore due to 
the lack of therapeutic alternatives these findings have not yet found their way into national 
treatment recommendations (NICE, 2001; NICE, 2007).  
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1.8.1.2. Clinical samples 
An ideal biomarker is one which can be detected using technology that is well established, is 
cost efficient, the procedure to take or measure the biomarker is not associated with 
unnecessary health risks and the test is acceptable to the patient. Determining the molecular 
profile of tumour tissue in patients before surgery or in those who have relapsed disease 
usually requires tumour biopsies. The sampling of which are associated with potential 
serious risks of infection, bleeding and damage to major organs. Efforts have thus been 
focused on detecting markers within the peripheral blood of cancer patients, which has the 
additional benefit of being able to be repeated at multiple additional time courses. Traditional 
approaches rely on the detection of proteins within the blood which are secreted from the 
tumour using ELISA techniques, such as CA125 in ovarian cancer and PSA in prostate 
cancer (Jacobs & Bast, 1989; Liedtke & Batjer, 1984). Although these tests are used 
clinically for diagnosis and monitoring purposes they suffer from poor sensitivity and 
specificity.  More recently the focus has shifted to determine epigenetic or genomic 
information of the tumour through the presence of cell-free circulating DNA (CFC DNA) (Jen 
et al, 2000), microRNA’s (Sita-Lumsden et al, 2013) or circulating tumour cells within the 
blood. A recent prospective study compared CA-153 tumour marker, somatic mutations in 
CFC DNA and circulating tumour cells with radiographic images to determine tumour burden 
in breast cancer patients (Dawson et al, 2013). Somatic genomic alterations in CFC DNA 
was detected in 97% of women compared to 78% detection of raised CA 153 and 87% 
detection of circulating tumour cells. CFC DNA was seen to be the preferred method for 
monitoring tumour burden due to a demonstrated serial change in concentration which 
generally correlated to treatment response.  Additionally increasing levels of CFC DNA was 
significantly associated with inferior OS.  
The presence of CFC DNA in the blood has been established for over 60 years (Jung et al, 
2010b). Historically CFC DNA was thought to be present in healthy subjects at 
concentrations between 0 to 100 ng/ml and 0 to 10,000 ng/ml in cancer patients (Shapiro et 
al, 1983). Newer techniques for the extraction of CFC DNA from plasma and measuring the 
concentration obtained has since developed, with more recent studies demonstrating that 
quantities of CFC DNA in healthy controls can be as much as 3.4 ug/ml (Jylhävä et al, 
2011). The majority of work associating CFC DNA and tumour and clinical characteristics 
address whole-genome or specific site sequencing to identify somatic mutations of the 
tumour. K-ras and TP53 mutations have been the most widely studied (reviewed in (Jung et 
al, 2010b)) in a variety of cancers including ovarian (Otsuka et al, 2004). Concordance 
between mutation in tumour and plasma was poor but this may be accounted for by 
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heterogeneous histology case and incomplete analysis of all possible mutations. An exciting 
recent development in a well conducted study performed serial sequencing on CFC DNA 
from breast, ovarian and lung cancer patients over a 1-2 year time course (Murtaza et al, 
2013). There was increasing mutant allele fraction in association with chemotherapy 
resistance, including for example a truncating mutation in RB1 (retinoblastoma 1) following 
treatment with cisplatin in ovarian cancer. In two cases synchronous tumour biopsies were 
also performed. There was concordance between the mutations found in plasma DNA and 
tumour DNA, 93-172 from 151-895 mutations identified were represented in both plasma 
and tumour samples.  
Determining DNA methylation on CFC DNA would be beneficial over sequencing techniques 
which are expensive, requiring high work-load and specialist analytical methods. Additionally 
as aberrant methylation of specific loci is demonstrated in tumours and not PBMCs only the 
smallest quantity of CFC DNA derived from tumour needs to be present to detect a 
methylated state. Determining DNA methylation in CFC DNA has been performed 
extensively in a variety of different tumour types (Begum et al, 2011; Guttery et al, 2013; 
Jung et al, 2010b; Liggett et al, 2010) with most methods using methylation specific PCR 
(MSP). The florescent MSP assay is extremely sensitive in detecting methylation down to a 
1:500 dilution of in vitro methylated DNA to human lymphocyte DNA (Gifford et al, 2004). 
Detection of BRCA1 and RASSF1A (RAS association domain family protein 1A) was found 
in plasma samples from EOC patients using MSP at a sensitivity of 82% and a specificity of 
100% (Ibanez de Caceres et al, 2004). This technique has also determined hMLH1 
methylation in plasma DNA to be significantly correlated to OS (HR 1.83, p=0.017, n=131) 
and a increase of number of samples with hMLH1 methylation from 12% before 
chemotherapy to 33% at relapse indicating the dynamic state of DNA methylation in tumour 
can be detected in the plasma (Gifford et al, 2004). 
1.8.2 Therapeutics  
Unlike genetic mutations DNA methylation and histone modifications are reversible and thus 
have shown great potential in the race for effective cancer treatments.  Indeed both 5-
azacytidine and decitabine (5-aza-2’-deoxycytidine) both demethylating agents, are currently 
used in clinical practise for myelodysplastic syndrome (MDS) and cutaneous T cell 
lymphoma.  These drugs classified as DNMT inhibitors exert their demethylating activity by 
incorporating into the DNA of S-phase cells in the place of cytosine. Covalent bonds are 
subsequently formed with DNMT resulting in a reduction of the active enzyme and a 
subsequent loss of methylation (Egger et al, 2004). In MDS patients, the use of DNMT 
inhibitors has been shown to improve quality of life, significantly improve OS (Silverman et 
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al, 2002) and have led to complete remission rates of up to 39% (Kantarjian et al, 2007). The 
use of demethylating agents in solid cancers has been more of a challenge possibly due to 
drug delivery and targeting issues, and a lower number of proliferating cells in solid tumours 
compared to haematological malignancies (Graham et al, 2009).  
Specifically in relation to ovarian cancer a few phase 1 studies have proven the safety of 
DNMT inhibitors albeit with common toxicities of allergy, rash and gastrointestinal 
disturbances (Bauman et al, 2012; Fang et al, 2010). Myelosuppression toxicities are also 
closely correlated to dose escalation (Appleton et al, 2007). Importantly for these phase-1 
studies demethylation has been demonstrated at clinically acceptable doses in PBMCs, CFC 
DNA in plasma and tumour biopsies proving mechanistic action of the drugs (Appleton et al, 
2007; Fang et al, 2010). Three phase-2 clinical trials have so far been published. The first 
published (Glasspool et al, 2009) randomised patients with relapse of EOC within 6-12 
months to either 6 cycles of carboplatin (AUC 6) or 90mg/m2 decitabine on day 1 and 
carboplatin on day 8. The dose of decitabine had to be reduced to 45mg/m2 after the first 4 
enrolled patients had frequent dose delays due to neutropenia. Despite this dose reduction 
none of the patients in the decitabine arm were able to complete 6 cycles of treatment due to 
hypersensitivity reactions and neutropenia. Additionally there was no RECIST response in 
this group compared to 6/14 responses in the carboplatin only group. The trial therefore 
closed early.  The second study (phase 1b-2a) (Fu et al, 2011) selected high grade EOC 
patients with platinum refractory or resistant disease (relapse within 6 months) to receive 
subcutaneous azacitidine 75mg/m2 daily for 5 days and carboplatin (AUC 4 or 5) on Day 2. 
From 29 evaluable patients, 17 received 6 or more cycles and no dose limiting toxicities or 
treatment-related deaths were observed. Clinical chemotherapy response was defined by 
WHO criteria, 1 patient had complete response, 3 patients had partial response and 10 
patients had stable disease which is particularly encouraging for patients with refractory 
disease. The final study (Matei et al, 2012) recruited patients with platinum refractory EOC 
disease. Treatment consisted of decitabine 10mg/m2 intravenously for 5 days and 
carboplatin on Day 8 (AUC 5). 17 patients enrolled into the study with most patients 
receiving 6 cycles of treatment. Grade 3-4 toxicities included neutropenia (n=4) and 
thrombocytopenia (n=2). From 17 patients, 1 had RECIST defined complete response, 5 had 
partial response and 6 had stable disease which lasted for more than 3 months. The authors 
concluded that the improved side effect profile in this study compared to (Glasspool et al, 
2009) was due to the low dose administration and growth factor support provided. 
Furthermore global and gene specific methylation was proven in PBMC, ascites and tumour 
DNA at this lower dose. Numerous in vitro and in vivo studies have demonstrated that the 
addition of DNMT inhibitors and HDAC inhibitors can reverse acquired drug resistance 
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(Coley et al, 2012; Li et al, 2009; Plumb et al, 2000; Steele et al, 2009; Strathdee et al, 1999; 
Wang et al, 2012a). The benefits of combination agents have been proposed through an 
increase in histone acetylation which leads to a more open chromatin structure and hence 
re-expression of silenced genes (Graham et al, 2009; Teodoridis et al, 2004) plus the 
synergistic activity of both DNA demethylating agents and HDAC inhibitors to work in 
combination to “unlock and open” the gene which has become epigenetically silenced 
(Egger et al, 2004).Thus showing great promise for these drugs to translate to the clinical 
setting for those with resistant disease. 
Other potential therapeutic targets which are currently less well developed include the 
histone acetyltransferase enzyme (HAT) inhibitors and histone methyltransferase inhibitors 
(Zeller & Brown, 2010). Further clinical approaches to epigenetic drug development include 
using single agents to switch on tumour-suppressor genes fundamental to particular cancer 
development, maintenance therapy to prevent relapse following a course of conventional 
treatment and prophylaxis to patients at high risk of developing disease such as those found 
through epigenetic risk biomarkers (Graham et al, 2009). Several concerns into the safety of 
epigenetic therapies include the unknown and non-specific effects on normal tissue, the high 
side effect profile and the potential carcinogenic effect. However it is important to remember 
that the majority of these treatments are being trialled as 2nd or 3rd line drugs where 
conventional chemotherapy has already failed and treatment options for the patient and the 
medical team are extremely limited.   
 
1.9 MSX1 function and dysregulation in cancer 
1.9.1 MSX1 function in development  
This work will demonstrate that differential methylation at intragenic regions of MSX1 is 
associated with primary chemotherapy response with lower levels of methylation being 
associated with primary chemotherapy resistance. MSX1 (also known as HOX7) is a 
homeobox gene critical for normal embryonic development. Homeobox genes are described 
as “regulatory genes which encode nuclear proteins that act as transcription factors during 
development and are subsequently involved in determining the spatial organisation of the 
embryo” (Gehring & Hiromi, 1986). Additionally homeobox genes have been shown to be 
involved in crucial biological processes in the adult in both normal and malignant cells (Cillo 
et al, 2001). Specifically to MSX1, this gene’s main developmental function appears to be in 
craniofacial, palate and tooth development. Homozygous MSX1-/- knockout mice do not 
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survive beyond 24 hours of birth and demonstrate complete cleft of the secondary palate, 
deficiencies in mandibular and maxillary bone development, tooth agenesis, abnormal skull 
and nasal bone development and middle ear abnormalities (deficiency in malleus bone 
formation) (Satokata & Maas, 1994). Additionally MSX1 is also involved in limb development 
with expression and regional localization occurring in limb buds (Robert et al, 1989). 
Homozygous MSX1-/- knockout mice do not demonstrate limb abnormalities but MSX1-/-, 
MSX2-/- double knockouts exhibit a severe limb phenotype with both oligodactyly and 
polydactyly displayed  due to a deficiency of the anterior mesenchyme (Lallemand et al, 
2005). These findings also suggest an overlapping function for both MSX1 and MSX2.  The 
function of MSX1 in developing limb buds is thought to be due to its ability to inhibit terminal 
differentiation and thus maintain proliferation at the distal limb as increased expression of 
MSX1 in myoblasts resulted in blocked or delayed terminal differentiation (Song et al, 1992). 
MSX1 expression appears to be closely related to BMP (bone morphogenetic protein) 
signalling (part of the transforming growth factor β (TGFβ) superfamily) with aberrant 
signalling contributing to cancer tumorigenesis (Hardwick et al, 2008). MSX1 mutant dental 
mesenchyme demonstrates a reduction in protein expression of BMP4 in the mesenchyme, 
BMP4 can also induce MSX1 expression in a reciprocal manner (Chen et al, 1996). 
Additionally BMP has been shown to regulate MSX1 & 2 expression in ventral limb ectoderm 
(Pizette et al, 2001).  
1.9.2 MSX1 dysregulation in cancer 
Dysregulation of a variety of HOX genes have been associate with a variety of human 
cancers (summarised in (Abate-Shen, 2002) . MSX1 itself has been associated with several 
of the Hallmarks of cancer (Hanahan & Weinberg, 2011) including resisting cell death, cell 
proliferation and invasion. One of the earliest suggestions of MSX1 and tumorigenesis was 
demonstrated by subcutaneous injection of myoblasts containing increased expression of 
MSX1 into nude mice. Subsequently tumours developed within 2.5 months compared to 
none in the control (Song et al, 1992).  MSX1 has been shown to cause a change in cell 
morphology and a reduction in cell growth thought to be due to an induction of apoptosis in 
HeLa cancer cells (Park et al, 2005). HeLa cells overexpressing MSX1 were found to have 
fragmented nuclei on DAPI-staining and fluorescence-activated cell sorting (FACS) 
characteristic of apoptosis as compared to control cells. This was thought to be due to the 
ability of MSX1 to stabilise p53 and increase its nuclear localization. The half-life of p53 
protein was shown to be 2 fold higher in MSX1 expressing cells which coincided with a 
decrease in cellular levels of HPV-E6 protein (known to cause p53 degradation through 
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protein ubiquitination). Furthermore the MSX1 homeodomain was shown to directly interact 
with p53 by GST pull-down assays and yeast two-hybrid assays leading the authors to 
summarise that the binding of p53 to MSX1, inhibits its nuclear export and thus protects p53 
from E6-mediated degradation in the cytoplasm. 
MSX1 expression has also been associated with Wnt signalling where epithelial and stromal 
cells from MSX1 and MSX2 deficient uteri demonstrated a significant increase in gene 
expression of several Wnt genes including Wnt4, Wnt7a, Wnt 7b when compared to 
controls. There was also corresponding increase in active β-catenin suggesting increased 
activation of Wnt signalling pathway (Nallasamy et al, 2012). Additionally overexpression of 
MSX1 in neuroblastoma cells lines has been shown to induce the expression of four different 
Wnt pathway inhibitor genes DKK1, 2 & 3 and SFRP1 although this change did not lead to 
differences in β catenin expression (Revet et al, 2010). Conversely to this, in a breast cancer 
cell line MSX1 has been shown to repress DKK1 causing an increase in β-catenin which 
subsequently regulates MSX1 expression (Menezes et al, 2012). These findings suggest 
that the function of MSX1 may differ dependent on cell type. Another paradoxical example in 
the literature is associated with MSX1 expression in association with the cell cycle. Up 
regulation of MSX1 in progenitor cells has been demonstrated to up regulate cyclin D 
expression in vitro and in vivo thus preventing exit from the cell cycle and inhibiting terminal 
differentiation (Hu et al, 2001). Conversely overexpression of MSX1 in an ovarian cancer cell 
line (OVCAR3) demonstrated a decrease in growth through increasing the length of G1 
phase and this was associated with a  decrease in protein expression of cyclins D1, D3, E, 
CDK4, rb and c-JUN proteins (Park et al, 2001). 
1.9.3 Differential methylation and expression of MSX1 in tumour tissue 
Variable MSX1 expression has also been demonstrated in human cancer tissue. MSX1 gene 
and protein expression has been shown to be increased in colorectal malignant tumours 
compared to normal colonic mucosa (Horst et al, 2009). Conversely reduced gene 
expression of MSX1 has been seen in cervical squamous cell carcinoma tumours compared 
to matched controls (n=10) (Shim et al, 1998) and statistically significant reduction of protein 
expression was seem in invasive stage 2-4 Wilms tumours compared to stage 1 non-
invasive cases (n=15, p=0.006). Additionally a homozygous deletion mutation in MSX1 was 
shown to increase the risk of breast cancer occurrence in a case control study (OR 2.2, 95% 
CI 1.41-3.44, p<0.05) (Sliwinski et al, 2010). Epigenetic changes have also been found in 
association with MSX1 in patients with cancer. In childhood T-cell acute lymphoblastic 
leukaemia MSX1 was seen to be methylated at the promoter in 25% of cases using MSP. 
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Lung cancer tumours were shown to show differential gene expression of MSX1 compared 
to controls with lower gene expression in the cancer cases determined by Affymetrix array 
(Shames et al, 2006). This correlated to promoter methylation determined by MSP in lung 
cancer tissue in both non-small cell (Shames et al, 2006) and squamous cell histological 
subtypes (Rauch et al, 2012). Promoter methylation of MSX1 was also found in 79-91% of 
breast cancer cases compared to 35% in benign breast tissue, 83% in prostate cancer 
compared to 42% in benign prostate and 88% in malignant colon tumour compared to 54% 
in benign colon tumours (Shames et al, 2006), although correlation to gene expression was 
not determined. 
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1.10 Summary and Hypothesis  
There is no doubt that further research is needed to fully understand the heterogeneous 
nature of EOC and how this can be applied to achieve truly personalised stratified medicine. 
The two most important prognostic factors for the majority of patients with EOC are surgical 
debulking success and response to primary chemotherapy and thus focus on these clinical 
outcomes is particularly important. This thesis begins with the hypothesis that clinical 
treatment outcomes can be predicted by clinical and molecular profiles. The discovery and 
validation of these potential biomarkers to aid treatment stratification is the overall aim of this 
work.  
 
1.11 Aims 
1) Determine clinical and molecular biomarkers associated with cytoreductive surgical 
outcomes and validate findings in independent datasets 
 
2) Determine DNA methylation profile of EOC tumours associated with surgical 
debulking outcomes, survival and primary chemotherapy response 
 
3) Validate potential candidates determined by initial analysis (for example MSX1) 
through independent datasets, determine the influence of these DNA methylation 
changes on gene expression and further explore potential mechanisms through 
biological functional assays 
 
4) Determine feasibility of measuring candidate gene DNA methylation in cell-free 
plasma by pyrosequencing 
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Chapter 2: Materials and methods 
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Materials 
2.1 Chemicals, kits and buffers 
Experimental Process Chemicals, Kits and Buffers Supplier 
General  Ethanol absolute analytic reagent 
grade 
VWR 
 Methanol analytic reagent grade Fisher Chemicals 
 Phosphate Buffered Saline Imperial College laboratories 
 Distilled Water  Imperial College laboratories 
 RNAse free, DEPC-treated water Ambion 
Antibiotics Ampicillin solution 100mg/ml Sigma 
 Kanamycin powder Gibco 
 puromycin solution 10mg/ml Gibco 
 Geneticin solution 50mg/ml Gibco 
Bisulphite Conversion EZ-96 DNA Methylation Kit Zymo 
 EZ methylation-Direct kit Zymo 
Cell culture RPMI 1640 Medium Sigma 
 Foetal calf serum  First Link UK 
 L-Glutamine Gibco 
 Trypsin 10x Sigma 
 EDTA Sigma 
 Trypan blue 0.4% Gibco 
 Dimethyl sulphoxide Thermo Scientific 
Cell line assays Cisplatin 1mg/ml Imperial College NHS Trust 
 Caspase-Glo 3/7 Assay Promega 
 CellTitre 96 Aqueous One Solution 
Proliferation Assay 
Promega 
 Crystal Violet  Merck 
Cell line transfection MSX1 re-expression plasmid Generous gift of Dr C Abate- 
Shen, Columbia University 
 HuSH shRNA plasmids Origene 
 One Shot Mach1-T1R Chemically 
Competent E. Coli 
Invitrogen 
 LB Culture Media Imperial College laboratories 
 HiSpeed Plasmid Midi Kit Qiagen 
 Turbofectin Origene 
 Lipofectamine-2000 Transfection 
Reagent 
Invitrogen 
 FuGENE HD Transfection Reagent Promega 
 Opti-MEM reduced serum media Gibco 
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Experimental Process Chemicals, Kits and Buffers Supplier 
DNA & RNA extraction  QIAamp DNA Mini-Blood Kit Qiagen 
 QIAamp DNA Mini Kit Qiagen 
 QIAshredder Qiagen 
 RNAeasy Mini Kit Qiagen 
DNA / RNA quantification Nanodrop ND1000 Thermoscientific 
 Quant-iT PicoGreen dsDNA Assay Kit Invitrogen 
PCR FastStart Taq DNA polymerase kit Roche 
 Agarose genetic analysis grade Fisher Scientific 
 TBE 10x Imperial College laboratories 
 Ethidium Bromide 10mg/ml Invitrogen 
 100bp DNA ladder Invitrogen 
 Orange DNA loading dye ThermoScientific 
Protein extraction Pierce RIPA buffer Thermo Scientific 
 Protease inhibitor Sigma 
 Phosphatase Inhibitor Cocktail 2 Sigma 
 Phosphatase inhibitor Cocktail 3 Sigma 
Protein quantification Pierce BCA protein assay kit Thermo Scientific 
Pyrosequencing PyroMark Gold Q96 Reagents Qiagen 
 PyroMark Binding Buffer Qiagen 
 PyroMark Annealing Buffer Qiagen 
 PyroMark Wash Buffer Qiagen 
 Sodium Hydroxide pellets  Sigma-Aldrich 
 Streptavidin Sepharose HP Beads GE Healthcare 
Real Time-PCR SuperScript VILO cDNA Synthesis Kit Invitrogen 
 Taqman Gene Expression MasterMix Applied Biosystems 
 Taqman Gene Expression Assays Applied Biosystems 
Western Blotting  NuPAGE Sample Reducing Agent 1x Novex 
 NuPAGE LDS Sample Buffer 1x Novex 
 NuPAGE 4-12% Bis Tris Gel  Novex 
 NuPAGE MOPS SDS Running Buffer 
20x 
Novex 
 NuPAGE Transfer Buffer 20x Novex 
 PageRuler Prestained Protein Ladder Thermoscientific 
 Tris Buffered Saline with Tween-20 10x Imperial College laboratories 
 Invitrolon PVDF membrane and filter 
paper 
Invitrogen 
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Experimental Process Chemicals, Kits and Buffers Supplier 
Western Blotting  Original Dried Skimmed Milk powder Marvel 
(continued) MSX1 (F22) rabbit polyclonal antibody Santa Cruz 
 Polyclonal anti-rabbit Ig HRP Dako 
 β-actin mouse IgG antibody Santa Cruz 
 Goat anti-mouse 1gG HRP Santa Cruz 
 Pierce ECL Western Blotting substrate Thermo Scientific 
 Restore PLUS Western Blot Stripping 
Buffer 
Thermo Scientific 
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2.2 Equipment and plastic ware 
Experimental 
Process 
Laboratory Equipment / plastic ware Supplier 
General Equipment  Accuspin Micro17 centrifuge (for 1.5ml tube) Fisher Scientific 
 Accuspin Micro17R centrifuge (for 4  C) Fisher Scientific 
 Miniplate spinner Labnet 
 Microplate shaker Scientific Industries 
 Tetrad2 thermal cycler Biorad 
 Multifuge X3R centrifuge (for 15ml and 50ml 
falcon tubes and 96 well plates)  
Thermoscientific 
General Plastics DNA loBind 1.5ml tube Eppendorf 
 0.2ml PCR tubes Starlab 
 96 well PCR plate and adhesive covers Starlab 
 Pipette tips (various size) Corning Inc 
 Stripettes (various size) Corning Inc 
 Falcon tubes (15 and 50ml) Corning Inc 
 Culture flasks (various size) Corning Inc 
 Culture plates and petri-dish (various size) Corning Inc 
DNA/RNA  Nanodrop ND1000 Thermoscientific 
quantification Lumistar optima plate reader BMG labtech 
Cell line assays Lumistar optima plate reader BMG labtech 
 OPTImax plate reader Molecular Diagnostics 
PCR Electrophoresis tank and power supply Fisher Scientific 
Protein 
quantification 
OPTImax plate reader Molecular Diagnostics 
Pyrosequencing PyroMark Q96 MD Qiagen 
 PyroMark Q96 Vacuum Workstation Qiagen 
 PyroMark Q96 Dispensing Tip Holder Qiagen 
 PyroMark Q96 Capillary & Reagent Tips Qiagen 
 PyroMark Q96 HS Plate Qiagen 
Real Time-PCR StepOnePlus Real-Time PCR Systems Applied Biosystems 
 Fast optical 96 well reaction plate Applied Biosystems 
 Optical Adhesive covers Applied Biosystems 
Western Blotting  Power-pack basic Biorad 
 Xcell SureLock Mini Cell gel tank Novex 
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Methods 
2.3 Systematic literature search for molecular biomarker study 
A systematic literature search was performed to identify publishes studies which associated 
gene and protein expression or DNA methylation with surgical debulking outcomes in 
PUBMED using the search terms ((debulking surgery) OR (optimal suboptimal) OR 
(cytoreduct*)) AND (ovarian cancer) AND ((microarray) OR (gene expression) OR (protein 
expression) OR (DNA methylation)). Inclusion criteria for the studies were as follows:  
primary diagnosis of EOC, primary peritoneal or fallopian tube carcinoma, tissue taken from 
patients undergoing primary surgery, optimal and suboptimal debulking categories defined. 
Articles were excluded if they were not written in English, if the study was not performed on 
human tissue, if there were no specific results in relation to surgical outcome, if surgical 
debulking was not defined or if patients had neoadjuvant chemotherapy or interval debulking 
surgery. From inclusive dates of January 1990 to September 2011 the search initially yielded 
144 articles in PUBMED. Inspection of abstracts to exclude publications lacking relevant 
clinical information narrowed the search to 41 potential studies, whose references were also 
searched for any additional relevant studies. 
 
2.4 Clinical data and tissue collection 
2.4.1 CT biomarker study 
Clinical data was collected retrospectively from the West London Gynaecological Cancer 
Centre database on patients with a diagnosis of stage 3 and 4 ovarian, fallopian and primary 
peritoneal cancer who underwent surgery. Data collected included age at surgery, 
histological subtype, stage and grade, timing of debulking surgery, details of operation 
received including any surgery to large or small bowel and residual disease status. 111 
patients undergoing treatment at the centre from August 2001 to June 2010 were randomly 
selected for the test set, and 70 patients undergoing treatment from June 2010 to December 
2012 for the validation set. Their pre-operative CT scans were assessed against previously 
reported criteria (Axtell et al, 2007; Bristow et al, 2000; Byrom et al, 2002; Meyer et al, 1995; 
Nelson et al, 1993; Qayyum et al, 2005; Risum et al, 2008) as being potential indicators for 
resectability by experienced gynaecological radiologists. The radiologists were blinded to the 
surgical outcome of each patient. CT scans were from a variety of referring institutions with 
no standardised protocol or equipment. In general, contrast medium enhanced thin slice 
multidetector CT data was reconstructed in axial and coronal sections for review by 
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radiology. Cut off for the presence or absence of disease was defined by size criteria to 
allow for reproducibility of measurements with, apart from focal lung metastases, 10mm 
being the minimum size for a positive result. The presence or absence of disease was noted 
in these particular regions; lung metastasis (>7mm)(Swensen et al, 2005), pleural effusion, 
diaphragm or superior surface of liver, lateral surface of liver, liver parenchyma, inferior  
surface of liver/ porta hepatis, gastrosplenic ligament, lesser sac, large bowel serosa, small 
bowel serosa, large bowel mesentery, small bowel mesentery, presence of a pelvic mass, 
largest diameter of pelvic mass and  ascites in >4 segments. The presence or absence of 
abnormal pericardiac lymph nodes, mesenteric/ portal nodes, suprarenal paraaortic nodes 
and infrarenal paraaortic nodes were also noted. Lymph nodes were considered abnormal 
when their short axis diameter exceeded 10mm.  
2.4.1.1 Statistics 
Permutation Kruskal Wallis and Pearson chi² tests with 10,000 permutations were used to 
determine whether surgical or clinical characteristics were significantly different from one 
another in the test and validation datasets.   A stepwise logistic regression model was first 
run associating debulking status, coded as suboptimal debulking (defined as residual 
disease >10mm ) versus optimal debulking (residual disease ≤10mm) against all available 
CT anatomical measures and age to find the optimal model based on statistical model fit 
using the Akaike information criterion (AIC).  A logistic regression was then run using the 
most important predictors of surgical debulking as determined by the AIC in the stepwise 
logistic regression.  A log risk score was created for each patient by using the beta 
coefficients from this final logistic model and multiplying them by their corresponding 
covariate.  The log score was then exponentiated to create the final score (as shown in box 
1).  The data was restricted to only those patients with complete observations for the new 
score variable as well as the surgical debulking variable (n= 94/111 patients). A receiver 
operating characteristic (ROC) curve was created depicting the ability of the score to predict 
surgical debulking status. This same predictive score was used in the validation set to 
ensure reproducibility of the score. Statistical analysis was performed in R (version 2.15). 
2.4.2 The Cancer Genome Atlas serous EOC dataset 
The Cancer Genome Atlas (TCGA) is a large-scale collaborative effort supported by the 
National Cancer Institute (NCI) and the National Human Genome Research Institute 
(NHGRI) to systematically characterize the genomic changes that occur in cancer. Data 
consisting of 311 high-grade serous ovarian tumours was obtained from the TCGA data 
portal (http://cancergenome.nih.gov/dataportal). Patients were recruited from the UK and US 
and were included into the data collection with a primary diagnosis of serous ovarian 
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adenocarcinoma at any stage or grade. The patients underwent primary debulking surgery 
and tissue was examined and frozen. Quality control was ensured by pathological 
examination of the tissue, samples were excluded if there was <70% tumour cell nuclei with 
>20% necrosis. Level 2 expression data on Affymetrix HGU133A microarrays, level 3 
methylation data on Illumina Human Methylation27 Beadchip and annotated clinical data 
were obtained. Methylation data had been previously summarized as β values, calculated as 
M/(M+U) where M is signal from methylated beads and U is signal from unmethylated beads 
at the targeted CpG site. The expression microarray data was pre-processed and 
normalised across samples.  
2.4.2.1 Statistics 
Analysis of this data was limited to the 279 patients with stage 3 or 4 serous EOC and 
details describing volume of residual disease. Univariate survival analysis was performed by 
logrank test and multivariate survival analysis by Cox proportional hazard models adjusting 
for clinical characteristics as necessary. Individual generalized linear models were used to 
determine differential gene expression and DNA methylation of specific loci in association 
with surgical debulking status. Multiple comparisons were accounted for in the models using 
false discovery rate estimation to calculate q values. All statistical analyses were performed 
using the R statistical package (version 2.10). 
2.4.3 The Hammersmith Hospital serous EOC dataset 
2.4.3.1 Selection criteria and tumour collection 
Ethics for blood and tumour collection was approved by The Imperial College NHS Trust 
Research and Ethics committee (formally Hammersmith and Queen Charlotte’s NHS Trust) 
reference 05/Q0406/178. Fresh-frozen EOC tumour tissue and formalin-fixed paraffin 
embedded (FFPE) EOC tumour tissue was collected and stored at Imperial College NHS 
Trust Biobank, Hammersmith Hospital from patients who had undergone debulking surgery 
for treatment of EOC. Tissue was included for this work if selection criteria were met: primary 
debulking surgery (no previous chemotherapy), advanced stage disease (FIGO stage 3 and 
4), serous histology, data available on residual disease status and surgery performed. 
Patients were excluded with mixed cell histology or if they did not meet the above selection 
criteria. Additional control samples were collected of benign ovarian and fallopian tube tissue 
from patients who received surgery for benign disease and had no prior history of EOC. In 
order to assess the quality of the individual fresh frozen tissue samples adjacent tissue was 
embedded in optimal cutting temperature (OCT) medium to provide sections for 
histopathology examination. Each sample was reviewed by a gynaecological-oncological 
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pathologist to confirm serous histology and per-cent of tumour nuclei per section. Fresh-
frozen tumour samples were included in analysis if there were ≥20% tumour cell nuclei. 
Those with <20% tumour nuclei, or samples containing borderline tumour were excluded.     
Clinical data was collected on all selected tissue samples including: ethnicity, age at surgery, 
stage and grade of disease, site and size of residual disease,  extent / type of surgery 
performed, adjuvant chemotherapy used and number of cycles, response to chemotherapy, 
CA125 levels pre and post chemotherapy, date of recurrence and death (if appropriate). 
Overall survival (OS) and progression free survival (PFS) were defined as the interval from 
the date of initial surgical resection to the date of last known contact, or death for overall 
survival and the interval from the date of initial surgical resection to the date of progression 
or recurrence for progression free survival. Stage was defined using FIGO criteria 
(International Federation of Gynecology and Obstetrics, 1987). Primary chemotherapy 
response was defined through RECIST 1.1 criteria (Eisenhauer et al, 2009). For RECIST 
response patients were required to have a post-surgical but pre-chemotherapy CT scan, in 
addition to a post-chemotherapy CT scan. CT scans were reviewed by two expert 
independent consultant radiologists at the Imperial College NHS Trust Imaging Department. 
Target and non-target lesions were evaluated before and after adjuvant chemotherapy and 
response was defined as per RECIST 1.1 guidance as described below.  
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph 
nodes must have a reduction in short axis to <10mm. If no target lesions were identified prior 
to chemotherapy CR was defined by a presurgical raised CA125 returning to normal level 
(<35 IU/ml).  
Partial Response (PR): At least 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters. 
Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions. 
In addition the sum must also demonstrate an absolute increase of at least 5mm. The 
appearance of one or more new lesions is also considered progression.  
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum of diameters whole on study. 
2.4.3.2 Statistics 
Kruskal-Wallis and permutation chi2 tests were performed to compare differences between 
groups. Univariate survival analysis was performed by logrank test and multivariate survival 
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analysis by Cox proportional hazard models adjusting for clinical characteristics as 
necessary.  
2.4.3.3 Blood samples 
Matched plasma and peripheral blood mononuclear cells (PBMC’s) archived samples were 
collected for a subset of patients before commencing primary surgery. 20mls of blood was 
collected in heparinised blood collection tubes, and stored at 4°C until ready for processing. 
Blood was centrifuged at 1100xg for 10 minutes and plasma and buffy coat (containing 
PBMC’s) removed from each layer respectively. Due to PBMC contamination difficulties 
experienced on archived plasma samples a prospective cohort of blood samples were 
collected to strict published standard operating procedures (Page et al, 2006). In the 
prospective cohort 20mls of blood was collected into blood collection tubes containing 
EDTA. The samples were then decanted into a 50ml falcon tube and centrifuged 
immediately at 850xg for 10 minutes. The plasma was removed and placed into a clean 
15ml falcon tube and centrifuged again at 850xg for 10 minutes. Following this the plasma 
was decanted into 1ml eppendorf tube leaving any cell debris behind and stored at   -80°C. 
2.4.3.4 Affymetrix HGU133A microarray 
Gene expression data produced by Euan Stronach and Ed Curry at the Ovarian Cancer 
Action (OCA) Centre, Imperial College London was available for analysis. This data was 
generated by the gene expression platform Affymetrix HGU133A. Data from the OCA array 
included 31 tumour RNA samples which were matched to DNA samples on the HH 
methylation array. Data was previously normalised against reference sample cell line PEO1 
and log2 transformed. 
2.4.4 PBMC datasets 
DNA methylation data derived from PBMC’s from normal controls was available for analysis 
from two independent studies. Both sets of data were produced by the Illumina Infinium 
HumanMethylation 450K platform. Only data derived from probes also covered on the 27K 
array was used to ensure consistency with the HH and TCGA 27K arrays. The EPIC study 
(Riboli & Kaaks, 1997) is a multicentre, European prospective cohort study initially designed 
to investigate the relationship between diet, nutritional and metabolic characteristics and life-
style factors and the risk of cancer. Blood sample collection began in 1992 to strict protocols 
and stored for future analysis. Patients have been followed-up for over 10 years to determine 
disease incidence. The Breakthrough Generations Study (BGS) (Swerdlow et al, 2011) was 
a multicentre UK prospective cohort study designed to investigate potential aetiological 
factors causing breast cancer. Blood samples were again, taken, processed and stored to 
66 
 
strict protocols. Follow-up is on-going through questionnaires at intervals of approximately 
every 2.5 years. DNA methylation datasets have been created from both cohorts by others 
and generously made available for use (Brennan et al, 2012). Only PBMC data from healthy 
controls was obtained.  
 
2.5 Clinical material processing 
2.5.1 DNA and RNA extraction (tumour and blood) 
Tumour tissue DNA and RNA extraction was outsourced to Gen-Probe Life Sciences Ltd. Up 
to 500mg of each fresh-frozen tissue sample was transferred to a pre-weighed sterile tube 
and weighed to determine the exact tissue weight. DNA was extracted from all tissue 
samples according to the chlorinated Nucleon extraction method. The tissue samples were 
initially digested using Proteinase K, followed by deproteinsation with sodium perchlorate 
and chloroform. Following centrifugation the DNA separated from the proteinaceous layer, 
which enabled the removal of the aqueous DNA for alcohol precipitation. DNA was 
resolvated in 150-1000ul TE buffer (10mM Tris, 1mM EDTA, pH8). 50–400ul additional TE 
Buffer was added to viscous samples. Up to 100mg of each tissue sample was transferred to 
a pre-weighed sterile tube and weighed to determine the exact tissue weight. RNA was 
extracted according to the Gen-Probe validated Tri-reagent based method. Precipitated RNA 
was resuspended in 50-200ul RNase-free water. Up to 100µg RNA was cleaned up using 
the Qiagen RNeasy Mini kit. 30-80ul RNase-free water was applied to the column to elute 
the RNA. Quantification was performed by Absorbance (OD A260nm) on the Nanodrop 
ND1000 instrument (Thermo Scientific). Two separate 1ul aliquots of neat sample were 
analysed and the mean concentration between the two reads calculated. If the difference 
between the two reads was >20% then a repeat quantification was performed. The 
A260/A280nm and A260/A230nm purity ratios were also determined to ensure a high quality 
sample. 
PBMC DNA was extracted using QIAamp DNA mini-blood kit (Qiagen) according to 
manufacturer’s protocol. Quantification of PBMC DNA was performed by Absorbance (OD 
A260nm) on the Nanodrop ND1000 instrument (Thermo Scientific) as explained above. 
Plasma DNA was extracted using the same kit but with a modified protocol according to 
previously published methods (Page et al, 2006; Shaw et al, 2011). 1000ul starting volume 
of plasma was used after a 3rd centrifugation step once the sample had thawed and ensuring 
not to include any cell debris. The elution volume is modified between 50-100ul. Due to the 
low quantities of DNA within plasma quantification was performed using Quant-iT PicoGreen 
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dsDNA Assay Kit (Invitrogen) as per manufacturers protocol. A standard curve was created 
using standardised samples between 0.05 ng/ul to 50ng/ul and fluorescence determined by 
LUMIstart optima microplate reader (BMG labtech). The standardised samples were plotted 
with fluorescence against concentration and plasma sample concentrations were determined 
by the linear regression equation.  
2.5.2 Bisulphite conversion 
Tumour DNA was bisulphite converted using the EZ-96 DNA Methylation™ Kit (shallow well 
format) (Zymo) for tumour and cell line DNA and EZ methylation-Direct kit (Zymo) for plasma 
DNA as per manufacturers protocol. 1ug of genomic DNA was used for tumour sample and 
between 10 to 200ng for each blood sample. Thermal cycler conditions used were: step 1, 
95°C for 30s, step 2, 50°C for 1hr, step 3, cycle from step 1 x 15, step 4, incubate 4°C 10 
minutes. Following thermal cycling the DNA samples were bound to resin beads in columns 
and desulphonated by desulphonation buffer, followed by washing (clean-up) to remove 
additional reagents and subsequently eluted in 50ul volume. 
Successful bisulphite conversion was confirmed by use of PCR to calponin primers which 
had been previously designed and shown to amplify bisulphite converted calponin 
sequences only (Teodoridis et al, 2005). Agarose gel electrophoresis confirmed the 
presence of PCR product (see pyrosequencing methods for details).  
 
2.6 DNA methylation microarray  
2.6.1 Illumina Infinium Assay Platform; HumanMethylation27 Beadchip 
Samples were processed as per the Infinium Assay Methylation Protocol Guide (Illumina) 
(http://www.illumina.com/products/infinium_humanmethylation27_beadchip_kits.ilmn#docum
entation). 80 malignant samples, 8 benign samples and 8 biological replicates of cell line 
PEO1 were included. Following bisulphite conversion as described above, samples were 
standardised to contain 50ng/ul of DNA and resuspending in DNAse/RNAse free water for a 
total concentration of 200ng per sample. Subsequent preparation was carried out by the 
Genomic Centre, Hammersmith Hospital, Imperial College London. Whole genome 
amplification of the samples was performed followed by end-point fragmentation of the 
amplified DNA, precipitation and resuspension in hybridization buffer. The whole genome 
amplified DNA fragments were hybridized to bead chips with 12 individual samples per chip. 
The fragments annealed to allele and locus-specific oligonucleotides, with methylated 
sequences hybridizing to corresponding methylated beadchip and unmethylated sequences 
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to unmethylated beadchip. Single-base extension with a labelled nucleotide allowed 
detection following fluorescent staining. The chip was scanned and the intensities of the 
methylated and unmethylated bead types measured.  
2.6.2 Quality control and data processing 
Quality control was performed to ensure adequate performance of the array through 
Genome Studio software (for further details see Supplementary data, section 8.1). All 
samples passed quality control analysis. The detection p value was calculated which is the 
confidence that a given probe is methylated above the background signal. Individual sample 
values were removed if the detection p value >0.05, probes were removed if >50% of 
samples had a detection p value >0.05. The β value for each signal was calculated using the 
formula M/(M+U) where M is signal from methylated beads and U is signal from 
unmethylated beads at the targeted CpG site. Therefore a β value of 0 equates to 0% of the 
DNA being methylated and a β value of 1 equates to 100% of the DNA being methylated.). β 
values were adjusted against background noise and data was log transformed to achieve a 
normal distribution. 
2.6.3 Array Statistics 
Statistical analyses were performed using the R statistical package (version 2.10 at 
http://www.r-project.org) and SPSS v19. Permutation Kruskal Wallis and Pearson chi² tests 
with 10,000 permutations were used to determine whether clinical characteristics were 
significantly different between criteria groups. 
Unsupervised hierarchical clustering analysis was used to determine similarities and 
differences of DNA methylation at a genome wide level determined by Euclidian distance. 
Pearson chi² tests were used to determine whether these DNA methylation clusters were 
associated with clinical characteristics of the samples. To determine whether clinical 
characteristics significantly affects differential methylation or gene expression at a probe by 
probe level on the array individual generalized linear regression models with adjustment of 
array batch (plus other clinical characteristics as necessary) were performed. To determine 
whether differential methylation or gene expression at individual probes was associated with 
survival outcomes (PFS and OS) Cox proportional hazard models were performed adjusting 
for array batch (plus other clinical characteristics as necessary). Multiple comparisons were 
accounted for in the models using false discovery rate estimation to calculate q values. For 
methylation data hazard ratios and 95% confidence intervals were derived for an increase of 
methylation by 10%. Thus the hazard ratio was calculated by the exponential of the beta-
coefficient*0.1, exponential of the beta coefficient*0.1 +/- 0.1*1.96*standard error was used 
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to derive the lower and upper 95% confidence intervals. Stepwise regression analysis was 
performed to find the optimal statistical model based on model fit using the Akaike 
information criterion (AIC) to determine which significant survival probes were most 
important in determining survival. A log risk score was created for each patient by using the 
beta coefficients from this final cox model and multiplying them by their corresponding log 
methylation beta value. 
 
2.7 Pyrosequencing  
2.7.1 Primers and PCR 
Primers were designed using Pyromark Assay Design 2.0 to cover selected regions of 
candidate loci and produced by Invitrogen. Four candidate loci were investigated for 
pyrosequencing for genes; HOXA11 (location derived from (Fiegl et al, 2008)), two specific 
CpG sites related to methylation array probes on MSX1 and the MSX1 SNP rs8670. Primer 
sequences are described in Table 2.1. 
Gene Primer Sequence 
HOXA11 
Forward AGTTTTTTTTTTATAGATTTGTTTTGGGAA 
Reverse** ACCACCAAACAAACACAT 
Sequence AGATTTGTTTTGGGAAG 
Sequence to 
analyse 
YGTTTTTGTTTTYGATTTTAGTYGGAATTTTTTYGGGG
TTGAGTTTGAAGTYGTGGATGTGTTTGTTTGGTGGTTT
GT 
MSX1 
cg01785568* 
 
Forward GGGATTTTTTATGTTAGGTGGTATATGT 
Reverse** ATACCTCTAACCCCTTCCA 
Forward GGTGGTATATGTTGTAGTT 
Sequence to 
analyse 
TATATGGGTYGTGTAGAGTTTTAYGGGYGTTATAGGT
AGY GYGGYGYGTTGGAAGGGGTTAGAGGTAT 
MSX1 
cg22609784 
Forward GTGGGGTTAGAGGGTTTT 
Reverse** TCTTTAAATTATCTCAATCCTCTAT 
Sequence GGTTAGAGGGTTTTGG 
Sequence to 
analyse 
YGTTAGGGGTGAA 
MSX1 SNP 
Rs8670 
Forward ATTTTTTATGTTAGGTGGTATATGT 
Reverse** ATACCTCTAACCCCTTCCA 
Sequence GGTGGTATATGTTGTAGTT 
Sequence to 
analyse 
YGATTTGGGATTTTTTATGTTAGGTGGTATATGTT 
 
Table 2.1. Primer sequences of candidate loci for PCR and pyrosequencing. 
* location of probe cg01785568 relates to 1st CpG site in sequence. 
** Biotin labelled primer 
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Primers were reconstituted with DNAse/RNAse free water to acquire concentrations for 
forward and reverse primers of 150ng/ul and sequencing primer of 10umol. Thermocycling 
PCR conditions were optimised using temperature gradients and correct PCR product size 
was confirmed with electrophoresis on agarose gel with comparison to a DNA ladder. For all 
PCR reactions the quantity of dNTP mix (1mM) 0.5ul, forward primer (150ng/ul) 1ul, reverse 
primer (150ng/ul) 1ul, FastStart Taq DNA polymerase (5U/ul) 0.2ul remained the same. 
Quantity of MgCl2 and PCR buffer was 3.5ul for all MSX1 related primers and 2.5ul for 
HOXA11. 1 to 4ul of bisulphite converted DNA was used for each reaction with the addition 
of DNAse/RNAse free water for a final volume of 25ul. 
Thermal cycling conditions were as follows (annealing temperature dependent on specific 
primers); 
Step 1 (denaturation): 95°C for 6mins 
Step 2: 95°C for 30s 
Step 3 (annealing): HOXA11 60°C, for 30s 
   MSX1 cg01785568 61°C, for 30s 
MSX1 cg22609784 52.3°C, for 30s 
MSX1 SNP rs8670 60°C, for 30s 
Step 4 (elongation): 72 °C for 30s 
Repeat steps 2-4 x34 
Step 5 (final elongation): 72 °C for 5mins 
Step 6 (final hold): 4°C 10mins. 
Following PCR the products were run by electrophoresis to ensure product, lack of 
contamination and correct DNA fragment size. 5ul of PCR product and 1ul DNA loading dye 
(ThermoScientific) was run for each sample on 1% agarose (Fisher Scientific) / TBE gel 
containing 2 drops of Ethidium Bromide (Invitrogen) at 100V for approximately 30 minutes. A 
100bp DNA ladder (Invitrogen) was used to ensure correct DNA fragment size dependent on 
assay.   
2.7.2 Pyrosequencing reaction and data analysis 
Following product amplification pyrosequencing was performed as per Pyromark Q96 CpG 
Line-1 handbook available at: 
(http://www.qiagen.com/literature/default.aspx?Term=PyroMark&Language=EN&Literature 
Type=1+2+3+4&ProductCategory=0).  
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10-20ul of PCR sample was prepared for DNA immobilisation with 2ul Streptavidin 
Sepharose HP beads (GE Healthcare), 40ul PyroMark Binding Buffer (Qiagen) and RNase-
free water (to make up to a final volume of 80ul) on a 96 well plate. The PCR product plate 
was then agitated for 10 minutes using a plate shaker at full speed. The pyrosequencing 
plate was prepared with 12ul of PyroMark Annealing Buffer (Qiagen) containing 0.3 
micromolar of sequencing primer. Following agitation the PCR product is captured onto filter 
probes of the Pyromark Q96 Vacuum Workstation tool and then washed with 70% ethanol, 
denaturing solution containing 4g of sodium hydroxide pellets (Sigma Aldrich) in 500mls of 
distilled water and Pyromark Wash Buffer 1x (Qiagen) before being released onto the 
pyrosequencing plate. The plate is then heated to 80°C on a heat block for 2 minutes to 
allow sequencing primer to anneal to the PCR product. The Q96 Reagent and Capillary Tips 
are then loaded with correct volumes of PyroMark Gold Q96 Reagents and dispensation of 
tips tested on an empty pyrosequencing plate.  The pyrosequencing plate (containing 
sequencing primer and PCR product) is then placed within the PyroMark Q96 MD 
pyrosequencer (Qiagen) and the run is commenced. Each pyrosequencing assay containing 
negative water PCR control, plus an unmethylated control generated from whole genome 
amplification of cell line DNA with GenomiPhi V2 amplification kit (Life Sciences) and a 
methylated control, universal methylated DNA (Millipore). Pyrosequencing samples were 
performed in duplicate or triplicate, replicate samples demonstrated reproducibility of 
percentage methylation of <5%. Methylation at individual CpG sites was determined by the 
Pyro Q-CpG pyrosequencing software. The programme calculates the ratio of unmethylated 
cytosines (thymine base following PCR amplification) to methylated cytosines (remains as a 
cytosine) at each individual CpG site to give a quantitative output of DNA methylation.  
2.7.2.1 SNP analysis 
The Pyromark Q96 was used to sequence individual tumours at SNP rs8670. For each 
sequence the individual base peak heights were used to determine the ratio of G to A bases. 
This enabled identification of the presence of a SNP and if present whether it was on one or 
both alleles.   
 
2.8 Real Time - PCR  
Copy DNA (cDNA) was produced using SuperScript VILO cDNA Synthesis Kit (Invitrogen) 
as per manufacturers protocol. 2ug of original RNA was used for each reaction in a total of 
20ul volume thus final concentrations of cDNA were 100ng/ul. Further dilutions were created 
prior to Real-Time PCR (RT-PCR) as required. The Fast Optical 96 well reaction plate 
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(Applied Biosystems was setup as per manufacturers protocol using Taqman Gene 
Expression Assays; MSX1 (Hs00427183_m1), CDKN1A (Hs00355782_m1 ), BAX 
(Hs00180269_m1) and endogenous control Human ACTB (β actin), VIC (Applied 
Biosystems).  Each reaction contained 100ng of cDNA, 10ul of Taqman Gene Expression 
MasterMix (Applied Biosystems) and 1ul Taqman Gene Expression Assay (applied 
Biosystems).  Target gene and endogenous controls were performed in triplicate for each 
sample in separate wells. Each RT-PCR reaction also had the addition of a negative water 
control to ensure no contamination within the samples. The plate was then run on the 
StepOnePlus Real-Time PCR Systems (Applied Biosystems) with standard thermocycling 
conditions; Step1: 50°C for 2 minutes 
Step 2: 95°C for 10 minutes 
Step 3: 95°C for 15 seconds 
Step 4: 60°C for 1 minute 
Repeat step 3-4 for 40 cycles. 
Quality control was performed through StepOnePlus Real-Time PCR Systems software 
(Applied Biosystems), efficiency of each reaction was ≥90%. The threshold for target gene 
and endogenous control was determined through the software analysis and threshold Ct 
determined for each sample. ΔCt was calculated by the Ct of target gene normalised to 
(minus) the Ct of endogenous control for each sample. Relative change calculated by 2-ΔΔCt 
(ΔΔCt calculated by the ΔCt of the sample normalised to (minus) the ΔCt of the reference 
sample). Statistical analysis was performed using two-tailed, unpaired t-test with unequal 
variance when comparing different cell lines and one-tailed, unpaired with equal variance t-
test when comparing transfected cell lines to each other. In relevant results figures, n= refers 
to the number of independent biological replicates. 
 
2.9 Cell line work 
2.9.1 Cell lines 
All cell lines were obtained from the Epigenetic group, Division of Cancer, Imperial College 
London, liquid nitrogen cell line store and described below. Cell lines were authenticated by 
STR DNA profiling performed by Genetica DNA Laboratories USA, with comparison to the 
reference database https://www.atcc.org/STR_Database.aspx for A2780/CP70 and previous 
publications for the other cell-lines not included in the database (McKie et al, 2012).  
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Cell line Description 
A2780 Unspecified cancer line (commonly used in the literature to represent 
epithelial ovarian cancer). Cisplatin sensitive. 
cp70 In vitro derived cisplatin resistant cell line, derived from A2780. Official name 
A2780/cp70. 
PEA1 Epithelial ovarian cancer cell line from patient with poorly differentiated 
adenocarcinoma prior to treatment. Cisplatin sensitive. 
PEA2 Derived from the same patient as PEA1 after treatment and relapse. Cisplatin 
resistant. 
PEO14 Epithelial ovarian cancer cell line from patient with well-differentiated serous 
adenocarcinoma. Cisplatin sensitive. 
PEO23 Derived from the same patient as PEO14 after treatment and relapse. 
Cisplatin resistant.  
 
2.9.2 Cell culture 
All cell culture was performed under aseptic technique using sterile plastic ware in a class II 
microbiological safety cabinet with vertical airflow. Cell lines were grown and maintained in 
RPMI 1640 Medium (Sigma) which contained 10% Foetal calf serum (FCS) (First link UK) 
and 2mM L-Glutamine (Gibco). Cells were grown at 37°C in a tissue culture incubator with 
5% CO2. Cell lines were grown in tissue culture flasks at a variety of sizes depending on 
need. Cell lines were passaged using 1% Trypsin in EDTA (Sigma) when confluency 
reached 70-80%. Cell count was determined using a haemocytometer and Trypan blue 0.4% 
(Gibco) at 1:1 ratio. When not in use, cell lines were stored in cryogenic vials at 
approximately 4.0x106 cells containing 10% Dimethyl sulphoxide (DMSO)(Thermo Scientific) 
in FCS, stored in Cryo-freezing container (Nalgene) at -80 C and then transferred to liquid 
nitrogen storage tank. Mycoplasma testing was performed on cultured cells on a monthly 
basis and results were always negative. 
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2.9.3 DNA, RNA and protein extraction 
Cells were removed from culture for DNA, RNA and protein extraction at 80% confluency 
using 1.2-4.6 x106 cells depending on requirement. Cells were trypsinised and then washed 
with cold PBS twice with centrifugation at 5000g at 4°C between steps. QIAamp DNA Mini 
Kit (Qiagen) and QIAshredder and RNAeasy Mini Kits (Qiagen) was used for DNA and RNA 
extraction respectively according to manufacturer’s protocol.  Protein extraction was 
performed using Pierce RIPA buffer (Thermo Scientific) containing Protease inhibitor 
(Sigma) 1:100, Phosphatase Inhibitor Cocktail 2 (Sigma) 1:100 and Phosphatase Inhibitor 
Cocktail 3 (sigma) 1:100 as per protocol. 150-300ul of RIPA buffer containing inhibitors was 
added to each tube and pipetted up and down several times for cell lysis. The tubes were 
then kept on ice for 15 minutes before centrifugation at full speed at 4°C. The cell debris was 
then removed from the tube and samples stored at -80°C. 
2.9.4 shRNA knockdown and re-expression vector transfection  
Stable knockdown of MSX1 was achieved using pGFP-V-RS vector containing MSX1 short 
hairpin RNA insert (HuSH shRNA plasmids (Origene)). Four plasmids containing unique 
constructs per gene were obtained in addition to 2 control vectors one containing a purified 
and sequence-verified plasmid without the shRNA cassette and another containing the 
plasmid and a non-effective 29-mer scrambled shRNA cassette. Origene vectors contained 
a kanamycin resistant gene for bacterial selection, a puromycin resistant gene for cell-culture 
selection and a GFP gene to monitor transfection efficiency (Figure 2.1A). Re-expression 
plasmid pcDNA3-msx1-mER was obtained by kind donation from Dr Cory Abate-Shen 
(Columbia University, USA) and methods described in (Hu et al, 2001). This vector 
contained ampicillin resistance for bacterial selection and geneticin (neomycin) resistance for 
cell-culture selection (Figure 2.1B). Plasmids were cloned and amplified using One Shot 
Mach1-T1R Chemically Competent E-coli (Invitrogen) as per protocol. 50ng of each unique 
plasmid was mixed into a vial of One Shot cells and incubated on ice for 30 minutes. Each 
vial was then heat-shocked for 30 seconds at 42°C and then returned to ice for 2 minutes. 
Bacterial clones were then incubated at 37°C overnight on agar plates containing selective 
antibiotics depending on vector resistance. Individual bacterial clones were then seeded in 
LB culture medium containing 0.1mg/ml ampicillin (Sigma) or 25ug/ml kanamycin (Gibco) 
and grown at 37°C on a plate shaker for 16-24hrs. Plasmids purification was performed 
using HiSpeed Plasmid Midi Kit (Qiagen) as per protocol. The DNA sequences of the 
plasmid constructs were confirmed by DNA sequencing of the shRNA insert performed by 
Beckman Coulter Genomics. For the Origene MSX1 knockdown vectors the shRNA insert is 
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2.9.5 Cell proliferation, apoptosis and clonogenic assays 
Cells were seeded at 15,000 cells per well in triplicate in 96 well flat bottomed cell culture 
cluster plate (Corning). After 24 hours cells were treated with Cisplatin at concentrations of 0 
micromolar to 60 micromolar (100ul per well) for 24 hours. Apoptosis was quantified using 
Caspase-Glo 3/7 Assay (Promega) after 24 hours of cisplatin treatment. 50ul of reagent was 
added to each well containing 50ul of media and luminescence read after 2 hours of 
incubation at room temperature using the LUMIstar optima plate reader (BMG labtech). Cell 
proliferation was quantified with MTT assay after a further 48 hours of culture after 24 hours 
of cisplatin treatment using CellTitre 96 Aqueous One Solution Proliferation Assay 
(Promega). 20ul of reagent was added to each well containing 100ul of media and 
colorimetric assay absorbance read using the OPTImax microplate reader (Molecular 
diagnostics) at 490nm after 2 hours incubation at 37°C. Values from a mean blank 
measurement (3 wells without cells containing media and assay) were subtracted from each 
absorbance reading and then normalised to each individual cell line at 0 micromolar.   For 
clonogenic assay, cells were seeded at 1,000 cells into a 10cm Petri-dish containing 8mls 
media, in duplicate. Cells were treated with a variety of cisplatin doses for 5 days and then 
cultured in fresh media for an additional 5 days. Media was removed and then washed twice 
with 5ml of PBS. Plates were fixed and stained using 100% methanol followed by Crystal 
Violet (Merck) 1% in 25% methanol, and each colony was counted per dish. All assays were 
normalised to each individual cell line at 0 micromolar, statistical significance was 
determined by unpaired two-tailed t-test, unequal variance. In relevant results figures, n= 
refers to the number of independent biological replicates. 
2.9.6 Expression of p53 downstream transcripts 
This work was performed in collaboration with Daisy Gooch, MRes student. To determine 
the expression of CDKN1A (also known as p21) and BAX in re-expression transfected cells, 
high and medium expression transfects and control cell lines were plated in a 6 well culture 
dish at 3x105 cell per well. After 24 hours either 10 or 25 micromolar concentration of 
cisplatin was added to the cells and incubated at 37°C for 24 hours. Following this RNA was 
extracted and mRNA gene expression was determined as described above.   
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2.10 Protein expression analysis 
2.10.1 Western Blotting 
Western blotting was performed to standard protocols. Protein concentration was 
determined using Pierce BCA protein assay kit (Thermo Scientific) and protein standards 
supplied. 200ul of BCA (containing 50 parts Reagent A to 1 part reagent B) was added to 
10ul of samples and standards. The colour change was read using OPTImax microplate 
reader (Molecular diagnostics) after 30 minutes incubation at 37°C at 560nm wavelength. 
The linear regression line of the standards was calculated to determine concentration of 
individual protein samples. Samples were purified and standardised by using 40ug of protein 
with NuPAGE Sample Reducing Agent 1x (Novex), NuPAGE LDS Sample Buffer 1x (Novex) 
1:4, and incubated at 90°C for 10 minutes.  
Samples were loaded onto NuPAGE 4-12% Bis Tris Gel (Novex) in Xcell SureLock Mini Cell 
gel tank (Novex) containing NuPAGE MOPS SDS Running Buffer 1x (Novex) at 200V for 1hr 
30mins. Samples were transferred onto PVDF membrane which had been previously soaked 
in 100% methanol using NuPAGE Transfer Buffer 1x (Novex) containing 10% methanol at 
30V for 1hr 30mins. For MSX1, blots were incubated overnight at 4°C in blocking buffer 
(containing 5% milk powder in Tris Buffered Saline with Tween 20 (TBS-T) 1x) and MSX1 
(F22) rabbit polyclonal IgG antibody (Santa Cruz) 1:200 followed by 1hr incubation in 
polyclonal anti-rabbit Ig HRP (Dako) 1:2000 for MSX1 blot (estimated MW 30.9 kDa). For 
endogenous control β-Actin, blots were incubated in blocking buffer overnight followed by β-
Actin mouse IgG (Santa Cruz) 1:10000 for 1 hour and Goat anti-mouse IgG HRP (Santa 
Cruz) 1:3000 for 1 hour (estimated MW 42 kDa). Blots were developed using Pierce ECL 
Western Blotting Substrate (ThermoScientific). Exposure time for β-Actin was 5 seconds and 
for MSX1 between 1 to 2 minutes. As both MSX1 and β-Actin have similar molecular weights 
blots were stripped using Restore PLUS Western Blot Stripping buffer (Thermo Scientific) 
prior to β-Actin blot.  
2.10.2 Immunohistochemistry 
FFPE tumour samples from patients whose fresh-frozen tumour DNA was included on the 
Infinium methylation array were identified for immunohistochemistry (IHC). All preparation 
and processing of the samples was performed by Dr Jenny Steel in collaboration with the 
Imperial Cancer Biomarker Resource Centre. FFPE blocks were cut to a thickness of 5 
microns and sections mounted on microscopy slides. Sections were deparaffinised by 
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immersing in Histo-clear (National Diagnostics) and rehydrated by immersing in 70% ethanol 
followed by distilled water. Antigen retrieval was performed by placing the slides in citrate 
buffer pH 6.0 and heating in the microwave for 15 minutes, followed by immediate immersion 
in cold distilled water. Blocking to endogenous peroxidase was performed by immersing the 
slides in PBS with 0.3% hydrogen peroxide for 15 minutes. Subsequently slides were 
incubated with rabbit serum (Sigma-Aldrich) 2:100 in PBS at room temperature for 30 
minutes to prevent non-specific antibody binding. Anti-MSX1 primary antibody (ab93287, 
Abcam) was diluted in PBS (1:1500) and incubated with the slides overnight at 4°C. 
Following this, secondary antibody with biotinylated rabbit, anti-goat Ig (Vector laboratories), 
diluted with PBS (1:200) was applied and incubated for 30 minutes at room temperature. 
Staining was achieved using VECTASTAIN Elite ABC kit (Vector Laboratories) 1:100 in PBS 
and ImmPACT DAB (Brown) (Vector Laboratories) for 1 minute as per manufacturers 
protocol. Cell nuclei are then counterstained with haematoxylin solution (Sigma-Aldrich) 
followed by dehydration through ascending concentration of ethanol and Histo-clear 
(National Diagnostics). Finally the slides were mounted using DPX-Mountant (Sigma-
Aldrich). 
Following staining, slides were scored for protein expression by the degree of staining by Dr 
Mona El-Bahrawy, Consultant Histo-pathologist. An overall assessment of each slide was 
made subjectively scoring each individual slide as weak, moderate or strongly staining. Dr 
El-Bahrawy was blinded to the clinical outcome of the patients.    
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Chapter 3: Determining clinical and molecular biomarkers 
associated with cytoreductive surgical outcomes 
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3.1 Introduction 
This chapter explores the association of clinical and biological variables with surgical 
success in EOC. The first aim was to determine whether surgical outcome could be 
predicted from computed tomography (CT) images determining anatomical location of 
disease prior to debulking surgery in a discovery and validation clinical dataset. The second 
aim was to validate biomarkers associated with surgical debulking in previously published 
literature using the high-grade serous EOC TCGA dataset (Borley et al, 2012).   
 
3.2 Background 
As previously discussed in the introduction, surgical debulking outcome is currently the most 
important prognostic indicator for patients being treated for EOC with a consistent significant 
association of OS and PFS with residual disease status (Eisenhauer et al, 2008). Therefore 
the aim for all patients undergoing primary surgery for EOC is maximum removal of disease 
at all sites (Pomel et al, 2008). Although achieving complete macroscopic debulking of an 
ovarian tumour may be routine in early stage disease it becomes much more difficult in 
advanced disease. Primary surgery normally involves, total abdominal hysterectomy, 
bilateral salpingoophrectomy, omentectomy (with or without lymphadenectomy), however as 
at least two-thirds of patients present with advanced disease more aggressive surgery is 
often required in order to achieve maximal debulking. This can include peritoneal and 
diaphragm stripping, splenectomy and bowel resection. Unfortunately this process is 
associated with increased morbidity to the patient and despite more radical surgery; surgical 
success is not always guaranteed. Rates of optimal surgical debulking differ between 
centres and countries but ranges from 58.4%-71.3% (Crawford et al, 2005) (optimal 
debulking defined in this study as <2cm residual disease) and results from multicentre 
randomised clinical trials (RCTs) suggest that UK debulking rates are inferior to other 
countries (Crawford et al, 2005; Vergote et al, 2010). Various reasons for the lower UK 
debulking rates have been cited including inadequate training, insufficient resources 
including theatre time and perioperative care and medico-legal concerns, fear of 
complications and lack of accountability (Naik et al, 2008). The benefits of being able to 
predict surgical debulking success would be two-fold; 1) Patients who were given a high 
probability of achieving surgical debulking would been given the appropriate resources to 
achieve this such as experienced appropriately skilled surgeons, adequate operating time 
and intensive care facilities, with additionally improved pre-operative counselling. 2) Those 
that were predicted as having a low probability of surgical success could be offered 
neoadjuvant chemotherapy with interval debulking and would be spared an unnecessary 
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open & close laparotomy which delays time to receiving chemotherapy. As discussed in the 
introduction of this thesis, imaging modalities have also been investigated in relation to 
accuracy of prediction of surgical debulking (Axtell et al, 2007; Bristow et al, 2000; Dowdy et 
al, 2004; Jung et al, 2010a; Lenhard et al, 2008; Meyer et al, 1995; Nelson et al, 1993; 
Qayyum et al, 2005; Risum et al, 2008; Salani et al, 2008). Most studies are retrospective 
and are heterogeneous in design, thus better predictors of surgical success are needed. If 
these predictors were successful, patients predicted to have a poor surgical outcome would 
avoid unnecessary surgery and be correctly stratified into neoadjuvant chemotherapy 
treatment pathways. 
3.2.2 Aims 
The aim of this work was thus to assess the role of CT in the pre-operative prediction of 
debulking status in patients with advanced EOC in the UK using statistical models and 
validate the findings with current data which is representative of surgical practises and 
debulking rates in the UK today. 
 
3.3 Results 
3.3.1 Prediction of surgical debulking from preoperative imaging 
3.3.1.1 Patient characteristics 
Table 3.1 illustrates the patient characteristics for both the test set (n=111) and the validation 
set (n=70). This study is therefore one of the largest studies to date, compared to the 
previous published literature (range of number of cases in previous studies n=28 to n=180) 
(Table 3.1). All patients had stage 3 or 4 disease. In the test set the majority of patients had 
ovarian (97.3%), serous (81.1%), high grade (grade 2 and 3, 90.1%) histology and had 
undergone primary debulking surgery (92.8%). In the validation set, 84.3% had serous 
histology and 92.9% were high grade. There was no statistical difference between disease, 
histology or stage in the test set and validation set.  There was a significant difference in 
residual disease status between patients in the test set and validation set (p<0.001). Optimal 
debulking rates (residual disease ≤ 10mm) and complete debulking rates (no macroscopic 
residual disease) dramatically improved over time in the study. The optimal debulking rate 
improved from 46.8% in the test set to 75.7% in the validation set and total macroscopic 
debulking from 30.4% to 54.3% respectively. This difference adds additional benefit to the 
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study to ensure anatomical markers of debulking are independent of surgical effort and 
relate to current surgical practise.   
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Patient characteristics 
Mean or n (%) Mean or n (%) p-
value* 
Test set n=111 Validation set n=70 
Age  (range) 61.6 (31-92) 61.3 (22-85) 0.73 
Date of surgery Aug 2001-Jun 2010 
Jun 2010 - Dec 
2012 NA 
Disease 
Ovarian 108 70 
0.29 Fallopian 1 0 
Peritoneal 2 0 
Histology 
Serous 90 59 
0.57 
Clear 5 3 
Endometrioid 5 0 
MMMT 1 0 
Mucinous 3 2 
Other  7 5 
Stage 
3A 3 5 
0.3584 
3B 7 8 
3C 61 34 
3(unknown) 1 0 
4 39 23 
Grade 
1 6 5 
0.02 
2 22 4 
3 78 61 
unknown 5 0 
Debulking 
Primary 103 70 
0.06 Interval 6 0 
Secondary 2 0 
Residual disease 
0mm 34 38 
<0.001 
1-10mm 18 15 
>10mm 46 17 
Unresectable disease 13 unknown 
Debulking rate 
Optimal  46.80% 75.70% NA 
Total 30.40% 54.30% NA 
Bowel surgery 
No 91 Unknown NA 
Yes 20 Unknown NA 
 
Table 3.1. Patient characteristics in CT prediction study test set and validation set 
* p value derived by Kruskal Wallis test and Pearson chi² test using 10,000 permutations   
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3.3.1.2 Determining sites of disease related to debulking outcome 
In order to establish whether findings on preoperative CT scans were associated with 
debulking outcome (optimal versus suboptimal debulking) a stepwise logistic regression 
model was performed to find the best model fit. Using this model, the presence of lung 
metastasis >7mm, pleural effusion, deposits which were >10mm on the large bowel 
mesentery and small bowel mesentery and infrarenal paraaortic nodes were associated with 
debulking status. A greater proportion of patients who were suboptimally debulked had 
disease in these sites compared to those optimally debulked. In the suboptimal group 5.8% 
had lung metastasis, 38.5% had pleural effusions, 36.5% had large bowel mesentery 
deposits, 21.2% had small bowel mesentery deposits and 26.9% had inferior renal 
paraaortic lymph nodes compared to 0%, 14.3%, 16.7% and 4.8% and 21.4% respectively in 
the optimally debulked group (Table 3.2).  
The effect estimates (beta coefficients) from these covariates were calculated using logistic 
regression modelling (Table 3.2) which enabled a surgical predictive score to be generated 
for each individual. The continuous prediction score was able to predict suboptimal 
debulking with an AUC of 0.749 (95%CI 0.652, 0.846) (Figure 3.1A). Patients were 
categorised into being above and below the median score (median=1.563). The predictive 
score above the median was able to significantly predict suboptimal debulking (OR=5.62, 
n=94, p=0.0001) with a sensitivity of 69.2% and a specificity of 71.4% a positive predictive 
value (PPV) of 75.0% and a negative predictive value (NPV) of 65.2%. Box 3 illustrates how 
this logistical regression model is used with an example.  
The prediction score was successfully validated in the validation set. As expected again a 
higher burden of disease was observed in the suboptimally debulked group with more 
patients having disease on each site compared to the optimally debulked group (Table 3.2). 
The previous prediction score was used, as before from the model beta coefficients (Box 3), 
to generate an individual risk score for each case and were also grouped by the individual 
score being above or below the test set median score. In the validation set a predictive score 
above the median was able to predict suboptimal debulking with a sensitivity of 64.7% and a 
specificity of 67.9%. The continuous score generated an AUC 0.721 (95% CI 0.594, 0.847) 
(Figure 3.1B).  The ability of the predictive score to predict total macroscopic debulking 
(0mm residual disease) compared to debulking with residual disease ≥1mm was also tested. 
This had a sensitivity of 65.6% and a specificity of 80% in the test set and a sensitivity of 
50.0% and a specificity of 68.4% in the validation set.  
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Table 3.2. Summary of CT scan covariates identified by stepwise logistic regression model associated with suboptimal debulking. 
Beta coefficients (effect size), percentage and number of cases of disease site (in parentheses) per group for both the test set and validation 
set. 
  
Test set (n=94) Validation set (n=70) 
Covariates 
Beta 
coefficients 
Optimal 
debulking 
(n=42) 
Suboptimal 
debulking 
(n=52) 
Optimal 
debulking 
(n=53) 
Suboptimal 
debulking 
(n=17) 
Intercept -1.15  
lung metastasis (>7mm) 16.394 0.0% (0) 5.8% (3) 7.5% (4) 11.8% (2) 
pleural effusion 1.915 14.3% (6) 38.5% (20) 15.1% (8) 41.2% (7) 
large bowel mesentery (>10mm) 1.597 16.7% (7) 36.5% (19) 45.3% (24) 76.5% (13) 
small bowel mesentery (>10mm) 2.302 4.8% (2) 21.2% (11) 9.4% (5) 23.5% (4) 
infrarenal paraaortic lymph node 1.088 21.4% (9) 26.9% (14) 17.0% (9) 23.5% (4) 
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Figure 3.1. ROC curve for CT logistic regression score to predict surgical debulking. 
A, test set. B, validation set. 
 
A 
B 
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Box 3 Logistic regression model for prediction of surgical success and a worked example 
 
 
 
 
 
 
 
 
 
 
For example Mrs P a 65 year old with stage 3C disease on CT disease present on large 
bowel mesentery and inferior renal paraaortic lymph node involvement 
Log score = -1.15 + 1.5965 + 1.08883 
Log score = 1.53533 
Score = 4.643 = high risk of suboptimal debulking  
 
  
If disease present; score=1 or absent; score=0 at each individual site. 
A=Lung metastasis  
B=Pleural effusion 
C=Large bowel mesentery 
D=Small bowel mesentery 
E=Inferior renal paraaortic lymph node  
 
Log score = -1.15 + 16.394(A) +1.9150(B) + 1.5965(C) +2.3020(D) + 1.0883(E) 
Log score =n 
Score = exp(n) 
A score >1.563 indicates high risk of suboptimal debulking, a score < 1.563 indicates low 
risk of suboptimal debulking.  
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3.3.1.3 Discussion 
In previously published studies (Table 1.1) the presence of disease in the upper abdomen, 
large volume of ascites and bowel mesentery involvement were often associated with 
suboptimal debulking status. This analysis found that the presence of lung metastasis, 
pleural effusion, deposits on the large bowel mesentery and small bowel mesentery and 
infrarenal paraaortic nodes were associated with suboptimal debulking. In contrast to 
previous studies, upper abdominal disease was not associated with suboptimal debulking in 
the test set. This may be due to an increase in extensive upper abdominal resections at the 
centre. Additionally as diaphragmatic involvement often presents as miliary disease, these 
patients may have achieved optimal debulking despite disease being present on CT scan. 
One of the key issues in predicting debulking is the ever-changing surgical goal with inherent 
variation on what accounts for truly resectable disease. Factors that reduce the likelihood of 
achieving successful cytoreduction previously cited include; diffuse small bowel involvement, 
infiltration into the porta hepatis and diffuse involvement of the right hemi diaphragm 
resulting in fixation of the liver (Pomel et al, 2008) or large liver metastasis (Chi & Schwartz, 
2008). Patient age, comorbidities and intensive care availability will also impact on outcome. 
Furthermore what was deemed as unresectable disease in the year 2000 has now become 
resectable through the development and emphasis of supraradical surgery (Chi et al, 2009a; 
Kehoe et al, 2008). This means that prior models of prediction become obsolete. These 
findings were validated in an independent dataset from patients recently treated at the centre 
and therefore suggest it is more current and clinically relevant. During the time course of this 
study there was a significant improvement in surgical debulking rates, with an improvement 
of optimal debulking from 46.8% to 75.7% and complete debulking from 30.4% to 54.3%. 
The model remains significant despite this change which indicates that these prediction 
markers are likely to be truly representative of being unable to achieve optimal debulking 
irrespective of surgical effort. The debulking rates at the centre are in line with other UK 
based cancer centres both historically (Crawford et al, 2005; Naik et al, 2010; Perren et al, 
2011) and in the current era of supraradical surgery (Doufekas et al, 2012; Naik et al, 2008). 
This adds evidence that our prediction model can be translated to other centres.  
Why the particular sites of disease (lung metastasis, pleural effusion, deposits on the large 
bowel mesentery and small bowel mesentery and infrarenal paraaortic nodes) are more 
associated with suboptimal debulking than others is unclear. It seems logical that deposits of 
>10mm on large and small bowel mesentery are associated with higher rates of suboptimal 
debulking if disease at this site is so extensive that disease clearance would require multiple 
(or complete) bowel resection. The appearance of infrarenal paraaortic nodes over other 
nodal disease to be strongly associated with suboptimal debulking is also of curiosity. 
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Although there were a larger proportion of cases with mesenteric or portal vein nodes in the 
suboptimal group compared to the optimal group (12/52, 23.1% versus 6/42, 14.3%) the 
model did not find this to be an indicator. There were only 5 cases of suprarenal paraaortic 
node involvement in total so for this disease site the analysis may not be adequately 
powered to determine a specific association. The involvement of these nodal sites and the 
presence of disease in the lung may simply be indicators of extensive and biologically 
aggressive disease making optimal resection within the abdomen less likely. There may well 
be inherent biological factors within these tumours which dictate specific spread and 
invasion to these sites and thus it is less the anatomical site per se that dictates the surgical 
outcome and more the biology of the disease. This may also explain the survival benefit 
experienced in those who undergo more successful surgery. Two possible causes for this 
survival benefit have been discussed (Chi & Schwartz, 2008); 
1) That with minimal residual disease there are fewer malignant cells present and 
thus improved subsequent ability for chemotherapy to reach the centre of the tumour. 
2) An intrinsic biological element of the tumour cells leads to a less aggressive, less 
invasive disease which incurs a survival advantage and additionally allows a more 
successful surgical outcome. 
If it were indeed biological factors which dictated survival, identification of those targets 
would be not only be prime therapeutic candidates but may also aid in the prediction of 
surgical success allowing personalised treatment stratification and improved surgical 
planning. Therefore validation of the biomarkers associated with surgical debulking found 
from a systematic review of the literature (see introduction section 1.4.3) was performed to 
explore this possibility further. 
 
3.3.3 Validation of targets identified through TCGA dataset 
Validation of the candidate genes and proteins identified in the published data (Tables 1.2, 
1.3 and 1.4) was attempted using the TCGA dataset. Data was available on 279 patients 
with stage 3 or 4 serous EOC who had details of residual disease volume. 36 gene 
expression probes were found to cover the individual gene and proteins previously identified 
as being significantly associated with surgical debulking (Table 1.2 and 1.3). There was no 
coverage of the genes SRA or BCAR1 (encodes protein P130cas). The list of 120 genes 
significantly associated with debulking status found (Berchuck et al, 2004), was not validated 
as the gene expression probe IDs were not made publically available. Using individualized 
linear models adjusting for microarray batch, age and stage and adjusting for multiple 
90 
 
comparisons using false discovery rate (FDR), 2 probes; MTDH (probe ID ‘212250_at’) and 
IGF1R (probe ID ‘208441_at’) were found to be significantly differentially expressed (p<0.05, 
FDR <5%) associated with optimal (≤1cm residual disease) or suboptimal (>1cm residual 
disease) surgery. MTDH, which tencodes AEG-1 protein, demonstrated increased gene 
expression in those suboptimally debulked compared to those optimally debulked (p=0.002, 
FDR 3.7%). This correlates with the previous data which found increased protein expression 
of AEG-1 was associated with suboptimal debulking (Li et al, 2011). IGF1R expression was 
found to be significantly decreased in those with suboptimally debulked disease (p=0.0004, 
FDR 1.4%). This contrasts to previously reported data (An et al, 2009) which found a 
significant association with increased gene expression of IGF1R and suboptimal debulking 
(>1cm residual disease). 
The TCGA survival data in relation to residual disease is not in keeping with previous 
published evidence and international agreement (to be discussed in more detail in Chapter 
4, section 4.3.1.5). Residual disease is not significantly associated with OS or PFS in this 
dataset, however there is a trend for improved survival when comparing total macroscopic 
debulking (0mm disease) versus ≥1mm macroscopic residual disease. Therefore the 
analysis was repeated with these criteria. In this analysis all three MTDH probes were 
significantly differentially expressed (p<0.05, FDR<5%) between groups (probe ID 
‘212251_at’ p=1.02E-05, q=0.0004, probe ID ‘212250_at’ p=0.0002, q=0.004, probe ID 
‘212248_at’ p=0.001 q=0.01). 
The TCGA DNA methylation data was used in an attempt to validate the previous published 
findings that differential methylation of HOXA11 was significantly associated with residual 
disease (Fiegl et al, 2008). Using individualized linear models adjusting for microarray batch, 
age and stage there was no significant difference in methylation between the optimal or 
suboptimal groups (p=0.681) or between those with ≤2cm residual disease or >2cm residual 
disease (p=0.559) as defined in the original study. Pyrosequencing primers were designed 
to explore this locus of interest further using the HH samples. However again there was no 
significant difference in methylation within the surgical debulking groups in univariate 
analysis. Samples taken from patients with 0mm residual disease (n=19) demonstrated 
slightly higher methylation compared to those with residual disease (n=63) but this was not 
significant (median methylation: 39.14% vs. 31.40%, p=0.640) and did not correlate with the 
previous findings of lower methylation in the <2cm residual disease group. Further analysis 
did not show a significant difference in these 2 groups (median methylation in 0-20mm 
group, 32.20% vs. >20mm group, 33.17%, p=0.423). There was also no significant 
difference in methylation when comparing surgical volume groups 0mm vs. 1-10mm, vs. 11-
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20mm, vs. >20mm (median methylation; 39.14% vs. 27.72% vs. 21.26 vs. 33.17%, 
p=0.681).  
3.3.3.1 Discussion 
Validation of the previous published literature has been poor with significant differential 
expression at p<0.05 and FDR <10%, only seen in 2 out of 36 available gene expression 
probes in TCGA data between optimal and suboptimal groups. Only one of these, 
determining expression of MTDH (also known as AEG-1) was found to correlate to the 
previous published study. Up regulation of MTDH has been found to inhibit apoptosis and 
increase the invasive ability of malignant cells (Emdad et al, 2007; Liu et al, 2010) and is 
involved in angiogenesis (Emdad et al, 2009). There are however several limitations to the 
published studies and so lack of validation may be in part to poor study design. Previous 
studies have been heterogeneous in design, were not primarily designed to answer the 
debulking question and do not fully fulfil REMARK criteria (McShane et al, 2005). The 
REMARK report stated the importance of transparent and complete reporting in the 
publication of research on tumour markers, highlighting the need for clear descriptions of 
patient and specimen characteristics, assay methods, study design and statistical analysis. 
In the majority of previous studies, early FIGO stage disease has been included in analysis. 
By its very definition; of disease confined to the ovary or pelvis (International Federation of 
Gynecology & Obstetrics, 1987), stage 1 and 2 disease can always or almost always be 
completely excised. Consequently a much higher proportion of optimally or total 
macroscopic debulked tumours will occur in those with early stage disease (Wimberger et al, 
2007). This is not adjusted for in the majority of analysis and thus any differences may be 
due to association to stage and metastasis rather than surgical outcomes. EOC is not a 
single disease entity but a general term applied to a distinct set of cancers which share an 
anatomical location (Vaughan et al, 2011), and therefore the majority of previous studies 
have extremely heterogeneous samples included. Interestingly, the study with the most 
homogenous of tumour samples; high grade, high stage serous EOC (Bonome et al, 2008) 
did not find any statistical significant differences in gene expression microarray between 
patients who were optimally and suboptimally debulked.   
There is also discrepancy between studies when defining surgical groups, with suboptimal 
debulking described as residual disease greater than 1 or 2cm. Much emphasis is now 
placed in achieving total macroscopic debulking (microscopic residual disease) with clear 
survival benefits (Winter et al, 2008). This would also be a more suitable classification for 
molecular studies because a category of presence or absence of macroscopic residual 
disease is likely to be less susceptible to errors in measurement. As the TCGA dataset did 
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not show a significant difference in terms of survival between optimal and suboptimal 
debulking but did show a trend for improved survival in total macroscopic debulked group the 
analysis was repeated with this new classification. This may explain the addition of 2 further 
MTDH gene probes in TCGA analysis which were found to be significantly differentially 
expressed when surgical groups were defined as microscopic residual disease or ≥1mm 
macroscopic residual disease. 
 
3.4 Summary 
This work has demonstrated that anatomical location of disease determined preoperatively 
on CT images can aid in the prediction of suboptimal debulking. What is more uncertain 
however is whether these specific locations are a marker of more aggressive disease and 
whether the tumour biology itself has a role in debulking outcomes. The limitations to the 
previously published studies provide inconclusive evidence in the role of tumour biology 
dependently affecting survival and debulking outcome. Therefore this question was further 
explored in the following chapter using well annotated Hammersmith Hospital and TCGA 
DNA methylation datasets. 
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Chapter 4: Differential DNA methylation associated with 
debulking surgery and survival   
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4.1 Introduction 
This chapter explores the DNA methylation profile of EOC tumours associated with surgical 
outcomes and survival through bioinformatics analysis of the publically available TCGA 
dataset and the independent Hammersmith Hospital (HH) dataset.  
4.2 Background 
As discussed in Chapter 3 previous studies exploring the relationship between debulking 
outcomes and biological variables have suffered from poor study design, heterogeneous 
tumour samples and confounders such as early stage disease. The TCGA high grade 
serous EOC dataset is a particularly useful resource to as it is clinically annotated with a 
relatively large dataset of patients with recorded residual disease status (n=279). The HH 
dataset (n=78) has the added benefit of even more detailed clinical annotation such as 
RECIST chemotherapy response. The two datasets allow for a discovery and validation 
analysis which is particularly important when dealing with large datasets and multiple 
analyses during the discovery phase (Hardy & Singleton, 2009; Wang et al, 2005). When 
using both datasets for discovery and validation analysis it is necessary to ensure both 
cohorts have comparable clinical characteristics. Following this both datasets were used to 
determine differential DNA methylation in association with surgical debulking outcomes and 
survival.  
The TCGA 27K methylation dataset was used to explore differential methylation of CpG sites 
associated with residual disease status. As the array covers over 27,000 CpG sites relating 
to over 14,000 genes, analysis of a relatively small number of samples can be hindered by 
high false discovery rates. Therefore a hypothesis driven approach to data analysis is 
advantageous with analysis focused on important cancer pathways such as the Wnt 
pathway. The Wnt signalling pathway has been associated with a large number of cancers, 
particularly colorectal carcinoma, where mutations of adenomatous polyposis coli (APC) 
causes dysregulation and an activation of growth-promoting genes through increased β-
catenin/Tcf-4 transcription complexes (Korinek et al, 1997). Wnt signalling has also been 
associated with ovarian tumorigenesis (Gatcliffe et al, 2008). β-catenin mutations are 
observed in endometroid EOC (Palacios & Gamallo, 1998) but are rare in other EOC 
histological subtypes. However in these other histological types epigenetic changes are 
thought to contribute towards gene silencing and aberrant Wnt signalling (Takada et al, 
2004). It has been shown that methylation at multiple CpG islands (CGI) associated with 
genes in the Wnt pathway is prognostic in high grade serous ovarian cancer from a Scottish 
Gynaecology Clinical Trials Group (SGCTG) cohort study using a DMH array (Dai et al, 
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2011). Seven Wnt loci correlating to genes; FZD4, DVL1, NFATC3, ROCK1, LRP5, AXIN1 
and NKD1, were independently prognostic in multivariate analysis from clinical parameters in 
the SGCTG cohort. Six of these 7 loci were also examined in TCGA using the Illumina 27K 
Infinium array. Methylation of DVL1, ROCK1, LRP5, AXIN1 and DVL1 were still prognostic in 
this independent patient cohort (one-sided p<0.05, FDR<10%, n=311), and methylation of 
FZD4 demonstrated marginal correlation with PFS in this patient cohort (one-sided p=0.06, 
FDR<10%). Consistent with their epigenetic regulation, reduced expression of FZD4, DVL1 
and ROCK1 was an indicator of early disease relapse in the TCGA tumour cohort (n=311, 
adjusted p<0.05). Given this association of DNA methylation of Wnt pathway genes with 
prognosis, analysis was performed to determine whether Wnt genes were also involved in 
surgical outcome.  
 
4.3 Results 
4.3.1 Analysis of clinical characteristics between HH and TCGA datasets 
4.3.1.1 Hammersmith Hospital dataset 
The Hammersmith Hospital (HH) Illumina 27K dataset was generated as described in 
Materials & Methods, section 2.6. The tumour samples originated from patients who 
received treatment for serous EOC at Hammersmith Hospital, Imperial College NHS Trust, 
London. 103 tumour samples were available which met the patient selection criteria and 21 
samples were excluded as they did not pass histopathological quality control. 80 from the 
available 82 samples were analysed on the HumanMethylation27 Beadchip. Unfortunately a 
further 2 samples had to be excluded from analysis due to incorrect grade (grade 2A) and 
incorrect histopathology quality control (borderline tumour). The clinical characteristics 
relates to the 78 malignant samples whose results were subsequently included in analysis 
(Table 4.1).  
All tumour samples were collected from patients at the time of primary debulking surgery 
prior to chemotherapy. The surgery was conducted between 1999 and 2010 (1 patient 1999, 
1 patient 2001, 1 patient 2003, 8 patients 2004, 7 patients 2005, 13 patients 2006, 17 
patients 2007, 10 patients 2008, 8 patients 2009, 12 patients 2010). All surgery was 
performed at the West London Gynaecology Cancer centre by Gynaecology Oncology 
Consultants (94.7%) or sub-speciality trainees (5.3%). 
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Optimal debulking rate was 57.7% and total macroscopic debulking rate was 23.1%, these 
figure are in keeping with other UK based centres at the time of surgery (Crawford et al, 
2005). All samples were of serous histology and 97.4% were high grade. All samples were 
from patients with stage 3B of higher. Seven patients received adjuvant chemotherapy 
elsewhere and therefore chemotherapy details were not available on these seven. All other 
patients received carboplatin chemotherapy either alone (34.6%), or in combination with 
paclitaxel (52.6%) or another agent (3.9%). RECIST 1.1 criteria response rates were 
available on 61 patients as follows; 24 (39.3%) patients had complete response (CR), 31 
patients (50.8%) had partial response (PR), 3 patients (5%) had stable disease (SD), 3 
patients (5%) had progressive disease (PD), again in keeping with previous published 
figures (Sandercock et al, 2002).    
 
  
HH TCGA 
*p= 
  
n=78 (%) n=279 (%) 
Age Mean (range) 61 (30-87) 60 (35-86) 0.5 
Grade 
1 2 (2.6%) 1 (0.4%) 
0.013 
2 15 (19.2%) 26 (9.3%) 
3 61 (78.2%) 248 (88.9%) 
Unknown 0 4 (1.4%) 
Stage 
3A 0 3 (1.1%) 
0.291 
3B 5 (6.4%) 14 (5%) 
3C 53 (67.9%) 213 (76.3%) 
4 20 (25.6%) 49 (17.6%) 
Residual 
disease 
0mm 18 (23.1%) 44 (15.8%) 
0.003 
1-10mm 27 (34.6%) 159 (57.0%) 
11-20mm 4 (5.1%) 16 (5.7%) 
>20mm 29 (37.2%) 60 (21.5%) 
Chemotherapy 
response**  
Complete Response 26 (33.3) 149 (53.4%) 
<0.001 
Partial Response 31 (39.7%) 37 (13.3%) 
Stable disease 3 (3.8%) 27 (9.7%) 
Progressive disease 3 (3.8%) 22 (7.9%) 
Unknown 17 (21.8%) 54 (19.4%) 
 
Table 4.1. Patient characteristic table for Hammersmith Hospital (HH) dataset and The 
Cancer Genome Atlas (TCGA) dataset 
 
*significance determined by Kruskal Wallis test for age and permutation chi2 test for grade, 
stage, residual disease and chemotherapy response 
**Chemotherapy response defined by RECIST 1.1 for HH dataset 
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4.3.1.2 Survival analysis 
Overall survival (OS) and progression-free survival (PFS) data was available on 70 and 63 
cases respectively. Missing data was due to a proportion of patients receiving chemotherapy 
and follow-up at other hospitals and therefore survival data was not available. Univariate 
logrank statistical tests were performed. There was a significant difference in both PFS and 
OS between optimal (≤10mm residual disease) and suboptimal groups (>10mm residual 
disease), log rank p=0.011, p=0.014 respectively (Figure 4.1A & B). Progression free median 
survival time was 549 (95%CI 466-908) days in the optimal group vs. 359 (95%CI 323-447) 
days in the suboptimal group. Overall median survival time was 1348 days (95%CI 1003-NA) 
in the optimal group and 808 days (95%CI 715-1347) in the suboptimal group. This data is in 
keeping with previously published UK and European studies conducted in a similar time 
period (Vasey et al, 2004; Vergote et al, 2010). Similarly to previous studies the greatest 
survival advantage came with those achieving complete macroscopic debulking (0mm 
residual disease), with median PFS time increasing to 1165 days (95%CI 473-NA) and 
median  OS time to 1807 days (95%CI 1003-NA) in the complete macroscopic debulking 
group. Classifying into volume of residual disease retained significance in PFS, p=0.007 and 
OS, p=0.006 (Figure 4.1C & D). There was no significant difference in OS for age (p=0.26), 
grade (p=0.387), stage (p=0.569), ethnicity (p=0.158), type of chemotherapy used (p=0.939). 
In multivariate Cox proportional hazards analysis adjusting for age, grade and stage, surgical 
debulking remained significant in OS for either classification of optimal vs. suboptimal 
debulking, p=0.033, HR 2.13 (95% CI 1.07-4.28) and total macroscopic debulking versus the 
rest, p=0.041, HR 1.54 (95% CI 1.02-2.35).  
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Figure 4.1; Kaplan-Meier plots for OS and PFS in HH dataset. A, OS and B, PFS dependent 
on optimal or suboptimal debulking. C, OS and D, PFS dependent on residual disease 
volume group. E, OS and F, PFS dependent on complete macroscopic debulking (0mm 
residual disease) versus any amount of residual disease (≥1mm residual disease).   
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4.3.1.3 The Cancer Genome Atlas dataset 
The Cancer Genome Atlas (TCGA) is a large-scale collaborative effort supported by the 
National Cancer Institute (NCI) and the National Human Genome Research Institute 
(NHGRI) to systematically characterize the genomic changes that occur in cancer. Patients 
were recruited from the UK, Europe and the US and were included into the data collection 
with a primary diagnosis of serous ovarian adenocarcinoma at any stage or grade. 
From the subset of 279 patients with detailed clinical annotation, 203 (72.8%) patients 
underwent optimal debulking surgery, of which 44 patients (15.8%) had total macroscopic 
debulking. 98.2% of patients had high grade disease. Stage 3C disease was the most 
prevalent stage with 213 patients (76.3%) and 49 patients (17.6%) had stage 4 disease. 
Chemotherapy response was not defined through RECIST 1.1 criteria however figures were 
in keeping with previously published data with 82.6% having either partial or complete 
response, 12% with stable disease and 9.8% with progressive disease. Univariate analysis 
demonstrated that age at diagnosis was significantly related to surgical outcome of 0mm 
residual disease versus ≥1mm residual disease (p<0.001) and was therefore adjusted for in 
subsequent statistical models. There was no difference in surgical outcome in those who 
presented with stage 3 disease versus those with stage 4 disease (p=0.259). 
4.3.1.4 Survival analysis 
OS and PFS data was available on 279 and 234 patients respectively. Univariate analysis 
did not demonstrate a significant difference in OS for any residual disease category (Figure 
4.2A, C & E). There was a trend towards improved survival for those with 0mm residual 
disease compared to  ≥1mm residual disease with median OS 55.2 months (95%CI 41.5-
NA) and 38.1 months (95%CI 34.9-41.3) respectively but again this was not significant 
(p=0.094)(Figure 4.2D). Likewise for PFS there was no significant difference between the 
residual disease categories and a trend for improved PFS in those with 0mm residual 
disease compared to the rest (p=0.059)(Figure 4.2B,D & E). Median PFS for 0mm residual 
disease group 16.7 months (95%CI 12.5-30.4) and 13.9 months (95%CI 12.8-16.3) in the 
group with ≥1mm residual disease. There was no significant difference on survival 
dependent on residual disease volume in multivariate cox analysis adjusting for age, stage 
and grade (p=0.418, HR=1.07, 95%CI 0.91-1.25). 
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Figure 4.2 Kaplan-Meier plots for OS and PFS in TCGA dataset. A, OS and B, PFS 
dependent on optimal or suboptimal debulking. C, OS and D, PFS dependent on residual 
disease volume group. E, OS and F, PFS dependent on complete macroscopic debulking 
(0mm residual disease) versus any amount of residual disease (≥1mm residual disease). 
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4.3.1.5 Comparisons between HH and TCGA datasets 
There are important differences in clinical characteristics between the two datasets. The 
most important difference is the lack of association between either OS or PFS with residual 
disease status in the TCGA dataset. The evidence for a significant improvement in survival 
in association with residual disease status has been demonstrated consistently independent 
of country, location or chemotherapy regimens. The HH data is in agreement with this 
evidence. There was a significant difference between residual disease in the two groups 
(p=0.003) with the optimal debulking rate from the TCGA data at 72.8% compared to 57.7% 
in the HH dataset. Despite this there was no significant difference in OS or PFS between the 
HH and TCGA datasets (p=0.775 and p=0.672 respectively) in univariate analysis, and when 
adjusting for residual disease (p=0.415, HR 0.86, 95%CI 0.602, 1.233). It has been reported 
that UK debulking rates are inferior to other countries and it appears that the HH debulking 
rate is equivalent to previously published UK figures (Crawford et al, 2005). As demonstrated 
in Chapter 3, in the Hammersmith Hospital (West London Gynaecology Cancer Centre) 
debulking rates have increased over the past decade with optimal debulking rates improving 
from 46.8% to 75.7% and complete macroscopic debulking rates of 30.4% to 54.3% 
respectively. In this cohort of patients the optimal debulking rate from patients operated upon 
from 1999 to 2005 was 31.8% and increased to 60% from 2006 to 2010. In the TCGA study 
it is unclear when the sample collection was commenced. However as many of the centres 
contributing tumour were based in the US is would appear reasonable that the debulking 
rates are higher in keeping with US based evidence. US studies support that increasing 
debulking rates comparably improves survival rates (Chi et al, 2009a) and thus this lack of 
survival improvement in the TCGA data is still unexplained. The categorisation of residual 
disease refers to the maximum diameter of any tumour deposits and is a subjective 
classification which can be prone to errors. In a prospective study of 72 gynaecologists (36% 
of whom were gynaecological oncologists) estimated tumour size measurements were 
subject to high level of variability, with a 13cm mass being estimated between 4 to 20cm and 
a 1 cm right diaphragmatic deposit being estimated between 0.3 to 3cm (Préfontaine et al, 
1994). In this study most surgeons appeared to underestimate rather than overestimate 
residual disease. It therefore seems plausible that misclassification of residual disease may 
have occurred in the TCGA data. A tumour deposit of 11mm could be easily mistaken for 
10mm and thus re-categorised into the optimal debulking group. The non-significant trend for 
improved OS and PFS in the TCGA data for total macroscopic debulking (0mm residual 
disease) compared to any amount of residual disease may support this hypothesis as the 
classification of no residual disease would be less prone to this measurement error.  
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Other differences between the two datasets include different chemotherapy regimens, 
significant differences between primary chemotherapy response and grade. 33.3% of 
patients in the HH dataset had complete response versus 53.4% in the TCGA dataset. 
However when looking at overall response rates (complete and partial response) between 
the two groups there is no significant difference between groups (p=0.492). Importantly 
whereas primary chemotherapy response from the HH dataset was categorised through 
RECIST 1.1 criteria, the TCGA dataset was not. RECIST enables a standard of reporting 
that has been validated in both retrospective and prospective studies (Therasse et al, 2006). 
Due to the multicentre nature of the TCGA data a standardised model appears particularly 
important and therefore this classification can also be prone to error. Additionally data on 
initial chemotherapy regime was not available for analysis from the TCGA dataset and 
therefore there may be major regime differences between groups that cannot be accounted 
for. This may explain the lack of improved survival dependent on residual disease, however 
adjusting for chemotherapy response in multivariate survival models dependent on debulking 
does not change significance (p=0.275, HR 1.42, 95%CI 0.756, 2.674). Additionally the 
proven survival benefit has been demonstrated irrespective of chemotherapy regime (Neijt et 
al, 2000; Vergote et al, 2010). There is a significant difference between individual grades in 
both datasets (p=0.013) however when categorising into low (grade 1) and high (grade 2 & 
3) groups there is no longer a significant difference (p=0.242). 
 
4.3.2 Differential methylation of Wnt pathway genes associated with residual disease in the 
TCGA dataset 
The first aim in this analysis was to identify differentially methylated loci which were 
associated with residual disease status. Due to concerns in regards to the TCGA survival 
data and its association with optimal versus suboptimal debulking, patients were grouped 
dependent on volume of residual disease following primary surgery into no macroscopic 
disease group (residual disease =0mm) or any residual disease group (residual disease ≥ 
1mm). A total of 536 methylation probes were found to be involved in the Wnt pathway as 
defined by Kyoto Encyclopedia of Genes and Genomes (KEGG) (entry ID:hsa04310). Using 
individualized linear models adjusting for microarray batch, age and stage and adjusting for 
multiple comparisons using false discovery rate (FDR), 180 probes were found to be 
significantly differentially methylated (p<0.05, q<0.05) between patients with ≥1mm residual 
disease versus those with 0mm residual disease (Supplementary data Table 8.1). 177 
probes demonstrated lower methylation levels in those with ≥1mm residual disease versus 
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no residual disease (negative beta-coefficient), whereas 3 probes demonstrated the reverse 
that is, higher methylation levels in those with any residual disease versus no residual 
disease (positive beta-coefficient). Median methylation was calculated for each probe per 
group, seven probes covering genes ACVRI, PCDHB2, PCDHB12, PCDHGB7, PCDHB7 
were found to have a median Δβ of >0.1 (equivalent to a difference of >10% methylation) 
(Figure 4.3, Table 4.2). In these probes methylation was significantly lower in the group with 
residual disease compared to no residual disease. All seven probes occur around promoter 
regions of each gene.  
Validation of the 180 significant methylation probes was not possible through the 
Hammersmith Hospital Illumina Infinium assay platform due to the small sample size in this 
dataset. Number of samples needed for significant validation was determined by power 
calculations. Power calculation was based on a mean average of the beta coefficients for 
effect size, assumed 25% of patients would be in the total macroscopic debulking group, 
85% power, an alpha of 5% and adjusting for 10% false positives. It was determined that 
1497 samples would be required for correct validation, or 911 samples without false 
discovery rate correction.  Therefore it can be concluded that HH dataset is too small for this 
validation. 
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Figure 4.3. Box-whisker plots demonstrating DNA methylation at individual probes in 0mm 
residual disease, >1mm residual disease and benign tumour samples in TCGA dataset. 
p values refer to linear regression model.  
 
Probe ID Gene Name 
Beta-
Coefficient* p value q value 
Median β  
(0mm RD) 
Median β 
(≥1mm 
RD) 
Methylation 
difference 
(%) 
cg14011639 PCDHGB7 -0.125 0.003 0.017 0.413 0.166 24.76 
cg23563234 PCDHGB7 -0.124 0.008 0.028 0.567 0.335 23.16 
cg12343638 PCDHB12 -0.121 0.002 0.015 0.501 0.272 22.88 
cg02260587 PCDHB2 -0.095 0.015 0.047 0.333 0.137 19.58 
cg07899016 PCDHB12 -0.106 0.011 0.038 0.581 0.456 12.47 
cg09499849 ACVR1 -0.096 0.006 0.025 0.527 0.402 12.45 
cg11809091 PCDHB7 -0.088 0.016 0.049 0.363 0.256 10.73 
 
Table 4.2. Summary of the 7 significant differentially methylated loci (with a methylation 
difference of >10%) in association with residual disease in TCGA dataset  
 
* Beta-coefficient of linear regression model adjusting for chip, age and stage.  
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4.3.2.1 Differential gene expression of significant methylation loci associated with residual 
disease  
Aberrant methylation is associated with gene inactivation so the TCGA data was further 
examined for the association between differential gene expression and surgical debulking 
status. Of the 180 significantly differentially expressed methylation probes there were 264 
corresponding genes on the Affymetrix gene expression microarray. 15 methylation probes 
did not have a counterpart gene expression probe and were therefore excluded from further 
analysis. Individual generalized linear models adjusting for batch, age and stage 
demonstrated 23 gene expression probes with significantly differentially expressed (p<0.05, 
q<0.1) between patients with no residual disease versus any amount of residual disease 
(Table 4.3). 17 gene loci demonstrated lower expression in the group with any residual 
disease versus no residual disease, whereas 6 loci demonstrated increased expression. For 
the seven probes with a Δβ of >0.1, there were no available gene expression probes for 
PCDHB2, PCDHGB7, PCDHB7 and no significant differential expression (p<0.05) for 
PCDHB12 and ACVR1. 
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Table 4.3. Summary of the 23 gene expression probes associated with surgical debulking in 
the TCGA Affymetrix gene expression array. 
 
*  Beta-coefficient of linear regression model adjusting for chip, age and stage 
  
Probe ID Gene Name 
Beta-
Coefficient* p value q value 
201073_s_at SMARCC1 -0.233 0.003 0.088 
201374_x_at PPP2CB -0.076 0.004 0.088 
202513_s_at PPP2R5D -0.194 0.005 0.088 
202981_x_at SIAH1 -0.236 0.002 0.088 
204051_s_at SFRP4 0.762 0.003 0.088 
206543_at SMARCA2 0.107 0.002 0.088 
208222_at ACVR1B -0.078 0.003 0.088 
210649_s_at ARID1A -0.299 0.005 0.088 
212669_at CAMK2G -0.201 0.003 0.088 
212757_s_at CAMK2G -0.229 0.003 0.088 
213369_at PCDH21 -0.244 0.001 0.088 
215520_at PYGO1 -0.064 0.004 0.088 
217049_x_at PCDH11Y -0.098 0.001 0.088 
221455_s_at WNT3 -0.073 0.005 0.088 
222351_at PPP2R1B 0.394 0.001 0.088 
204052_s_at SFRP4 0.594 0.007 0.091 
207419_s_at RAC2 0.219 0.006 0.091 
208003_s_at NFAT5 -0.356 0.007 0.091 
213603_s_at RAC2 0.418 0.006 0.091 
215517_at PYGO1 -0.075 0.007 0.091 
218629_at SMO -0.164 0.007 0.091 
209468_at LRP5 -0.309 0.008 0.092 
214322_at CAMK2G -0.088 0.008 0.092 
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4.3.3 Differential methylation of adhesion and migration pathway genes associated with 
residual disease in the HH dataset  
There are obvious benefits to using the TCGA dataset in analysis, particularly the relatively 
large sample size and the stringent quality control of the originating tumour samples. 
However the concerns over the survival data not matching to surgical debulking is worrying 
and may indicate inaccurate annotation of samples, estimation of residual disease or follow-
up data. Therefore the HH dataset, accurately annotated from the case notes was used for 
further analysis to explore this question further. 
Further statistical analysis was performed to find associations between differential DNA 
methylation and surgical debulking. Linear regression models were fit between individual 
methylation β values for each probe and surgical debulking. Patients were classified into 2 
groups, those with total macroscopic debulking with 0mm residual disease versus those with 
≥1mm residual disease. The success of surgical debulking is associated with the ability of 
tumour cells to invade and metastasise and additionally many probes identified in TCGA 
analysis were involved with cell adhesion (the protocadherin genes are a particular 
example). Therefore associated pathways identified were the ‘Focal Adhesions’ and 
‘Adherens junction’ pathway, involved with cell surface adhesion and the ‘Regulation of actin 
cytoskeleton’ pathway involved with cell migration. Genes involved in these pathways were 
defined by Kyoto Encyclopedia of Genes and Genomes (KEGG) and data was reduced to 
the corresponding 732 methylation probes. 32 probes from a total of 732 were found to be 
differentially methylated at p<0.05 but false discovery rate was high at 29.9% - 99.1%. 22 
probes were found to have lower methylation in the group with ≥1mm residual disease 
versus 0mm residual disease and the remaining 10 probes had higher methylation in the 
group with ≥1mm residual disease compared to the group with 0mm residual disease. The 
TCGA dataset was used as a validation set against these 32 significant probes, five probes 
were not contained within TCGA data and therefore were unable to be validated. 15 / 27 
probes were found to be significantly differentially methylated at p<0.05 and a FDR of <10% 
(Table 4.4). The Δ methylation was calculated from the median methylation in each group 
with only a very small change in methylation demonstrated (<3% methylation difference). 
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  Hammersmith Hospital dataset TCGA dataset 
Probe  ID Gene Name 
Beta 
Coefficient* p value 
Median 
β  
(0mm 
RD) 
Median 
β  
(≥1mm 
RD) 
Δ 
methylation 
(%) 
Beta 
Coefficient* p value q value 
Median 
β  
(0mm 
RD) 
Median 
β  
(≥1mm 
RD) 
Δ 
methylation 
(%) 
Gene exp. 
Validation  
cg14094960 EGFR -0.036 0.001 0.056 0.037 1.9 -0.013 0.005 0.018 0.031 0.016 1.5 ● 
cg18700967 SSH2 -0.009 0.010 0.048 0.032 1.6 -0.015 0.035 0.063 0.058 0.030 2.8  ns 
cg22375192 IGF1R -0.034 0.007 0.055 0.043 1.2 -0.016 0.002 0.010 0.026 0.019 0.7 
cg20550520 ARHGAP5 -0.013 0.026 0.104 0.092 1.2 -0.022 0.014 0.034 0.119 0.087 3.2 ● 
cg24979630 PPP1R12A -0.007 0.043 0.056 0.045 1.1 -0.016 0.019 0.040 0.069 0.038 3.1 ● 
cg20566118 TNC -0.008 0.011 0.057 0.048 0.9 -0.008 0.001 0.004 0.035 0.028 0.7 
cg04185037 VIL2 -0.009 0.022 0.045 0.037 0.8 -0.021 0.000 0.003 0.026 0.018 0.9 
cg24266238 PFN2 -0.008 0.032 0.042 0.035 0.7 -0.014 0.017 0.037 0.046 0.032 1.4 ● 
cg09881855 SNAI2 -0.025 0.006 0.055 0.049 0.6 -0.028 0.001 0.004 0.051 0.042 0.9 ns  
cg01753595 COL5A1 -0.005 0.032 0.037 0.031 0.6 -0.011 0.034 0.063 0.035 0.029 0.6 ● 
cg23906291 ERBB2 -0.024 0.041 0.049 0.044 0.5 -0.023 0.004 0.016 0.049 0.024 2.5 ● 
cg01708964 MYL7 0.014 0.046 0.908 0.913 0.5 0.018 0.010 0.026 0.928 0.935 0.7 ● 
cg23093462 PARD3 -0.004 0.026 0.042 0.039 0.3 -0.008 0.008 0.024 0.034 0.028 0.6 ● 
cg16427670 ARHGEF7 -0.028 0.032 0.071 0.068 0.3 -0.042 0.003 0.013 0.074 0.060 1.4 ● 
cg13378388 VEGFC -0.008 0.026 0.050 0.048 0.2 -0.026 0.001 0.004 0.042 0.033 0.9  ns 
 
 
Table 4.4. Summary of loci significantly differentially methylated in association with residual disease status in the HH dataset, with evaluation in 
TCGA dataset. Residual disease groups; 0mm versus ≥1mm.  
 
* Linear regression model adjusting for chip, age and stage 
● probe not available for analysis,  p<0.05, FDR<15%, ns represents “not significant” 
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4.3.3.1 Differential gene expression of significant methylation loci associated with residual 
disease  
The relationship between gene expression and surgical debulking of these 15 loci was 
explored through analysis of the TCGA Affymetrix HGU133A microarray gene expression 
data. Only genes, VIL2, TNC, IGF1R, VEGFC, VIL2, SNAI2 had corresponding gene 
expression data available with a total of 13 different probes. Using individual generalized 
linear regression model adjusting for chip, age and stage, 4 from 13 gene expression probes 
were significantly associated with debulking  (p<0.05, q<0.15). Probe 208621_s_at  (one of 
six probes covering VIL2) and 201645_at, (one of two probes covering TNC) were found to 
have significantly lower expression in those with 0mm residual disease compared to those 
with ≥1mm disease (Figure 4.4C & D, Table 4.5). Two probes corresponding to IGF1R were 
found to have significantly higher expression in those with 0mm residual disease compared 
to those with ≥1mm disease (Figure 4.4A & B, Table 4.5). However for all gene expression 
probes the differences between the groups are again small and again may well have been 
found by chance (strongly indicated by the false discovery rate) and may be unlikely to 
contribute to a difference in actual protein synthesis between those who received total 
macroscopic debulking versus those with ≥1mm residual disease.
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Figure 4.4. Box-whisker plots demonstrating significant differential gene expression loci in 
0mm residual disease and ≥1mm residual disease groups in TCGA dataset. A, IGF1R 
(probe ID 203628_at). B, IGF1R (probe ID 208441_at). C, VIL2. D, TNC. 
p values refer to linear regression model. 
 
     
Median gene exp 
(log2) 
Probe ID 
Gene 
name 
BetaCoef* p value q value 0mm RD ≥1mm RD 
x208621_s_at VIL2 0.312 0.027 0.133 6.95 7.25 
x201645_at TNC 0.484 0.035 0.133 3.65 4.28 
x203628_at IGF1R -0.371 0.038 0.133 5.93 5.68 
x208441_at IGF1R -0.050 0.042 0.133 3.01 2.99 
 
Table 4.5. Summary table of loci significantly differentially expressed in the TCGA Affymetrix 
gene expression array in association with residual disease. 
* Linear regression model adjusting for chip, age and stage. RD residual disease.  
A 
C 
B 
D 
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4.3.4 Predicting survival in optimally debulked patients to aid surgical stratification 
4.3.4.1 Background 
Prognostic biomarkers associated with survival in EOC have been widely investigated in the 
literature. Overexpression of individual genes such as VEGF, HER2 and progesterone 
receptor have been associated with PFS and OS (Yu et al, 2013; Zhao et al, 2013). 
Differential methylation at promoter regions of Wnt pathway genes has been found to be 
associated with PFS in independent datasets (Dai et al, 2011) and gene signatures identified 
through microarray have also been associated with different survival outcomes (The Cancer 
Genome Atlas, 2011; Tothill et al, 2008). These findings greatly improve our understanding 
of specific tumour biology and highlight potential therapeutic targets for drug development. 
They indicate groups of patients who survive differently independent of treatment regimens 
and thus additionally demonstrate potential in the development of personalised treatment 
stratification. In the management of patients with EOC there are a minority of patients who 
respond poorly to treatment despite receiving optimal debulking surgery. Despite the 
significantly improved survival time in optimally debulked patients in the HH dataset, 8.9% of 
optimally debulked patients were deceased by 1 year and 15.5% were deceased by 2 years. 
It is possible that these patients received supraradical surgery in order to achieve optimal 
debulking. If these patients were able to be identified prior to surgery as having a poor 
prognosis despite optimal debulking, radical surgery may have been withheld which may in 
turn decrease surgery related morbidity and potentially lead to a quicker time to adjuvant 
chemotherapy. Additionally this group of patients may benefit to a larger degree to 
neoadjuvant chemotherapy followed by interval debulking surgery compared to patients with 
a more favourable prognostic outlook. If these patients could be identified through molecular 
biomarkers, RCT’s could then be designed to robustly answer this hypothesis.   
 
4.3.4.2 Differentially methylated loci associated with overall survival in optimally debulked 
patients 
In order to determine probes with differential methylation associated with survival, the HH 
data was divided into an optimal debulking group (0-10mm residual disease, n=45) and a 
suboptimal debulking group (≥10mm residual disease, n=33). To identify if methylated loci 
are associated with survival in those who have the best clinical prognosis (those optimally 
debulked) , multivariate Cox proportional hazard models adjusting for chip, age, stage and 
volume of residual disease was performed on optimally debulked patients only. The analysis 
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was again performed on 732 probes covering genes involved with adhesion and migration 
pathways as a hypothesis driven approach. 65 from 732 loci were found to show differential 
methylation associated with overall survival (p<0.05) in optimally debulked patients. Thirty-
six probes were found to have a difference between maximum and minimum β values of 
>0.2 (equivalent to a methylation range of >20%). For each loci the mean β value was 
calculated and individual cases were divided into either high methylation group (≥ mean 
value) or low methylation group (< mean value). To investigate whether those patients who 
were optimally debulked but with a poor prognostic marker performed as poorly as those 
suboptimal debulked, cases were grouped dependent on methylation above or below the 
median and debulking outcome. The nonparametric logrank test was then used to 
investigate if patients had different survival distributions per loci depending on methylation 
above and below the median and debulking status. 27 / 36 loci were found to be significant 
at logrank test p<0.05 and FDR<10% (Table 4.6). Four loci on MYL9, VAV1, CHAD and 
LAMA1 genes demonstrated methylation below the median to be associated with improved 
survival whereas the rest demonstrated methylation above the median to be associated with 
improved survival. The six probes with the largest effect size equivalent to a HR>1.7 covered 
genes MYL7 (myosin, light chain 7, regulatory), MYLK 2 (myosin light chain kinase 2), MLCK 
(myosin light chain kinase), FGF4, FGF21 (Fibroblast growth factor 4 and 21) and ITGAE 
(integrin alpha E).  
Kaplan-Meier survival plots (Figure 4.5) illustrate the survival advantage for these top 6 
significant probes in those undergoing debulking surgery. It can be seen that there is a clear 
survival advantage for those patients optimally debulked and with high methylation (above 
the mean) at these specific loci. Additionally in those patients who have achieved optimal 
debulking but without the positive survival advantage of high methylation, outcome appears 
similar to those who only achieved suboptimal debulking. As the original Cox proportional 
hazard model was adjusted for residual disease this survival advantage is not due to 
confounding of 0mm residual disease.  
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Probe ID Gene Name 
Median 
methylation 
(%) 
Cox 
model 
(p=)* 
HR 95% CI logrank test (p=) q value 
Improved survival 
associated with 
Stepwise 
regression 
best fit 
Gene exp. 
validation 
TCGA 
validation 
cg14578030 FGF4 85.23 0.011 2.565 (1.237, 5.319) 0.007 0.048 high methylation   ns 
cg21856603 ITGAE 77.52 0.042 2.085 (1.025, 4.240) 0.032 0.060 high methylation  ns ns 
cg16155702 FGF21 74.30 0.031 2.015 (1.064, 3.815) 0.002 0.034 high methylation  ns ns 
cg13247990 MLCK 80.05 0.008 1.963 (1.195, 3.225) 0.017 0.052 high methylation  ● ns 
cg19961522 MYLK2 73.19 0.024 1.768 (1.079, 2.897) 0.019 0.052 high methylation ns ns  
cg23370883 MYL7 61.73 0.026 1.742 (1.069, 2.838) 0.012 0.048 high methylation ns ns ns 
cg09528351 PIK3R5 72.32 0.015 1.347 (1.059, 1.714) 0.040 0.064 high methylation ns ns ● 
cg09517019 ARHGEF6 36.05 0.014 1.337 (1.060, 1.687) 0.011 0.048 high methylation ns ns ns 
cg17177660 VEGFC 43.44 0.002 1.335 (1.108, 1.610) 0.012 0.048 high methylation ns  ns 
cg08816023 FGF1 68.72 0.017 1.298 (1.048, 1.608) 0.011 0.048 high methylation   ns 
cg21030598 PAK2 48.07 0.048 1.264 (1.002, 1.594) 0.029 0.060 high methylation  ns ns 
cg14176836 ITGAL 59.21 0.037 1.253 (1.014, 1.549) 0.044 0.065 high methylation  ns ns 
cg05313261 MAPK3 11.01 0.036 1.228 (1.014, 1.486) 0.049 0.065 high methylation  ns  
cg03543593 TNXB 28.63 0.012 1.220 (1.045, 1.425) 0.037 0.063 high methylation   ns 
cg04663194 ACTN3 65.22 0.017 1.209 (1.034, 1.414) 0.018 0.052 high methylation  ns ns 
cg00833777 ITGAM 62.98 0.028 1.208 (1.020, 1.431) 0.014 0.052 high methylation ● ns ● 
cg20795401 ITGA6 21.77 0.037 1.173 (1.009, 1.364) 0.028 0.060 high methylation ns ns ● 
cg03731616 MYLK 16.82 0.006 1.148 (1.041, 1.266) 0.007 0.048 high methylation   ● 
cg21902327 FGF6 53.08 0.042 1.147 (1.005, 1.309) 0.048 0.065 high methylation  ns ns 
cg09538287 CTNNA3 38.30 0.043 1.140 (1.004, 1.294) 0.027 0.060 high methylation  ns ns 
cg17694877 DIAPH2 22.39 0.018 1.134 (1.022, 1.258) 0.026 0.060 high methylation  ns ● 
cg16154416 RASGRF1 18.83 0.017 1.095 (1.016, 1.179) 0.049 0.065 high methylation   ns 
cg17286640 KDR 8.92 0.040 1.090 (1.00, 1.182) 0.041 0.064 high methylation   ● 
cg06958829 CHAD 49.49 0.043 0.918 (0.845, 0.997) 0.031 0.060 low methylation  ns ● 
cg14950072 LAMA1 8.77 0.028 0.887 (0.797, 0.987) 0.003 0.034 low methylation ns ns ns 
cg26571739 VAV1 29.59 0.043 0.873 (0.765 ,0.995) 0.034 0.061 low methylation ns ns ns 
cg21671476 MYL9 17.72 0.017 0.825 (0.704, 0.966) 0.002 0.034 low methylation ns ns ns 
 
Table 4.6. Summary of 27 significant differentially methylated survival loci in HH dataset. 
* p value determined by Cox proportional Hazard model adjusting for chip, age, stage and residual disease 
● probe not available for analysis     p<0.05    ns; not significant 
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Figure 4.5. Kaplan-Meier plots for OS dependent on candidate loci methylation 
categorised by optimal or suboptimal debulking. A, FGF4. B, FGF21. C, ITGAE. D, MLCK. 
E, MYL7. F, MYLK2. 
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4.3.4.3.Candidate loci validation  
The HH Affymetrix gene expression dataset was used to determine whether differential gene 
expression of these significant loci was associated with OS. Again limiting the data to only 
optimally debulked patients (n=31) Cox proportional Hazard models adjusting for age, stage 
and residual disease, determined seven genes differentially expressed (p<0.05, n=20). 
Improved survival was significantly associated with lower expression of VEGFC (HR46.6, 
95%CI 1.99-1091.7, p=0.017), TNXB (HR63.3, 95% CI 2.01-1988.2, p=0.018), KDR (HR 
31.0, 95% CI 1.55-616.5, p=0.025), RASGRF1 (HR 783.3, 95% CI 1.94-316380.8, p=0.030), 
MYLK (HR 4.51, 95% CI 1.09-18.67, p=0.037) and FGF1 (HR 2.90, 95% CI 1.02-8.28, 
p=0.046). Improved survival was associated with higher expression of FGF4 (HR 0.0001, 
95% CI 3.03E-08-0.75, p=0.043). No significant correlation was found between gene 
expression and methylation at these probes but this may be explained by the small sample 
size on the gene expression array. 
Further validation of the 36 significant methylation probes was attempted through the TCGA 
dataset. 11 probes were not covered on the TCGA dataset and therefore analysis was 
reduced to 25 probes. Through Cox proportional hazard models of patients in optimal 
debulking category adjusting for chip, age, stage and volume of disease, 2 probes were 
found to be significantly differentially methylated, MYLK2 - cg19961522 (HR1.26, 95% CI 
1.06-1.49, p=0.007) and MAPK3 - cg05313261 (HR 1.52, 95% CI 1.10-2.10, p=0.012). 
Patients were then categorised into low and high methylation groups and logrank test was 
performed as described previously. This was not significant for either probe when 
categorising into optimal and suboptimal groups (MYLK2; p=0.788, MAPK3; p=0.241), but 
may be due to the discrepancy between the TCGA and HH datasets. 
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4.3.4.4 Stepwise regression model 
To determine which combination of the 27 significant survival probes were most important in 
determining survival a stepwise regression analysis was performed to find the optimal 
statistical model. The model requires all probes to be independent to one another; therefore 
correlation between each probe was determined. Probe cg00833777 (ITGAM) was highly 
correlated to both cg04663194 (ACTN3) and cg09528351 (PIK3R5)(Pearson correlation, 
rho=0.71 and 0.74 respectively) and thus was excluded from further analysis. Stepwise 
regression analysis determined that 17 from the 26 probes were most important in the model 
for predicting OS independent of residual disease status. A log risk score was created for 
each patient by using the beta coefficients from this final cox model and multiplying them by 
their corresponding log methylation beta value. This score was then used in the cox 
proportional hazard model, adjusting for residual disease and was significantly associated 
with OS (p<0.001). Each patient was then categorised into having an individual survival 
score above or below the median, this categorisation was again significantly associated with 
OS (HR 7.18, 95% CI 3.30-15.64, p<0.001). Those patients who had a survival score above 
the median had a seven times increased risk of poor survival compared to those below the 
median (Figure 4.6). 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. Kaplan-Meier plot for OS dependent on risk score as defined by the stepwise 
regression analysis and subsequent Cox model. Cases are categorised into above or below 
the median methylation risk score.  
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4.4 Discussion 
4.4.1 Protocadherin genes may play a role in surgical debulking success 
Analysis of the TCGA data demonstrated 180 probes (p<0.05, FDR < 5%) corresponding to 
genes in the Wnt pathway which were differentially methylated in those with macroscopic 
residual disease versus those with no residual disease present. For the majority of loci 
methylation was seen to be lower in tumours from patients with residual disease versus no 
residual disease. The reason for this is unclear. Possible active or passive demethylation is 
occurring in these tumours in association with increased proliferation and invasion. However 
these same loci were found to have higher methylation in malignant tumour DNA compared 
to benign fallopian tube and ovarian tissue DNA, which would indicate the evolution from 
benign to malignant samples at these loci is associated with an increase in methylation 
(Figure 4.3). Additionally, the methylation range for each loci is large (β value from <0.2 to 
>0.8 in all probes) indicating a wide variability of methylation amongst these tumours. 
Therefore these perceived differences between DNA methylation in residual disease groups 
may be found by chance without any biological relevance. 
Seven of the 180 probes associated with debulking were found to have a median Δβ value 
of >0.1, equivalent to a difference in methylation of >10%. Six of these loci relating to genes 
PCDHB2, PCDHGB7, PCDHB7, PCDHB12 belong to the proto-cadherin family and are 
thought to be involved in cell-cell connections and in the migration and invasion of cancer 
cells (Haruki et al, 2010). The altered regulation of cell adhesion would theoretically alter the 
ability of malignant cells to spread throughout the abdomen and invade into tissue which 
would also have an impact on surgical operability. It has also been shown that epigenetic 
silencing of other proto-cadherin genes through DNA promoter hypermethylation occurs in 
oesophageal squamous cell carcinoma (Haruki et al, 2010) and Wilms’ tumours (Dallosso et 
al, 2009). There were no available gene expression probes for PCDHB2, PCDHGB7 or 
PCDHB7 and there was no difference in gene expression between surgical groups for 
PCDHB12. Currently in the literature, there is limited knowledge regarding these specific 
genes in relation to cancer and thus functional studies would aim to improve understanding 
of the role that these genes play in cancer invasion. An additional methylation locus, ACVR1 
was also found to be significantly differentially methylated with median Δβ value of >0.1. 
Significantly lower methylation at the promoter of this gene was found in those with residual 
disease versus those without. ACVR1 (also known as ALK2) is an activin receptor which is 
involved in growth and differentiation signalling through the TGF-β pathway (Jung et al, 
2009). Upstream signalling of this pathway though bone morphogenetic proteins has been 
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shown to promote cell proliferation in EOC cell lines (Herrera et al, 2009). Due to the small 
sample size in the HH dataset these results could not be validated in an independent dataset 
and thus a large validation set would be required to conclusively prove these findings. 
An additional fifteen methylation probes covering genes in adhesion and migration pathways 
were significantly associated with residual disease in both HH and TCGA datasets. Of note 
probes of interest include VEGFC and IGF1R, which have been previously been shown in 
the literature, from gene expression data to be associated with surgical debulking (An et al, 
2009; Sinn et al, 2009). The majority of the loci demonstrated overall hypomethylation, 
methylation <10% for 13 / 15 significant loci at promoter regions of the genes. One loci was 
highly methylated for gene MYL7 (median methylation >90%). This probe cg01708964 is 
located at a CpG island approximately 1000 bases downstream of the promoter region of the 
gene however methylation difference between the two debulking groups was less than 0.5%. 
Thus biological relevance of these significant differences is doubtful. In gene expression 
analysis, genes IGF1R, VIL2 and TNC were found to be significantly differentially expressed, 
however again perceived differences are incredibly small. For IGF1R gene expression was 
lower in those with residual disease. This is the opposite to a previous published study which 
found increased gene expression of  IGF1R was associated with suboptimal debulking 
(>10mm residual disease)(An et al, 2009). Limitations of this work include the relatively small 
sample size in the HH dataset inconsistencies with survival and debulking data between the 
two datasets and the small effect sizes seen. There is also doubt into whether a methylation 
difference of a few per cent would impact on functional biological differences and 
furthermore whether this small difference would be able to be reliably detected in other 
methylation detection technology such as pyrosequencing. It has also become apparent 
from exploring this debulking question that one of the largest difficulties comes from the 
many potential confounding factors that may also be involved. 
4.4.2 Variability within residual volume classification  
The decision and ability to perform optimal surgical debulking is in reality dependent on 
several influencing factors. The most obvious of these relates to FIGO stage of disease 
whereby stage 1 and 2 disease (disease confined to the ovary and pelvis respectively) can 
almost always be completely removed. Consequently a much higher proportion of optimally 
or total macroscopic debulked tumours will occur in those with early stage disease 
(Wimberger et al, 2007). In this analysis only tumours with advanced stage were included, 
plus multivariate statistical models were adjusted for stage of disease in an attempt to 
eliminate bias.  Additionally patients performance status, age and co morbidity can also 
influence surgical outcome (Wimberger et al, 2007). The need for intestinal resection has 
been shown to significantly increase the risk of major postoperative complications compared 
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to those without bowel resection (OR 2.8, 95% CI 1.4-4.2, p=0.01) (Fotopoulou et al, 2010). 
Thus if bowel resection was required to achieve optimal debulking in a case of an elderly 
patient with co-morbidities or reduced performance status, the surgeon may not proceed due 
to fear of serious complications. Surgical debulking rates are known to differ dependent on 
surgical institution and country, with the UK historically being behind other countries in 
regards to optimal debulking success rates (Crawford et al, 2005; Skírnisdóttir & Sorbe, 
2007). This is mainly due to personal and institutional philosophy on what determines 
unresectable disease (Chi & Schwartz, 2008) and also requires the appropriate skill, time 
and expertise to be able to perform the operation appropriately, in addition to appropriate 
post-operative care facilities and staff to aid patient recovery (Nguyen et al, 1993; Verleye et 
al, 2009). It has been shown that the incorporation of extensive upper abdominal procedures 
such as diaphragm peritonectomy, splenectomy and partial liver resection increased 
successful cytoreductive outcomes and consequently significantly improves survival (Aletti et 
al, 2006b; Chi et al, 2009a; Kehoe et al, 2008; Tsolakidis et al, 2010). Thus two patients with 
the same stage of disease, same location and size of disease and same tumour biology 
could receive very different debulking outcome dependent on the centre of treatment. 
Therefore to account for these factors detailed descriptions of surgical effort involved to 
achieve debulking outcomes should be considered in any analysis which involves the 
association between residual disease and tumour biology. Additionally the site and size of 
tumour deposits should be accounted for in analysis as patients may present with very 
different patterns of disease. For example, widespread miliary disease with small deposits 
dispersed throughout the abdomen compared to more bulky disease with large solitary 
deposits at specific sites. This pattern of disease spread is likely to affect debulking 
outcomes in the majority of departments (Fotopoulou et al, 2010; Wimberger et al, 2007).  
4.4.2.1 Accuracy of residual disease measurement 
An additional problem with using residual disease as an outcome in analysis is the potential 
for inaccurate measurement and bias. As discussed earlier in this chapter, residual disease 
tumour estimation has been demonstrated to show large variability between surgeons with 
underestimation of the size of disease occurring  (Préfontaine et al, 1994). There is also the 
potential for reporting bias especially if units are part of large consortiums where success 
rates may be compared. The classification of presence or absence of residual disease may 
be found to be less susceptible to errors in measurement, as anecdotal evidence would 
suggest it is far easier to be certain that no disease is present compared to whether disease 
is 10mm in diameter or more than 10mm in diameter. The findings in randomised controlled 
trials (Vergote et al, 2010) that demonstrate that patients who receive neoadjuvant 
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chemotherapy and interval debulking surgery compared to primary debulking have greater 
rates of optimal debulking but do not demonstrate an improved PFS or OS may be an 
example of how misclassification of residual disease can affect results. This curious lack of 
correlation between improved debulking rates and OS in the neoadjuvant group may be 
explained if surgeons misidentified active residual disease as fibrosis or scar tissue. If some 
cases in the neoadjuvant group were classified as optimally debulked but were in truth 
suboptimally debulked survival outcomes may differ. This may account for why patients 
receiving optimal debulking in the primary surgery group had a median OS of 45 months 
compared to 38 months in the neoadjuvant chemotherapy group.  
Tumour biology may well influence the ability to perform optimal debulking surgery but the 
multiple factors also involved in the final surgical outcome make identification and 
interpretation of results difficult. It would be worthwhile repeating this analysis in a large 
prospective dataset where the multiple of other influencing factors could be accurately 
recorded and adjusted for in analysis. 
 
4.4.3 Differentially methylated loci in association with OS 
Survival analysis identified 27 loci from 732 in adhesion and cell migration pathways, where 
differential methylation was significantly associated with OS independent of residual disease 
status. To demonstrate that this survival advantage in the optimally debulked cases was not 
due to patients receiving total macroscopic debulking (0mm residual disease) the data was 
further divided into those cases only. Kaplan-Meier plots demonstrate that methylation at 
these loci is still associated with survival despite them receiving the best surgical outcome 
possible (Supplementary Figure 8.7). The small sample size in this subgroup should be 
noted, but again there are clear survival advantages to having high methylation (above the 
mean) in these locations.  
Stepwise regression models identified the 17 best predictors and generated a score which 
patients could enable categorisation to predict those that had a good survival versus poor 
survival. It should also be noted that only a small subset of loci were investigated in this 
analysis. There are likely to be other important loci which are associated with survival in 
optimally debulked patients that have yet to be discovered. Different pathways that may be 
investigated include angiogenesis, apoptosis and p53 signalling pathways, and extracellular 
matrix production and remodelling (Tothill et al, 2008) and the Wnt pathway (Dai et al, 2011) 
which have previously been shown to be associated with survival in EOC cohorts.  
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4.4.3.1 Biological function of candidate “survival” loci 
From the list of candidates identified, biological function adds weight to the importance of 
these findings. FGF-1, -4, -6 and -21 were significantly differentially methylated in the HH 
dataset, with FGF-1 and -4 demonstrating differential gene expression as well. These genes 
are part of the fibroblast growth factor family which translate to proteins which are involved in 
normal development and wound healing and become dysregulated in tumour development 
and progression (Powers et al, 2000). FGF-4 is a known oncogene discovered in the 1980’s 
from Kaposi’s sarcoma (Delli Bovi et al, 1987) and overexpression of FGFs has been found 
in numerous cancer types including gliomas (Takahashi et al, 1990) and bladder cancer (di 
Martino et al, 2012). They appear to have important roles to play in tumour angiogenesis. 
Blocking FGF receptors with targeted drugs has been demonstrated to inhibit tumour 
angiogenesis and growth (Bono et al, 2013). Increased methylation in FGF-1, -4, -6, and -21 
were associated with improved survival in the HH dataset. These probes were all located at 
promoter regions of the genes and thus as hypermethylation is related to gene silencing, the 
expected outcome of this differential methylation would be a decrease in gene expression. 
There was an associated significant decrease in gene expression of FGF-1 associated with 
improved OS seen on the Affymetrix array in keeping with this. Conversely higher gene 
expression of FGF-4 was seen in relation to improved overall survival. However due to the 
small sample size in this set (n=20) confidence interval are extremely large and thus no 
definitive conclusions should be drawn from this analysis.  
Differential methylation and expression of genes involved in myosin / actin contractility 
MYLK, MYLK2, MYL7 and MYL9 were also identified to be associated with survival, with 
MYLK2 validating in the TCGA dataset. MYLK has been shown to be crucial for cell 
migration (Webb et al, 2004) and invasion and also related to survival in lung and breast 
cancer cohorts (Hsu et al, 2013). MYLK, MYLK2 and MYL7 loci were located at gene 
promoters and demonstrated increased methylation associated with improved survival, in 
keeping with gene silencing. Although expression of MYLK was found to be lower in 
improved survival, there was no significant correlation between methylation and gene 
expression of this locus, and large confidence intervals again highlight the need for caution 
in conclusion. High methylation of MYL9 also at the gene promoter was conversely 
associated with poor OS. MYL7 and 9 are within the same family of genes encoding myosin 
light chain proteins. If it is to be assumed that differential methylation impacts on gene 
expression and thus overall function of the cell it is unclear why two very closely related 
structures would affect survival differently. This demonstrates the importance of further 
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validation of array studies as results found by chance despite statistical significance are still 
possible.  
Only two loci MYLK2 and MAPK3 were found to be significantly differentially methylated in 
the TCGA dataset. However as discussed previously there are major differences between 
survival outcomes in optimally debulked patients within the two datasets and thus TCGA 
may not be a suitable dataset to confirm these findings. Best evidence to validate or reject 
these previous significant findings would be in a new cohort of samples (stage 3 and 4, high 
grade serous only) demonstrating significant improved survival in those with minimal residual 
disease. A power analysis determined the number of samples required to detect a hazard 
ratio 2.0 between the methylation loci and OS.  Assuming 85% power, an alpha of 0.05, a 
proportion of known OS events of 0.56 (based on the Hammersmith population) and 
assuming that patients could be dichotomized into a 50% “poor prognosis” group and a 50% 
“good prognosis” group based on their methylation marker median, at least 134 patients 
would be needed for a validation study. Any future work should therefore focus on validation 
of these candidate loci, plus analysis of further biologically important pathways in large 
independent cohorts. 
 
4.5 Summary 
This work has highlighted the challenges of determining a biological profile for tumours 
dependent on debulking due to the variability of surgical outcomes. Prediction of survival in 
these cohorts however appears more promising with further validation planned for the future.   
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Chapter 5: Candidate loci associated with primary 
chemotherapy response in tumour tissue, and evaluation 
in plasma and in vitro models   
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5.1 Introduction 
This chapter explores differential DNA methylation and gene expression in the HH dataset 
(with evaluation in the TCGA dataset) in association with chemotherapy resistance and 
recurrence. Further evaluation of candidate loci identified is performed through in vitro cell 
line models and assays of chemotherapy resistance The ability to find these loci of interest in 
matched plasma from patients with EOC is then investigated. 
 
5.2 Background 
Chemotherapy resistance remains a major challenge in the management of cancer 
sufferers. In EOC that challenge is particularly prominent with the majority of patients 
developing chemotherapy resistance within 5 years of diagnosis. Patients who relapse within 
6 months of treatment are classified as platinum-resistant and only 10% will respond to 
further platinum based compounds (Gore et al, 1990). There are additional subsets of 
patients who have platinum resistant disease from the outset (platinum refractory), do not 
respond to first line platinum and are classified as having progressive disease with an 
increase in tumour burden throughout chemotherapy cycles. As discussed in the introduction 
of this thesis it is obvious that a wide range of mechanisms can lead to chemotherapy 
resistance and epigenetic mechanisms have been shown to contribute to this.  
No previous published study has investigated genome wide differential methylation in EOC 
tumours with annotated RECIST response. Therefore the HH dataset was used to assess 
differential methylation in these tumour samples in an attempt to find reliable biomarkers of 
chemotherapy response. 
 
5.3 Results 
5.3.1 Differential methylation in association with chemotherapy response  
5.3.1.1 HH dataset 
To investigate whether differential methylation was associated with chemotherapy resistance 
in the HH dataset patients were categorised into two groups. Those with chemotherapy 
complete response (n=31), partial response (n=20) and stable disease (n=7) were classified 
as responders and those with progressive disease (n=5) as non-responders. Linear 
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regression models adjusting for microarray chip determined that 12 from a total of 27,578 
loci were significantly differentially methylated at p<0.05 and FDR<5%. Interestingly, four of 
these 12 significant probes covered the same gene MSX1. As the primary chemotherapy 
response categorisation was not standardised through strict criteria, all patients with 
samples on the array who received chemotherapy at Hammersmith Hospital were re-
categorised using RECIST 1.1 response (see Materials and Methods, section 2.4.1). This 
changed the categorisation of 25 patients, with two further patients excluded due to the 
absence of CT imaging. Table 5.1 shows clinical characteristic data for the included cases 
with evaluable RECIST 1.1 criteria. 
All patients received carboplatin as adjuvant chemotherapy with 65.6% also receiving 
paclitaxel. 24 patients had complete response (CR), 31 patients had partial response (PR), 3 
patients had stable disease (SD) and 3 patients had progressive disease (PD). There  was 
no significant difference between debulking rate, stage or chemotherapy regime in patients 
who had response to chemotherapy or stable disease compared to those with progressive 
disease, there was a statistically significant difference in grade between the 2 groups 
(p=0.0168) and was therefore adjusted for in subsequent analysis.  
 
Table 5.1 Clinical characteristics grouped by chemotherapy response for HH and TCGA 
datasets. Chemotherapy response from HH data determined by RECIST 1.1 criteria. 
 
*complete response, partial response and stable disease 
** p value determined by Kruskal-Wallis and chi2 test
  
Hammersmith dataset TCGA dataset 
  
Response 
group*,  
n=58 
Progressive 
disease 
group, n=3 
p 
value** 
Response 
group*, 
n=231 
Progressive 
disease 
group, 
n=21 
p 
value** 
Age (mean) 60.26 62 0.244 58.92 63.84 0.057 
Grade 
Grade 1 1 1 
0.017 
19 2 
0.7 
Grade 2 13 1 203 17 
Grade 3 44 1 3 0 
0.286 
Stage 
3B 1 1 
0.13 
14 0 
3C 13 1 177 15 
4 44 1 37 6 
Chemotherapy 
Carboplatin 58 3 
0.547 
unknown unknown 
N/A 
Paclitaxel 38 2 unknown unknown 
Residual 
disease 
Optimal debulking 31 1 
0.105 
151 12 
0.049 Suboptimal 
debulking 27 2 49 9 
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Following re-categorisation into RECIST classification the individualised linear regression 
analysis was repeated for loci corresponding to the MSX1 gene. Adjusting for array chip and 
grade, 8 from 18 available loci were significantly differentially methylated (p<0.05, FDR<5%). 
For all but one significant probe (cg09563795), methylation was significantly lower in the 
group with PD versus those with response to chemotherapy (Figure 5.1, Table 5.2).  
 
 
Figure 5.1. Box-whisker plots for DNA methylation at 8 significant MSX1 loci, grouped by 
RECIST chemotherapy response in HH dataset. 
 
CR, complete response. PR, partial response. SD, stable disease. PD, progressive disease 
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  Chemo response 
Median methylation 
(β)  Recurrence 
Median methylation 
 (β) 
Correlation to 
gene exp.  
(Affymetrix array) 
Probe ID Probe location Beta-coeff* 
p 
value q value Response 
PD 
group 
Δ 
methylation 
% 
Beta-
coeff** 
p 
value 
q 
value 
PFS>12 
mths 
PFS<6 
mths p value rho 
cg20588069 Before promoter -1.005 0.002 0.007 0.47 0.14 32.2 -0.566 0.050 0.127 0.47 0.20 <0.001† 0.438 
cg15696627 Promoter 0.072 0.74 0.866 0.03 0.04 -0.5 0.025 0.864 0.975 0.03 0.04 0.647 -0.087 
cg26615830 Promoter 0.007 0.976 0.976 0.03 0.03 0.2 -0.023 0.867 0.975 0.03 0.03 0.84 -0.038 
cg15755084 1st exon 0.033 0.818 0.866 0.04 0.03 0.1 -0.020 0.862 0.975 0.03 0.03 0.542 -0.115 
cg11930592 1st exon -0.139 0.49 0.735 0.02 0.02 0.1 0.003 0.985 0.989 0.02 0.02 0.67 0.081 
cg06677140 1st exon 0.064 0.784 0.866 0.04 0.04 -0.3 -0.003 0.989 0.989 0.04 0.04 0.005† -0.363 
cg03717979 Intron 0.06 0.681 0.866 0.04 0.04 -0.4 -0.021 0.823 0.975 0.04 0.03 0.048 -0.366 
cg03199651 Intron -0.204 0.621 0.86 0.07 0.06 0.8 -0.655 0.097 0.160 0.07 0.05 0.008 -0.479 
cg14167596 Intron -0.402 0.299 0.489 0.08 0.07 1 -0.532 0.130 0.195 0.11 0.07 0.053 -0.358 
cg20161179 Intron -0.482 0.279 0.489 0.20 0.12 7.3 -0.658 0.088 0.159 0.22 0.10 0.023 -0.417 
cg22609784 Intron -0.639 <0.001 0.002 0.65 0.27 38.6 -0.402 0.009 0.032 0.65 0.53 0.726 -0.067 
cg09573795 Intron -0.296 0.018 0.045 0.76 0.78 -2.1 -0.202 0.082 0.159 0.76 0.67 0.603 -0.099 
cg27038439 Intron -0.243 <0.001 0.002 0.91 0.73 17.7 -0.167 0.011 0.034 0.91 0.75 0.805 -0.047 
cg24840099 2nd exon -0.671 <0.001 <0.001 0.78 0.34 44.9 -0.526 <0.001 0.001 0.78 0.34 0.026† 0.289 
cg09748975 2nd exon -0.384 <0.001 <0.001 0.88 0.55 33 -0.315 <0.001 0.001 0.88 0.56 0.783 0.052 
cg03843978 2nd exon -0.188 0.028 0.055 0.61 0.46 14.8 -0.121 0.089 0.159 0.61 0.48 0.042† 0.263 
cg20891301 2nd exon -0.192 0.021 0.046 0.75 0.57 18 -0.197 0.002 0.010 0.75 0.57 0.575 0.106 
cg01785568 2nd exon -0.427 0.005 0.015 0.69 0.43 25.9 -0.387 0.002 0.010 0.71 0.45 <0.001† 0.55 
 
Table 5.2. Summary of HH dataset analysis, differential methylation of MSX1 loci in association with chemotherapy response and recurrence.  
 
* Linear regression model adjusting chip and grade ** and residual disease 
† gene expression determined by RT-PCR 
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5.3.1.2 Differential methylation of MSX1 in association with disease recurrence 
To investigate whether differential methylation of MSX1 associates with PFS, patients were 
grouped into those who had disease recurrence within 6 months or less of primary debulking 
surgery (n=5) and those that had disease recurrence at more than or equal to 12 months 
(n=34). Individualised linear regression adjusted for chip, grade and residual disease, 
demonstrated 6 / 18 probes which were significantly differentially methylated (p<0.05, 
q<0.05) (Table 5.2, Figure 5.2). 
 
5.3.1.3 TCGA dataset evaluation 
Following the above discovery analysis on the limited sample set available from HH, the 
TCGA data was used in an attempt to validate the findings, although it should be noted that 
heterogeneous 1st line chemotherapy agents were used and that the response was not 
defined through RECIST 1.1 criteria. Data was available on 252 patients with high grade 
serous tumours with chemotherapy response recorded. 21 had progressive disease and 231 
had CR, PR or SD. Clinical characteristics are describe in Table 5.1, there was a significant 
difference in residual disease status between the response and non-response groups and 
therefore this was additionally adjusted for in subsequent analysis. Data was available on 15 
probes that correspond to MSX1. Linear regression models adjusting for  array batch, grade 
and residual disease found 3 probes significantly differentially methylated cg14167592 
(p=0.005, FDR<5%), cg20161179 (p=0.001, FDR<5%)  and cg20588069 (p=0.041, 
FDR=15%) (Table 5.3). Corresponding to the HH dataset these probes demonstrated a 
lower level of methylation in patients with PD versus response. Methylation at the 3 probes 
in the response group was 9.1%, 20.9% and 51.7% and 5.0%, 12.0% and 39.0% in the PD 
group respectively.  
Differential methylation of MSX1 was also significantly associated with PFS in the TCGA 
dataset. 31 patients had recurrence at ≤6 months and 115 had recurrence at ≥12 months. 
Repeating linear regression models adjusting for chip, grade and residual disease 
demonstrated 5 from 15 probes were significantly differentially methylated (p<0.05, 
FDR<15%) in association with PFS (Table 5.3, Figure 5.2), 2 from 5 probes were significant 
at a FDR of <5%.  This again demonstrated that methylation at these CpG sites in MSX1 
was significantly lower in patients who relapsed within 6 months of treatment.  
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 Chemotherapy response 
Median methylation 
(β) Recurrence 
Median methylation 
(β) 
Correlation to gene 
exp. 
Probe ID BetaCoef* p value 
q 
value Response PD BetaCoef* 
p 
value 
q 
value 
PFS>12 
mths 
PFS<6 
mths p value rho 
cg20588069 -0.308 0.041 0.152 0.517 0.390 -0.218 0.159 0.265 0.507 0.412 <0.001 0.351 
cg15696627 -0.031 0.762 0.803 0.032 0.031 -0.011 0.895 0.895 0.031 0.029 0.176 -0.085 
cg26615830 -0.082 0.495 0.571 0.036 0.024 -0.088 0.393 0.536 0.025 0.023 0.816 -0.015 
cg15755084 -0.115 0.240 0.361 0.029 0.028 -0.057 0.442 0.552 0.027 0.027 0.261 -0.071 
cg11930592 -0.134 0.396 0.519 0.018 0.021 -0.073 0.594 0.686 0.019 0.017 0.590 -0.034 
cg06677140 -0.031 0.803 0.803 0.037 0.040 -0.051 0.667 0.714 0.037 0.040 0.003 -0.186 
cg14167596 -0.590 0.006 0.043 0.091 0.050 -0.604 0.002 0.018 0.093 0.050 0.376 -0.056 
cg20161179 -0.593 0.001 0.015 0.209 0.120 -0.698 <0.001 0.001 0.245 0.120 0.126 -0.097 
cg22609784 -0.143 0.078 0.152 0.746 0.677 -0.179 0.023 0.114 0.768 0.677 0.058 0.119 
cg09573795 -0.126 0.075 0.152 0.823 0.779 -0.124 0.039 0.115 0.828 0.793 0.013 0.157 
cg24840099 -0.144 0.072 0.152 0.850 0.797 -0.147 0.053 0.115 0.853 0.821 0.003 0.184 
cg09748975 -0.111 0.081 0.152 0.958 0.945 -0.124 0.042 0.115 0.958 0.952 0.019 0.147 
cg03843978 -0.040 0.415 0.519 0.667 0.672 -0.057 0.188 0.283 0.668 0.667 0.019 0.148 
cg20891301 -0.068 0.150 0.250 0.893 0.880 -0.082 0.050 0.115 0.899 0.872 0.031 0.136 
cg01785568 -0.217 0.063 0.152 0.813 0.625 -0.208 0.067 0.126 0.802 0.626 <0.001 0.497 
 
Table 5.3. Summary of TCGA dataset analysis, differential methylation of MSX1 loci in association with chemotherapy response and 
recurrence. 
 
* Linear regression model adjusting for chip, grade and residual disease 
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5.3.1.5 Correlation between DNA methylation and gene expression 
To determine the relationship between differential DNA methylation at individual loci at the 
MSX1 gene and gene expression, gene expression data was obtained through real time-
PCR (RT-PCR) and the Affymetrix gene expression array of tumour samples. RT-PCR of 
MSX1 was performed on 60 tumour samples and 31 cases from the Affymetrix data 
corresponded to cases on the methylation array. This data demonstrated that 8 individual 
methylation probes significantly correlated to gene expression (Table 5.2, Figure 5.2). Four 
probes demonstrated that an increase in methylation and was significantly associated with 
an increase in gene expression (Figure 5.4A-D). The first locus (cg20588069) occurs 
approximately 1000 bases upstream of the 5’ UTR of the gene and the latter three loci 
(cg24840099, cg03843978 and cg01785568) are at intragenic regions (2nd exon). Four 
additional loci at the 1st exon (cg06677140) and intron region (cg03717979, cg03199651, 
cg20161179) demonstrated decreased methylation correlating to increased gene expression 
(Figure 5.4E-D). There was no significant difference between gene expression determined 
through RT-PCR and RECIST response in univariate analysis (unpaired t-test p=0.656) or 
multivariate analysis adjusting for grade of disease (p=0.989). 
The TCGA data was also used to relate DNA methylation and gene expression of MSX1. 
Confirming the above findings, 8 from 15 available probes were significantly correlated 
(p<0.05) to gene expression with direction again correlating to location of the probe (Figure 
5.2). Probes at intragenic regions demonstrated a significant correlation between a decrease 
in methylation and a decrease in gene expression.  Again, there was no significant 
difference in gene expression dependent on chemotherapy response in both univariate 
(p=0.697) or multivariate analysis (n=252, p=0.803). See section 5.5.2 for further discussion 
of these findings. 
5.3.1.6 Summary 
This analysis has demonstrated multiple CpG loci at MSX1 were significantly associated with 
chemotherapy resistance and recurrence in two independent datasets, and differential 
methylation significantly correlated to MSX1 gene expression as summarised in Figure 5.2. 
Further evaluation of these significant loci was then achieved by pyrosequencing, SNP 
analysis and immunohistochemistry.   
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Figure 5.4. Correlation between DNA methylation at specific CpG loci and gene 
expression of MSX1. A-D, H RT-PCR data. E-G, Affymetrix gene expression array data 
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5.3.2 Technical validation through pyrosequencing 
To ensure the measure of DNA methylation at candidate loci determined by the Infinium 
HumanMethylation 27K microarray was accurate, technical validation was performed 
through pyrosequencing. This also enabled optimisation of the pyrosequencing assay to 
enable measurement of DNA methylation within cell-free DNA in patient plasma samples, as 
detailed in section 5.3.5.3. Pyrosequencing assays were designed and optimised for probes 
cg01785568 and cg22609784. Pyrosequencing was performed on 83 matched samples in 
the HH dataset. There was a significant correlation between pyrosequencing assays and the 
corresponding beta values as determined by the 27K array (Figure 5.5A & B). In multivariate 
linear regression model again adjusting for grade, both pyrosequencing assays were 
significantly associated with chemotherapy RECIST response with lower median methylation 
in the PD group (n=61, cg22609784: p<0.001, median methylation response group = 64.5%, 
median methylation in PD group = 30.2%, cg01785568: p=0.003, median methylation 
response group = 59.5%, median methylation in PD group = 26.1%).  
 
 
Figure 5.5. DNA methylation of MSX1 determined by pyrosequencing against DNA 
methylation of MSX1 determined by 27K array. A, for CpG site cg22609784. B, for CpG site 
cg01785568  
A B 
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5.3.3 SNP analysis 
On further interrogation of the data one of the significant MSX1 probes cg01785568, was 
found to contain a site for a single nucleotide polymorphism (SNP) (ID: rs8670). This 
particular SNP, with a minor allele frequency (MAF) of 0.19 (19%), leads to thymine 
replacing cytosine 41 bases downstream from the CpG site of interest. SNPs are known to 
affect methylation (Bell et al, 2011; Hellman & Chess, 2010) and could lead to inaccurate 
beta values on the Illumina array due to hybridisation problems of array technology 
(Benovoy et al, 2008; Sliwerska et al, 2007) and therefore this particular region was 
investigated further. In order to sequence the region of interest a pyrosequencing assay was 
designed on the lower strand with a correlating adenine (A) to guanine (G) SNP.  For 92 
tumour tissue samples; 61 were homogenous GG, 20 were heterogeneous GA and 11 were 
homogenous AA. There was no significant difference in methylation at probe cg01785568 
between each group (Kruskal-Wallis test, p=0.952) indicating that the presence of a SNP did 
not affect the methylation at this particular locus (Figure 5.6).  
 
 
 
 
 
 
 
 
Figure 5.6. DNA methylation of MSX1 at CpG site cg01785568 categorised by SNP. 
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5.3.4 In vitro assays of chemotherapy resistance 
5.3.4.1 Differential methylation, gene and protein expression in ovarian cancer cell line pairs 
In order to further evaluate the findings that differential methylation and protein expression of 
MSX1 was associated with chemotherapy response and early disease recurrence, 
methylation, gene and protein expression was investigated in in vitro models of 
chemotherapy resistance. As described in Chapter 2: Materials and Methods, section 2.9.1, 
three cell line pairs were used which are commonly used in the literature as cell line models 
of EOC (Domcke et al, 2013). These cell lines pairs consist of a platinum sensitive parental 
cell line (A2780, PEA1 and PEO14) and a platinum resistant cell line derived from the 
sensitive cell either in vitro (A2780/cp70 (for purposes of this thesis referred to as cp70) or in 
vivo (PEA2 and PEO23). Cisplatin sensitivity of the individual cell lines was determined 
through MTT assay (Figure 5.9B).  
RT-PCR of the individual cell lines normalised to endogenous control was performed to 
determine MSX1 mRNA expression in the 3 cell line pairs in two independent experiments. 
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Figure 5.8. Kaplan-Meier plot for PFS dependent on IHC weak protein staining versus 
moderate and strong protein staining. 
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Gene expression for each cell line was analysed relative to gene expression in cp70 cells 
(Figure 5.9A). A2780 cells had almost 10 fold higher mRNA levels compared to cp70 cells 
(unpaired t-test, unequal variance, p<0.001), PEA1 and PEO14 cells had more than 2 fold 
higher expression compared to PEA2 and PEO23 (p=0.015 and p<0.001 respectively). The 
level of protein expression of MSX1 was determined by Western blotting using β- actin 
protein as an endogenous loading control. This demonstrated a qualitative decrease in 
protein expression in both resistant PEA2 and PEO23 lines compared to PEA1 and PEO14 
(Figure 5.9C). DNA methylation of two intragenic CpG sites within MSX1 gene was 
determined through pyrosequencing (correlating to probes cg01785568 and cg 22609784). 
For CpG site cg01785568 there was no significant difference in methylation between PEA1 
and PEA2 (97.6% versus 90.1%, p=0.16) and PEO14 and PEO23 (91.9% versus 88.6%, 
p=0.30). Similarly for CpG site cg22609784 there was no significant difference in methylation 
for either cell line pairs (96.1% versus 93.3%, p=0.36, and 88.5% versus 95.0%, p=0.07 
respectively). There was a significant difference in methylation at both sites for A2780 and 
cp70. However unlike previous findings methylation was significantly lower in A2780 than in 
cp70 (5.9% and 5.2% versus 39.3% and 64.8%, p=0.03 and p<0.001). This work indicates 
that for in vitro EOC cell lines lower gene and protein expression is associated with cisplatin 
resistant cell lines and corresponds to the previous findings in patient tumour samples. 
However unlike tumour samples DNA methylation at intragenic locations within these cell 
lines does not correspond to cisplatin sensitivity (considered further in the discussion 
section). Despite this these cell lines are suitable for further investigation of the biological 
function of MSX1 when differentially expressed at a gene level.   
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Figure 5.9. A, MSX1 gene expression in cisplatin sensitive (blue bar) and resistant 
(purple bar) cell line pairs (biological replicate n=2, in technical triplicate). B, 
cisplatin IC50 for cell line pairs (n=1, in triplicate). C, Western blot of MSX1 protein 
expression and β-actin control in cell line pairs in 40ug total protein (n=1). 
 
Error bars, standard error of the mean (SEM). p value *<0.05, *** <0.001  
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5.3.4.2 Stable knockdown of MSX1 in A2780 sensitive cells 
As a decrease in mRNA levels of MSX1 were associated with resistant cell lines it was 
interesting to investigate whether decreasing mRNA levels in sensitive cell lines would lead 
to resistance. To determine this stable knockdown of MSX1 was created in A2780 cells (for 
full details see Materials and Methods, section 2.9.4). Small hairpin RNA (shRNA) vectors 
were used for knockdown studies to ensure a stable transfection. The shRNA when 
transfected into cells silences target gene expression via RNA interference. Four separate 
shRNA constructs which silenced MSX1 and two control constructs were transfected into 
A2780 cells. Following selection by puromycin resistance individual transfected clones were 
selected and cultivated. RT-PCR determined 8 clones with mRNA levels equivalent to or 
lower than cp70 (Figure 5.10A). Three clones demonstrating a clear decrease in MSX1 at a 
protein level were subsequently used for cisplatin sensitive assays (Figure 5.10B). The 
mRNA knockdown was confirmed to be stable in culture with decreased mRNA levels 
demonstrated at passage 10 (Figure 5.10F). Cell viability and proliferation was determined 
for each individual knockdown clone, control and A2780 and cp70 (not transfected) cell lines 
at a variety of cisplatin concentrations through MTT assay and clonogenic assay (as 
described in Materials and Methods, section 2.9.5). There was no significant difference in 
cell viability and proliferation between the knock down clones, controls and A2780 cells 
(Figure 5.10C & E). The relative number of apoptotic cells was determined in the same cell 
lines using the caspase 3/7 assay with the addition of cisplatin. There was no significant 
difference in levels of caspase 3/7, inferring no significant difference in apoptosis between 
the knock down clones, controls and A2780 cells (Figure 5.10D). The decrease in MSX1 
mRNA did not affect cisplatin sensitivity in sensitive cells possible due to other driver 
mechanisms being required. To investigate further, the converse experiments were 
performed to determine whether an increase in MSX1 could lead to cisplatin sensitisation. 
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Figure 5.10. MSX1 shRNA knockdown  and cisplatin sensitivity assays. A, MSX1 gene 
expression in knockdown clones normalised to A2780 (n=2, in triplicate). B, western blot of MSX1 
protein expression in knockdown clones in 40ug total protein (n=1). C, MTT proliferation assay 
following 24 hours of cisplatin treatment (n=2, in triplicate). D, Caspase apoptosis assay following 
24 hours of cisplatin treatment (n=2, in triplicate). E, clonogenic assay following 5 days cisplatin 
treatment and 5 days subsequent culture (n=1, in duplicate). F, repeat MSX1 gene expression in 
knockdown clones after repeated passage (P10) normalised to A2780, (n=1, in triplicate). 
Error bars represent standard error of the mean (SEM) 
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5.3.4.3 Re-expression of MSX1 in resistant A2780/cp70 cell line 
Re-expression of MSX1 in platinum resistant cp70 cells was achieved by stable transfection 
using the mammalian expression vector pcDNA3-msx1-mER kindly donated by Dr Abate-
Shen from Colombia University, USA. MSX1 cDNA was cloned into the pcDNA3-mER vector 
at BamHI site as described in (Hu et al, 2001)(see Materials and Methods, section 2.9.4 for 
vector maps). Two clones expressing MSX1 were established which correlated to high (25 
fold higher expression) and moderate MSX1 mRNA expression (10 fold higher expression) 
when compared to cp70 and control vector, these changes were consistent over several 
passages (Figure 5.11A).  With the addition of cisplatin there was significantly less cell 
viability determined by MTT assay in both MSX1 re-expression lines compared to vector 
control (Figure 5.11B). IC50s were calculated for each cell line, CP70 and control vector 
IC50 were 39 µmolar and 40 µmolar respectively, the moderate expression vector IC50 was 
35 µmolar and high expression vector IC50 was 27 µmolar. Additionally in clonogenic 
assays there was significantly less colony formation in high and moderate expression 
transfects compared to control at both 2 and 4 micromolar concentrations (Figure 5.11C & 
E).   Corresponding to this there was also a significant increase in apoptosis of the re-
expression lines compared to cp70 and vector control as indicated by the caspase 3/7 assay 
(Figure 5.11D).  Both moderate and high expression transfects demonstrated over 50% 
more apoptosis compared to control.  
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Figure 5.11. MSX1 re-expression transfects in cisplatin 
sensitivity assays. A, MSX1 gene expression in re-expression 
clones and cell lines normalised to A2780 (n=2 in triplicate). B, 
MTT proliferation assay following 24 hours cisplatin treatment 
(n=2, in triplicate). C, Clonogenic assay plates with 2 and 4 
micromolar cisplatin concentration (n=1 in duplicate). D, 
Caspase apoptosis assay following 24 hours cisplatin 
treatment (n=2, in triplicate). E, Bar chart representing 
clonogenic assay at 4 micromolar cisplatin concentration (n=1 
in duplicate), normalised to mock treatment. 
Error bars SEM, p value * <0.05, ** <0.01, *** <0.001 
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5.3.4.4 Re-expression of MSX1 and p53 downstream transcripts 
How re-expression of MSX1 causes resensitisation to cisplatin in CP70 cells is yet to be 
proven. MSX1 has been shown to stabilise p53 and increase its nuclear localization in HeLa 
cells (Park et al, 2005)(see Discussion 5.4.2.1 for further details). p53 is a principal tumour 
suppressor that induces apoptosis, cell-cycle arrest and senescence in response to a variety 
of stress signals (Bieging & Attardi, 2012). DNA damage induced by chemotherapeutic 
agents is a key stress signal which induces p53 activity, resulting in apoptosis and 
therapeutic response. In response to cellular stress, such as from chemotherapy, wild-type 
p53 acts as a transcription factor which directly regulates over 125 gene targets (Riley et al, 
2008). This in turn leads to tumour suppression through a variety of different mechanisms 
including cell-cycle arrest and apoptosis. 
To establish whether MSX1 function was related to p53 signalling, the expression of  two 
downstream p53 transcripts, CDKN1A (also known as p21) and BAX, were investigated in 
the re-expression cell lines (please note as discussed in Materials & Methods this 
experimental work was performed in collaboration with Daisy Gooch, MRes student). Cells 
were treated with cisplatin at a concentration equivalent to the IC10 and IC50 of the high 
expression vector. Following 24 hours treatment there was a significant increase in 
expression of CDKN1A and BAX in the re-expression transfects compared to vector control 
(Figure 5.12A & B). In the re-expression transfects CDKN1A expression was 10 to 17-fold 
higher than control vector and BAX was almost 3 to 5-fold more highly expressed. This 
preliminary data suggests that MSX1 may well be causing its sensitising effects through the 
p53 pathway.   
  
145 
 
0
1
2
3
4
5
6
0µm
cisplatin
10µm
cisplatin
25µm
cisplatin
R
e
la
ti
ve
 g
e
n
e
 e
xp
re
ss
io
n
 (
B
A
X
) 
0
2
4
6
8
10
12
14
16
18
20
0 µm
cisplatin
10 µm
cisplatin
25 µm
cisplatin
R
e
la
ti
ve
 g
e
n
e
 e
xp
re
ss
io
n
 (
C
D
K
N
1
A
) Control
Medium expression
High expression
 
 
  
Figure 5.12. Gene expression of p53 downstream targets in MSX1 re-expression transfects 
with cisplatin treatment for 24 hours normalised to control mock treatment  (n=1, in triplicate). 
A, CDKN1A (p21). B, BAX.  
Error bars represent minimum and maximum range of triplicate. 
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5.3.5 Establishing specificity and sensitivity of plasma biomarkers 
5.3.5.1 Background 
As discussed in the introduction of this thesis the clinical need for highly sensitive and 
specific biomarkers is well established. In the treatment of EOC, biomarkers which will aid in 
clinical decision making and treatment stratification would be of great benefit. For example a 
biomarker that could predict response to primary chemotherapy prior to treatment start 
would enable informative counselling when discussing pros and cons of the chemotherapy 
and may enable stratification for more suitable drugs.  
The differential methylation of MSX1 associated with chemotherapy response is a continous 
numerical variable, rather than a categorical methylated versus unmethylated variable. The 
majority of previous studies have determined methylation of candidate genes of interest in 
plasma through methylation specific PCR (MSP)(Begum et al, 2011; Gifford et al, 2004; 
Ibanez de Caceres et al, 2004). These studies examine methylation at CGI’s where the CpG 
site is either unmethylated or methylated and thus has a categorical outcome. MSP is a 
qualitative and not quantitative method (fluorescent MSP is semi-quantitative) and therefore 
may not be suitable to detect continuous methylation differences equating to for example, 
20% methylation versus 40% methylation. Newer techniques for quantitative analysis of CFC 
DNA such as pyrosequencing have yet to be validated in this research field. Therefore the 
next stage of this work was to determine whether pyrosequencing is a suitable method for 
detecting DNA methylation in cell-free plasma and whether this could be used to determine 
methylation of MSX1 in matched plasma samples.   
5.3.5.2 Validation of pyrosequencing assay in plasma  
Extraction of CFC DNA was performed on 18 archived plasma samples matched to tumour 
DNA covered on the 27K array. Concentrations of DNA yielded from 1ml of plasma varied 
from 0.29 to 18.43 ng/ul. DNA was eluted in 50 to 100ul volume and therefore total amounts 
of DNA ranged from 14.8ng to 1843.6ng (median 168.6ng). To ensure pyrosequencing was 
suitable for such low amounts of DNA, validation was performed on serial dilutions of tumour 
DNA samples. Serial dilutions of 8 tumour DNA samples were created to obtain 
concentrations between 1ng/ul to 100 ng/ul before and after bisulphite conversion and the 
samples were then processed for pyrosequencing designed for MSX1 (cg22609784). The 
results obtained were then compared to the “true” methylation result determined by 
pyrosequencing and 27K methylation array of a 1ug sample. 
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Samples which were bisulphite converted using 1000ug of DNA and then serially diluted 
demonstrated reproducibility between matched samples to within 5% methylation difference 
at a concentration of less than 10ng (Figure 5.13A). Samples which were diluted prior to 
bisulphite conversion demonstrated consistent results within 5% methylation difference at 
100ng and within 10% methylation at amounts as low as 10ng when compared to a sample 
at 1000ug (Figure 5.13B). These results suggest that pyrosequencing is a robust and 
suitable technique for measuring methylation at 100ng of DNA. 
 
5.3.5.3 Pyrosequencing CFC DNA 
Pyrosequencing was successfully performed on 12 plasma derived CFC DNA samples. 
Mean methylation ranged from 17.56 to 39.28% in the plasma samples. This methylation 
was consistently lower and poorly correlated to methylation of the matched tumour samples,  
which ranged from 30.13% to 83.39% (r2 =0.097) (Figure 5.14A). To determine whether 
contamination from PBMC lysis was possibly affecting the methylation values DNA from 7 
matched  PBMC samples was extracted and processed for pyrosequencing. DNA 
methylation of PBMC samples ranged from 23.25% to 38.43% and were closely correlated 
to the plasma DNA methylation values (r2=0.906) (Figure 5.14B). This suggests that a large 
proportion of DNA extracted from the plasma samples was PBMC in origin. The importance 
of careful blood processing when isolating CFC DNA has been well documented (Board et 
al, 2008; Page et al, 2006). Therefore 7 additonal samples were collected from patients 
receiving surgery at HH for ovarian cancer and were processed under strict conditions (see 
Materials and Methods, section 2.4.3). Correlation between plasma and PBMC DNA 
samples was lower than the previous set (r2=0.688)(Figure 5.14C) however as tumour DNA 
was not available on these samples it is not possible to determine whether methylation of 
CFC DNA correlated to tumour DNA. 
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Figure 5.13. Graphical representation of Δ methylation between serially diluted DNA and 1ug 
standard for individual tumour DNA samples (series legend). A, Serial dilution of samples 
after bisulphite conversion. B, Serial dilution of samples prior to bisulphite conversion. 
Red dotted line represents 5% methylation difference. Blue dotted line represents 10% 
methylation difference.  
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Figure 5.14. Correlation between MSX1 DNA methylation within different tissue samples. 
A, tumour DNA versus plasma CFC-DNA in archived samples. B, PBMC DNA and plasma 
CFC-DNA in archived samples. C, PBMC DNA and plasma CFC-DNA in prospective 
samples. D, using an ideal DNA methylation locus to determine percentage of tumour DNA 
in a plasma sample. The locus is unmethylated in PBMC DNA and hypermethylated in 
tumour DNA. 
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5.3.5.4 DNA methylation loci to measure normal DNA: tumour DNA ratio within plasma 
sample 
Healthy controls, free from cancer, have measurable amounts of CFC DNA (Jylhävä et al, 
2011; Mouliere et al, 2011; Shapiro et al, 1983). Therefore despite strict isolation and 
extraction protocols there will always be some level of non-tumour DNA within CFC DNA 
samples in cancer patients. This has less implications for qualitative results such as the 
presence of absence of any amount of DNA methylation within a sample (as determined by 
MSP) or for sequencing studies to determine mutations within the DNA. However for a 
quantitative measurement of CFC DNA methylation the true ratio of normal DNA to tumour 
DNA within a sample needs to be determined accurately. DNA methylation values would 
then be adjusted accordingly dependent on the ratio calculated. This identification would be 
possible if a locus was found which was exclusively hypomethylated in PBMCs and 
hypermethylated in tumours. Methylation at this specific locus within CFC DNA would then 
define the percentage of tumour DNA present within the sample. Figure 5.14D illustrates this 
hypothesis as an example, a beta value of 0.3 would determine that 44.6% of the sample 
contained tumour DNA. Therefore two large PBMC datasets (description of datasets in 
Materials and Methods, section 2.4.4) (BGC n=92 and EPIC n=328) were explored in an 
attempt to find such loci. In the PBMC datasets, 12,234 individual loci had DNA methylation 
consistently less than 10%. In the HH tumour dataset, 10,438 loci were consistently 
methylated at more than 20% in tumours. From these candidates, 26 loci were identified that 
were both hypomethylated in PBMC datasets and hypermethylated in the HH tumour 
dataset. However only 2 loci from 26 were also consistently hypermethylated (>10%) in the 
TGCA tumour dataset (Figure 5.15A). Median methylation for probes cg12069309 
(SEMA3B) was 1.4% in the PBMC datasets (range 0.3 – 5.3%), 67.4% (range 38.3%-90.0%) 
in the TCGA tumour dataset and 63.1% (range 29.6%-90.0%) in the HH dataset (Figure 
5.15B). Median methylation for probe cg17518965 (S1PR4) was 1.1% in the PBMC datasets 
(range 0.03 – 3.7%), 79.0% (range 11.3%-96.8%) in the TCGA tumour dataset and 73.7% 
(range 27.1%-93.3%) in the HH dataset (Figure 5.15C). The large methylation variability at 
these specific CpG sites indicates that at present it would not be possible to accurately 
define tumour:PBMC ratio using these markers. For example, if a sample was found have 
30% DNA methylation (beta value 0.3), the percentage of tumour cells within the sample 
would be anything from 30.6% to 87.6% (Figure 5.15D). Alternative methods to determine 
PBMC contamination are discussed in section 5.4.4.1 below. 
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Figure 5.15. Scheme of overall 
analysis to find potential 
biomarker of PBMC 
contamination. 
A, number of methylation probes 
identified. Red circle represents 
two probes which validate in 
TCGA data. 
B, box-whisker plot for DNA 
methylation at SEMA3B in 4 
datasets. C, Box-whisker plot for 
DNA methylation at S1PR4 in 4 
datasets. 
D, example of biomarker 
inaccuracy due to large DNA 
methylation variability within 
tumour samples (depicted by the 
minimum and maximum range). 
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5.4 Discussion 
5.4.1 DNA methylation of MSX1 within tumour is a potential biomarker of chemotherapy 
resistance 
This work explores genome-wide differential methylation of high grade serous EOC tumours 
related to RECIST defined primary chemotherapy response. These results demonstrate that 
differential methylation of MSX1 occurred at intragenic regions and at one site approximately 
1000 bases upstream of the 5’ UTR region. There was a significant association with 
differential methylation and chemotherapy response, although it should be noted the small 
sample size in the progressive disease group (n=3) in the HH dataset. As these results were 
validated in the TCGA dataset further strength is added to these findings. The chemotherapy 
response category included patients with RECIST stable disease. Patients with stable 
disease have ambiguous classification which is not able to be defined into response or 
progression categories. Therefore the analysis was repeated excluding the SD tumours, all 
probes except cg03843978 remained significant (p<0.05, FDR<10%)(Supplementary Table 
8.2). To ensure the tumours with low methylation were not due to low percentage of tumour 
nuclei on histopathology quality control spearman rank correlation tests were performed to 
compare methylation of individual loci to tumour nuclei percentage. There was no 
association between methylation and tumour nuclei percentage by spearman rank 
correlation tests (Supplementary, Figure 8.8).    
Differential methylation of MSX1 has not been identified in the previous study reported in the 
introduction of the chapter (Lum et al, 2013). However this study used a DMH array with 
customised primers designed for largely promoter regions and therefore it is not clear if the 
relevant regions of the MSX1 gene were covered in this array. A previous genome wide 
gene expression array analysis also failed to identify MSX1 as a gene important in 
chemotherapy response (Ferriss et al, 2012). However this study used a mixed histology 
FFPE sample set without strictly defined chemotherapy response which led to a high 
proportion of non-responders in the cohort (41.8%). In both HH and TCGA datasets a 
decrease in methylation was associated with a decrease in gene expression. In the HH 
dataset gene expression was found to be lower in the PD group compared to the response 
group however this was not significant. This may be a consequence of inadequate sample 
size and tissue heterogeneity in the HH dataset. There may also be other epigenetic events 
in action which impact on overall gene expression which cofounds the relationship. For each 
sample fresh frozen tumour tissue was divided in half for DNA and RNA extraction, so subtle 
differences in numbers of inflammatory cells, stromal and normal tissue between the 
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samples may have impacted on overall gene expression but not DNA methylation. Future 
research using micro-dissected tissue may clarify this issue. As discussed in the introduction 
of this thesis the full cause or consequence of intragenic methylation (IGM) is yet to be fully 
understood. Therefore the functional consequences of this differential methylation of MSX1 
may be occurring in alternative transcripts or downstream targets which have not yet been 
investigated and may cause chemotherapy response consequences. There was also a 
significant association between differential methylation of MSX1 and recurrence of disease 
before 6 months compared to after 12 months including in patients who responded to first 
line chemotherapy. This may suggest that MSX1 may also influence other cellular pathways 
involved in disease recurrence such as proliferation, invasion and metastasis. Additionally it 
may identify cancer cells which were intrinsically resistant but in proportionally smaller 
numbers which then consequently proliferate once the sensitive cells are destroyed. 
Immunohistochemistry also demonstrated that low protein expression of MSX1 was 
associated with a shorter PFS in the HH dataset. This was not statistically significant likely 
due to the small sample size (n=48) and future research validating these findings in an 
independent dataset would be beneficial.   
5.4.2 Evidence from in vitro assays 
This in vitro work adds further support to the findings that differential methylation in EOC 
tumours and increase MSX1 expression was associated with resistance to platinum-based 
chemotherapy. There was a correlating decrease in MSX1 expression in resistant cell lines 
compared to sensitive ones. There was however no correlation between DNA methylation 
and chemotherapy resistance at intragenic loci in these cell lines. Numerous studies have 
demonstrated that methylation changes substantially in vitro at promoter and intragenic 
regions (Antequera et al, 1990; Jones et al, 1990; Markl et al, 2001) which may explain 
these findings. It also suggests that in cell lines at least, different mechanisms, such as 
histone modifications for example, may be driving these gene expression changes. Knocking 
down MSX1 in sensitive cells did not alter cisplatin sensitivity. One possible hypothesis to 
explain this is that differential expression of several genes is needed to cause resistance. If 
other genes upstream of MSX1 were crucial for resistance mechanisms, MSX1 would be 
known as a “passenger” rather than a “driver” of resistance. Evidence against this however, 
is that the inverse relationship has been shown, that is increasing expression leads to an 
increase in sensitivity. In embryological development MSX2 interacts closely with MSX1, 
with the knockout of both genes being required to display certain phenotypic phenomenon in 
mice (Lallemand et al, 2005). It is possible that knock down of MSX2 or others is required for 
development of resistance in this cell line model, but not in the converse manner. However 
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in the TCGA tumour dataset there was no correlation between MSX1 and MSX2 gene 
expression and additionally no significant association with MSX2 DNA methylation or gene 
expression with chemotherapy response (Supplementary, Figure 8.8 and Table 8.3).  
5.4.2.1 MSX1, p53 and chemotherapy resistance 
In order to further determine the function of MSX1 in tumour cells, its relation to the p53 
transcripts CDKN1A (a cell-cycle regulator) and BAX (a pro-apoptotic protein) was 
investigated in the re-expression lines. This preliminary data demonstrated that both 
transcripts were up regulated in the presence of MSX1 compared to a relative absence of 
MSX1.  This suggests that in keeping with previous studies (Park et al, 2001; Park et al, 
2005) MSX1 up regulates or stabilises p53 signalling. It is well established that p53 is a 
crucial regulator in DNA damage-induced apoptosis (Brady & Attardi, 2010) and therefore it 
appears logical that aberrations to this pathway can lead to chemotherapy resistance. 
Several historical in vitro studies have demonstrated cell lines with deficient p53 exhibit less 
growth inhibition from a panel of clinically used drugs compared to cell lines with functioning 
p53 (O'Connor et al, 1997) and introduction of deficient p53 into cisplatin sensitive A2780 
cells leads to resistance (Branch et al, 2000). Furthermore IGROV cells which developed 
cisplatin resistance demonstrated reduced cell susceptibility to cisplatin-induced apoptosis 
and the presence of p53 mutation (Perego et al, 1996). Downstream transcripts of p53 such 
as pro-apoptotic proteins BAX and BAD have also been associated with chemotherapy 
resistance in vitro although evidence in clinical studies is lacking (reviewed in (Agarwal & 
Kaye, 2003). Furthermore epigenetic silencing of other downstream effectors of p53 such as 
APAF-1 has been demonstrated in chemotherapy resistant melanoma cells and re-
expression of APAF-1 by 5-aza-2’-deoxycytidine lead to enhanced chemosensitivity 
(Soengas et al, 2001). Despite this evidence it should be noted that as all (or almost all) of 
high grade serous ovarian cancers have TP53 mutations (Ahmed et al, 2010) and that 80% 
of these respond to first line chemotherapy, other mechanisms of chemotherapy resistance 
are obviously important.  
5.4.2.2 p53 mutation and stability 
Whether the effects of MSX1 are variable depending on whether wild-type or mutant p53 is 
present is yet to be determined. p53 is regulated through numerous mechanisms including a 
negative feedback loop where the p53 target, MDM2, promotes degradation of p53 through 
ubiquitination, therefore shortening p53 half-life (Riley et al, 2008). Other regulators of p53 
include other E3 ubiquitin ligases such as PIRH2, and COP1 and other MDM2-family 
members such as MDMX (Brady & Attardi, 2010; Wade et al, 2013). Unlike other tumour 
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suppressor genes which require the loss of both alleles, mutation of one allele of p53 can 
lead to loss of function in a dominant-negative fashion (Harvey et al, 1995). This is due to 
the p53 protein functioning as a tetramer in cells, and therefore the mutated protein inhibits 
the wild-type protein from binding to target gene promoters (Willis et al, 2004). p53 function 
is also regulated through upstream signal mediators such as ATM, ATR and CHK2. These in 
turn act by modifying the p53 tetramer by phosphorylation and thereby leading to an active 
protein (Riley et al, 2008). Other signal mediators such as p14 ARF activate p53 through its 
inhibiting effect on MDM2. It therefore appears plausible that MSX1 may act by stabilising or 
reactivating p53 which in turn leads to an increase in apoptosis in resistant cells. Restoration 
of wild-type conformation and activity to p53 mutants is a promising strategy for cancer 
therapy (Bassett et al, 2008). This potential has been demonstrated by the development of a 
peptide, named CDB3, that can bind and stabilise wild-type p53 in the presence of mutant 
p53 (Friedler et al, 2002). An additional molecule CP-31398 has been shown to stabilise 
wild-type p53 by blocking its degradation, this in turn increases steady-state levels of wild-
type protein by up to 5-fold in cells with mutant p53 present (Bassett et al, 2008). This 
molecule has also been shown to cause subsequent inhibition of tumour xenografts by up to 
75% in vivo (Foster et al, 1999). More recently resuscitation of wild-type p53 has been 
demonstrated through post-transcriptional processes by disrupting ceramide glycosylation 
(Liu, 2011).  Further work should be performed to clarify the effects of MSX1 in the presence 
of mutant p53. 
5.4.2.3 MSX1 and other signalling pathways  
As overexpression of MSX1 has also been shown to increase expression of Wnt pathway 
inhibitors (Revet et al, 2010), this may be another mechanism by which MSX1 exerts its 
effects on response to cisplatin therapy. Wnt signalling has been implicated in chemotherapy 
resistance in a variety of cancer types. SFRP4  a pro-apoptotic signal and a negative 
regulator of Wnt signalling has been demonstrated to be up regulated in sensitive A2780 cell 
lines compared to cp70, with a correlating change in sensitivity depending on knockdown 
and re-expression assays (Saran et al, 2012). In keeping with this epigenetic silencing 
through promoter methylation of another antagoniser of the Wnt pathway, SFRP5 has been 
demonstrated in EOC tumour samples to be significantly associate with clinical 
chemotherapy resistance (Su et al, 2010). Gene expression profiling of hepatocellular 
carcinoma samples found enrichment of genes involved in Wnt signalling in association with 
interferon-alpha and 5-flurouracil combination treatment resistance and furthermore 
activation of Wnt signalling by glycogen synthesis kinase-3 inhibitor induced chemotherapy 
156 
 
resistance in vitro (Noda et al, 2009). Further work to establish whether MSX1 expression in 
ovarian cancer cell lines affects Wnt signalling is obviously needed.  
5.4.2.4 Limitations of cell line work  
The cell line A2780 and its in vitro derived platinum resistant daughter line cp70 is the 
second commonest cell line in use for studying high grade serous ovarian cancer with over 
1363 related PubMed citations (Domcke et al, 2013). Despite this its origins are unclear and 
were never specified when the cell line became available to researchers over 25 years ago. 
A recent study evaluating presumed high grade serous ovarian cancer cell lines with 
correlation to the TCGA dataset (Domcke et al, 2013) has illustrated how A2780 is actually a 
poorly suited model for high grade serous tumours. Unlike high grade serous tumours there 
is no TP53 mutation in A2780 cells, although despite wild-type TP53 there is dysfunction of 
the protein. A2780 cells also show the presence of ARID1A, BRAF, PIK3CA and PTEN 
mutations which are found in other histological subtypes such as low grade (Singer et al, 
2003), endometrioid (Obata et al, 1998; Wiegand et al, 2010) and clear cell carcinomas 
(Campbell et al, 2004; Wiegand et al, 2010), but not in high grade serous tumours. 
Furthermore A2780 gene expression clustering analysis reveals this cell line to be more 
closely related to lung, liver and gastric cancer cell lines with its copy-number profile showing 
no resemblance to TCGA tumour samples (Domcke et al, 2013). PEA1 is a cell line derived 
from poorly differentiated adenocarcinoma of the ovary derived from cells within malignant 
pleural effusion and subsequent PEA2 cell line derived from the ascites from the same 
patient on relapse after cisplatin and prednimustine treatment (Langdon et al, 1988). 
Similarly PEO14 were derived from ascites of a patient with well differentiated serous 
adenocarcinoma of the ovary prior to treatment and PEO23 from the same patient following 
relapse of cisplatin and chlorambucil (Langdon et al, 1988). These cell lines have been 
previously shown to have TP53 mutations and no mutation of KRAS, BRAF, or PIK3CA 
consistent with high grade serous histotype (Cooke et al, 2010). Therefore all of the above 
work should be repeated using these cell-lines to definitively conclude the role of MSX1 in 
high grade serous EOC.  
5.4.3 MSX1 methylation cannot currently be reliably quantified in cell-free plasma 
It was not possible to reliably determine quantitative DNA methylation within cell-free plasma 
of patients with EOC due to normal cell contamination complications. Careful blood 
processing to obtain only CFC DNA when extracting DNA from plasma is crucial. Plasma is 
seen to be preferred to serum due to early studies demonstrating more contamination of 
normal DNA within serum samples (Board et al, 2008). Quick processing (Gormally et al, 
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2004) and extra centrifugation steps has demonstrated loss of larger DNA fragments thought 
to be from normal cellular DNA (Page et al, 2006). Additionally adding heparin to blood as 
the anticoagulant agent was thought to inhibit downstream RT-PCR analysis. However there 
is no conclusive evidence that CFC DNA extraction from blood containing heparin is inferior 
to EDTA (Lam et al, 2004). The archived samples were collected in heparinised tubes 
without the extra centrifugation steps and an unknown time from collection to processing. 
Therefore the finding that DNA methylation within the plasma closely correlated to that in the 
PBMC samples is not surprising. Prospective samples were therefore collected and 
processed to strict protocols. Unfortunately as tumour DNA was not available for these 
samples limited interpretation can be made of the results.  
5.4.3.1 Determining PBMC contamination within a sample 
CFC DNA is found in variable amounts in cancer patients and at variable proportions of 
tumour DNA to normal DNA (Hibi et al, 1998; Jahr et al, 2001). Three  mechanisms for the 
release of tumour DNA into the blood are proposed (Gormally et al, 2007), 1) apoptosis and 
necrosis of tumour cells with the cell contents releasing into the circulation, 2) release of 
intact cells into the blood stream with subsequent lysis, or 3) spontaneous release from living 
cells (Stroun et al, 2000). How free DNA from non-tumour cells enters the circulation is more 
unclear, one hypothesis is that a large majority comes from dying normal cells that surround 
the tumour although this has not been conclusively proved (Jahr et al, 2001) and also does 
not explain why controls without cancer also contain CFC DNA within the plasma. The 
addition that CFC DNA is found in patients with liver cirrhosis (Chang et al, 2008) and aging 
(Jylhävä et al, 2011) may suggest an underlying systemic inflammatory condition or 
oxidative stress mechanism. Clearly more robust methods are needed to accurately quantify 
the amount of tumour derived CFC DNA found within a sample. As almost 100% of high 
grade serous tumours contain TP53 mutations (Ahmed et al, 2010), RT-PCR comparing 
mutated versus wild-type DNA would be possible and the mutant allele fraction determined. 
However as over 700 TP53 mutations have been identified in cancer (Petitjean et al, 2007) it 
would be an unmanageable work load to determine this frequency on every sample. Another 
possible solution may come from sequencing technology allowing deep next-generation 
sequencing of a sample. Thus sequencing of the material would enable a proportion of 
mutant TP53 to wildtype TP53 thus giving a tumour to normal DNA ratio (assuming an 
absence of germline TP53 mutation). However this process would require previous 
knowledge on whether the TP53 mutation involved one or both alleles in the tumour, 
something which could only be determined by sequencing of the tumour itself. Additionally 
as tumour bulk consists of heterogeneous cellular mix there may be variable mutations at 
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variable allele frequency within the tumour all of which could contribute to DNA circulating 
within the plasma.      
As tumour CFC DNA is widely believed to arise from apoptotic cells previous studies have 
determined cellular contamination by DNA fragment length with DNA originating from tumour 
having a lower molecular weight  (Board et al, 2008; Jahr et al, 2001; Mouliere et al, 2011; 
Page et al, 2006; Wu et al, 2002). RT-PCR primers designed to amplify different fragment 
lengths could be performed to determine the quantity of these variable fragment lengths in 
the sample. However these findings have not been consistent in all cancer types particularly 
in prostate (Boddy et al, 2006) and in a mixture of plasma samples from patients with breast, 
ovarian and endometrial cancer longer DNA fragments were demonstrated in the cases 
compared to controls (Wang et al, 2003). There is also a lack of evidence for this variable 
fragment size in EOC and therefore this method would require further optimisation and 
validation to be of use. 
 
5.5 Summary 
This chapter has demonstrated that MSX1 appears to be an exciting candidate loci for 
determining primary chemotherapy resistance and PFS, with interesting biological findings in 
in vitro models of resistance. Future potential studies on this gene are discussed further in 
Chapter 6. 
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Chapter 6: General discussion 
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6.1 Biomarkers for surgical outcome, survival and future directions  
This work has demonstrated that differentially methylated loci found through bioinformatic 
analysis may be useful biomarkers of treatment success. In the case of the prediction of 
surgical debulking, a highly sensitive and specific biomarker is difficult to identify due to the 
multifactorial nature of the primary outcome of surgical success. With the advancement of 
surgical techniques a larger majority of these tumours are now resectable in expert centres. 
However there are still certain sites and volumes of disease which make complete debulking 
impossible even in the most skilled hands. There are likely to be biological determinants that 
affect how tumour cells invade and spread within the abdomen and this may also dictate 
sites of metastasis. However in reality, this spread of disease is more likely to be defined 
through preoperative imaging as demonstrated in Chapter 3, rather than specific molecular 
biomarkers. NICE guidance (NICE, 2011) has specifically recommended further research 
into this subject through a large multicentre case-control study to compare the accuracy of 
CT versus MRI in predicting optimal cytoreduction prior to surgery. It is also expected with 
emerging tumour-specific imaging technology this analysis will be repeated in the future, and 
may well demonstrate higher sensitivity and specificity compared to CT. It should also be 
noted that the clinical and financial relevance of correctly predicting surgical outcome has 
not been formally evaluated. It will also be necessary to determine how accurately predicting 
surgical outcomes influences patient survival, quality of life and the impact on NHS service 
planning and provision. Only then will these markers of suboptimal debulking be usefully 
incorporated into the care and management of patients with advanced ovarian cancer. 
6.1.1 Future work  
Through the development of this work it has become apparent that perhaps a clinically more 
important question, rather than the prediction of debulking, is whether there is clinical benefit 
to that individual if the disease is completely or optimally debulked. When looking at a 
population level there is no doubt that complete or optimal debulking is beneficial, however 
this analysis has identified some patients who do just as badly as those suboptimally 
debulked. Differential methylation at 27 loci were independently associated with survival, 17 
of these were found to be most important in stepwise regression model and when combined 
into a risk score were found to be significantly associated with OS. Unfortunately these 
findings did not withstand multiple analysis correction, but this may be due to the very small 
sample in this cohort. Clearly further validation is required to prove the results are genuine. 
Two loci, MYLK2 and MAPK3, remained significant in multivariate TCGA analysis, however 
they did not group accordingly when suboptimal debulked cases were reintroduced into the 
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analysis. As discussed in Chapter 4, the TCGA debulking and survival data does not mirror 
the HH dataset which may explain the lack of validation in this dataset. To achieve adequate 
validation to the highest quality this analysis should be repeated in a set of (ideally 
prospectively) collected tumour tissue with accurately annotated surgical details, and 
survival data which is regularly updated. Power calculations suggest that 134 cases would 
be needed to find significance, which would be very achievable in a busy centre with 150 
new diagnoses a year. Once validated the survival score determined through stepwise 
regression analysis would translate to a prospective trial. The definitive trial would be to 
recruit patients with advanced stage, high grade serous EOC and predict survival score by 
means of determining DNA methylation in a tumour biopsy. If a patient is given a poor 
outcome score they are then randomised into receiving debulking surgery with or without 
supraradical surgery (for example extensive upper abdominal or gastrointestinal surgery). 
This would translate into the two randomised groups receiving different debulking outcomes. 
If the survival outcome was the same for both groups this would prove that for poor outcome 
patients there is no survival benefit gained by extensive surgery and achieving an optimal 
debulk. In reality this trial would never be approved by medical ethics due to the 
overwhelming evidence of the benefit of achieving optimal debulking through extensive 
surgery and the potential to do harm in those randomised to “purposeful” suboptimal 
debulking. It may well be the case that those patients with a poor prognosis do even worse 
when they achieve suboptimal debulking. What may be more feasible is a trial where 
patients are stratified into a good outcome and poor outcome group and then randomised 
into primary surgery and adjuvant chemotherapy or neoadjuvant chemotherapy followed by 
interval debulking (Figure 6.1). As both modes of treatment scheduling have been shown to 
be as effective as each other (Morrison et al, 2012; Vergote et al, 2010) no group would 
have inferior treatment. This approach would aim to confirm that patients with poor outcome 
biomarkers do not benefit from extensive debulking surgery but will also assess whether 
they benefit from earlier chemotherapy instead. 
These survival biomarkers may also highlight potential targets for therapy. However before 
such a long and expensive process of drug development is started these loci have to prove 
themselves as drivers rather than passengers of tumorigenesis. This would be achieved first 
by relating these methylation changes to gene and ideally protein expression in matched 
tissue. The function of these changes could then be determined through knockdown and re-
expression cell line assays designed to mimic tumour behaviour (Hanahan & Weinberg, 
2011), such as invasion and metastasis through invasion, scratch and migration assays, and 
resisting cell death and sustaining proliferation through MTT, clonogenic and caspase 
assays. This could then also be replicated using in-vivo models.  
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6.2 Biomarkers for chemotherapy response and future directions 
This work has identified differential DNA methylation and expression of MSX1 to be 
associated with primary chemotherapy resistance. Hypomethylation at intragenic regions is 
associated with RECIST progressive disease. Figure 6.2 illustrates a simplified model of the 
mechanism leading to these findings. A heterogeneous mix of tumour cells are either 
methylated or unmethylated at a MSX1 CpG site. The quantity of methylated to 
unmethylated cells is responsible for the overall methylated value obtained. Those cells with 
methylated CpG site are sensitive to chemotherapy and die, leading to tumour shrinkage 
and thus RECIST responsive disease. Unmethylated cells are resistant to chemotherapy, 
survive treatment and proliferate and thus tumour bulk expands leading to RECIST 
progressive disease. This model is obviously simplified as methylation of other cells within 
the tumour bulk such as inflammatory cells, connective tissue and endothelial cells will also 
contribute to the overall methylation pattern. Some cells may indeed also be hemi-
methylated (one allele methylated whereas the other allele is unmethylated) which would 
further complicate the interpretation. In addition, other epigenetic and genetic mechanisms 
are also likely to impact on the sensitivity of individual cells to treatment and thus may 
override the mechanism in some cells.     
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6.2.1 Future work 
Hypomethylation of intragenic CpG sites was associated with a correlating decrease in gene 
expression of MSX1 in resistant tumours. Additionally in resistant cell lines a decrease in 
gene expression also correlated with a decrease in MSX1 protein expression. It is still 
unknown whether this hypomethylated locus is a cause or consequence of gene expression 
changes. In cell lines there are clearly other mechanisms causing this differential gene 
expression, as methylation was not related to resistance or gene expression. Other 
epigenetic mechanisms could account for this such as promoter methylation, histone 
modification or interfering microRNAs for example. This work has only just begun to explore 
the functional relevance of differential expression of this gene. In resistant cp70 cells 
increasing the expression of MSX1 resensitises the cells to cisplatin. This work should be 
repeated in other cell line models which more closely replicates high grade serous tumours 
such as PEA2 and PEO23, both of which have also demonstrated a significantly lower 
expression of MSX1 compared to its sensitive parental cell line. If this work was successfully 
carried out it would further support the data. In addition to this, preliminary data suggests 
that MSX1 up regulates downstream transcripts of the p53 pathway and this should be 
repeated again with MSX1 re-expression transfections in PEA2 and PEO23 cells. CDKN1A 
is a potent cyclin-dependent kinase inhibitor which functions as a regulator of cell-cycle 
progression at G1. Further experimental work to support these findings would be to assess 
cell-cycle progression through BrdU labelling and flow cytometry of re-expression transfects 
to determine the proportion of cells in each phase of the cell cycle. In those with activated 
p53 pathway and CDKN1A expression a higher proportion of cells should be held within 
G0/G1 phase.  
6.2.2 MSX1 biomarker limitations 
Following further evaluation of the function of MSX1 in tumour cells the question remains, 
how can these findings be developed further to improve the outlook for women with EOC? 
Dividing methylation in low or high groups and then combining results of two of the MSX1 
probes was able to predict chemotherapy response with a sensitivity of 79.7% and a 
specificity of 57.1%. 184 from a total of 231 people with responsive disease had a positive 
(high) score, and 12 from a total of 21 people with resistant disease had a negative (low) 
score.  Unfortunately 47 patients with a negative score had a complete, partial or stable 
response to chemotherapy (illustrated by the low negative predictive value of 20.3%). Thus if 
this scoring system was currently used an unacceptable large number of patients would be 
miss out on life-prolonging treatment. In reality there are likely to be a large proportion of 
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different genes which are dysregulated leading to chemotherapy resistance and thus a 
predictive “signature” which includes methylation of MSX1 may be more robust in accurately 
determining chemotherapy response. In the initial analysis 12 from 27,500 loci were found to 
be differentially methylated, 8 of these loci covered 7 different genes which have not been 
investigated any further.  It is possible that following validation in a RECIST defined cohort a 
combination of these loci may improve the predictive test.   
It was also not possible to accurately determine tumour DNA methylation of MSX1 in 
circulating cell-free (CFC) DNA in plasma due to PBMC contamination. However in reality, 
for this particular locus, detection in plasma would not be needed as all patients would 
receive debulking surgery prior to adjuvant chemotherapy and thus there would be a plentiful 
supply of tumour to assess DNA methylation and IHC protein expression. Further work 
should focus on how to accurately define the ratio of tumour DNA to PBMC DNA within a 
plasma sample. Once this is achieved, using pyrosequencing to accurately determine 
tumour methylation within plasma should be achievable. 
This work has not been validated in those that develop chemotherapy resistance after 1st line 
treatment (acquired chemotherapy resistance). The findings that differential gene expression 
of MSX1 was found in cell lines which mimic acquired chemotherapy response are 
encouraging. However, tumour cells are constantly undergoing evolution and change, as 
highlighted by emerging resistance to targeted therapy.  Therefore the mechanisms of 
primary chemotherapy resistance and secondary resistance may well be different and further 
work is needed to explore this further. This work would need to be replicated in tumour 
samples which are collected before and after acquired chemotherapy resistance. 
Unfortunately these samples are often difficult to obtain as repeated tumour biopsy is not 
part of routine treatment for these patients. Fortunately the development of the national 
tumour sample biobank, briTROC (Ovarian Cancer Action, 2012) will focus on collection of 
multiple biopsies throughout patients treatment and become available for use by researchers 
in the future. Another source of tumour cells comes from ascites, an accumulation of fluid 
(exudate) in the peritoneal cavity. Almost all patients with EOC tumour progression develop 
ascites (Woopen & Sehouli, 2009) which often needs to be drained for symptom control, and 
thus is a good practical source of tumour cells for research purposes. In the case of 
quantitative methylation analysis it would also be important to remove other cells within the 
ascites such as fibroblasts, macrophages and leucocytes or similar issues seen with PBMC 
contamination in CFC DNA may be observed.    
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6.2.3 Potential drug targeting 
MSX1 is a target for therapeutic manipulation due to its involvement in chemotherapy 
resistance. The aim of any drug would be to increase gene expression in resistant cells (or 
prevent gene suppression in sensitive cells). Intragenic hypomethylation was associated with 
a decrease in gene expression. It is currently unknown whether increasing methylation at 
these sites would lead to gene transcription, and there are no chemical compounds available 
which are able to methylate specific CpG sites. A reverse approach would involve preventing 
demethylation by the use of TET inhibitors which may be a possible strategy to prevent 
resistance in the future. In collaboration with DNA methylation changes the transcription of 
MSX1 is also likely to be controlled by histone modification. Further work is obviously 
needed to corroborate this, but if for example histone deactylation was also involved in 
MSX1 silencing, there may be a therapeutic role for HDAC inhibitors.  Classical targeted 
therapeutic approaches concern inhibition of molecular targets which are up regulated in 
cancer cells. For example the wide spread use of Herceptin, a monoclonal antibody which 
targets Human Epidermal Growth Factor Receptor 2 (HER2) when it is overexpressed in 
breast cancer. This work has demonstrated that a decrease in MSX1 is detrimental and that 
that increasing MSX1 expression through re-expression vectors in vitro leads to 
resensitisation. Therefore targeted molecular therapies would not be suitable in this case 
(unless inhibitors of MSX1 could be targeted). However if the current challenges of gene 
therapy can be overcome and become a reality in clinical cancer treatment, this gene could 
be incorporated into resistance cells leading to what would hopefully be an increase in 
chemotherapy response and survival.  
 
6.3 Overall Summary 
This work has highlighted how the process of bioinformatic analysis of DNA methylation 
arrays can be successfully applied to find not only biomarkers of treatment response but also 
as a platform to discover new cancer targets for biological evaluation. This further increases 
our understanding of some of the molecular components and cellular pathways involved in 
tumorigenesis and treatment response. Further work within the Epigenetics Research group 
will address some outstanding questions in the near future.  
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8.1 Illumina Infinium HumanMethylation27 Beadchip - Quality Control 
The Illumina HumanMethylation27 Beadchip (27K array) has 8 control probes to ensure 
quality of results. There are 4 sample independent controls: staining controls, extension 
controls, target removal controls and hybridization controls. These allow evaluation of the 
specific steps in the microarray process which is independent from any errors in the 
processing of original DNA samples. The sample dependent controls: bisulphite conversion 
controls, specificity controls, negative controls and non-polymorphic controls evaluate the 
original quality of the DNA samples.  
8.1.1 Sample independent controls 
8.1.1.1 Staining 
This determines the efficiency of the fluorescent staining. Staining control beads are 
attached to DNP or biotin and neither the hybridization nor extension step are necessary. In 
this study both red (DNP) and green (biotin) staining performed as expected with minimal 
background noise (Figure 8.1A). 
8.1.1.2 Extension 
These test the efficiency of extension of all 4 nucleotides. The control beads are attached to 
a hairpin probe and thus not reliant on sample hybridization. Bases A and T are monitored in 
the red channel and C and G in the green channel. These controls performed as expected 
(Figure 8.1B). 
8.1.1.3 Target removal 
This control evaluates the efficiency of stripping the probe after the extension reaction. Low 
signal should be generated in the green channel indicating that the biotin labelled controls 
have been removed. The signal should be low in comparison to the hybridization controls 
which is demonstrated in these samples of intensity less than 2000 (Figure 8.1C).  
8.1.1.4 Hybridization 
This tests the overall assay performance by use of synthetic targets which complement the 
oligonucleotides on the probes perfectly. Three different concentrations (high, medium and 
low) are used to result in various signal intensities as demonstrated on the samples (Figure 
8.1D).  
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8.1.2 Sample dependent controls 
8.1.2.1 Bisulphite Conversion 
This control assesses successful bisulphite conversion of the genomic DNA by using 
controls which always convert from a C to a T base. There should be low signal of the 
unconverted probes and high signal in the converted probes as demonstrated (Figure 8.2A). 
8.1.2.2 Specificity 
These control probes test for specificity and ensure low signal if an unmethylated sequence 
binds to a methylated probe. Control probes are either perfectly matched (PM) with no-
mismatching or have 12 mismatched nucleotides (MM). Both MM probes should 
demonstrate low signal in both channels with the red PM probe showing high signal in the 
red channel and green PM probe showing high signal in the green channel (Figure 8.2B).  
8.1.2.3 Negative Control 
Negative control probes are random oligonucleotide sequences which should not hybridize 
to any DNA sequence. The mean signal from these probes indicates the background signal 
from the array. The signal should be low in both the red and green channels as indicated 
here (note change in scale) (Figure 82C). 
8.1.2.4 Non- Polymorphic 
These test the overall assay performance, from amplification to detection. Each probe is 
designed to match each of the 4 nucleotides at non-polymorphic regions. It allows 
comparison of performance across all samples The red channel detects signal in probes 
assigned to A and T and the green channel detects signal in C and G probes. These 
samples demonstrate high signal in both channels (Figure 8.3). 
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Figure 7.9. Non-polymorphic controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1. Sample independent controls for 27K array. A, red and green staining control. B, 
red and green extension control. C, target removal control. D, hybridization control.  
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Figure 8.2. Sample dependent controls for 27K array. A, bisulphite conversion control. B, red 
and green specificity control. C, red and green negative control. 
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Figure 8.4 Correlation of β values between chips on 27K array. A, Chip 031 and 032 which 
corresponds to technical replicate of ovarian cancer cell line PEO1. B, poor correlation of β 
values between chip 031 and 005 which corresponds to biological replicate of PEO1 cell 
line. Samples were harvested at different passage and DNA extracted at different time point. 
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Figure 8.5. Correlation of β values per biological replicate per chip on 27K array. 
r2 correlation: A, r2=0.9975. B, r2=0.9961. C, r2=0.9971. D, r2=0.9973. E, r2=0.9961. 
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8.2 Chapter 4: Supplementary data 
Table 8.1. 180 significant Wnt probes differentially methylated dependent on residual 
disease in the TCGA dataset 
* Δ methylation between groups >10% 
Probe ID Gene Name Beta-
Coefficient 
p value q value 
(FDR) 
Median β 
(0mm RD) 
Median β 
(=>1mm) 
Methylation 
difference % 
cg14011639 PCDHGB7* -0.125 0.003 0.017 0.413 0.166 24.76 
cg23563234 PCDHGB7* -0.124 0.008 0.028 0.567 0.335 23.16 
cg12343638 PCDHB12* -0.121 0.002 0.015 0.501 0.272 22.88 
cg02260587 PCDHB2* -0.095 0.015 0.047 0.333 0.137 19.58 
cg07899016 PCDHB12* -0.106 0.011 0.038 0.581 0.456 12.47 
cg09499849 ACVR1* -0.096 0.006 0.025 0.527 0.402 12.45 
cg11809091 PCDHB7* -0.088 0.016 0.049 0.363 0.256 10.73 
cg10887021 PCDHB2 -0.130 <0.001 0.002 0.198 0.118 8.07 
cg01086895 DCHS1 -0.070 0.003 0.017 0.174 0.094 7.95 
cg27124774 PCDHB10 -0.055 0.015 0.048 0.170 0.094 7.56 
cg15182360 PCDH20 -0.058 0.001 0.007 0.126 0.067 5.84 
cg26764244 GNG12 -0.064 <0.001 0.001 0.124 0.066 5.75 
cg22832044 CDH1 -0.034 0.014 0.046 0.179 0.126 5.23 
cg24115571 FZD6 -0.041 0.000 0.001 0.088 0.042 4.64 
cg01441777 CSNK1E -0.054 0.005 0.024 0.162 0.119 4.26 
cg08455548 PCDH11Y -0.040 0.016 0.048 0.234 0.192 4.23 
cg00462311 NFATC4 -0.044 0.003 0.019 0.121 0.081 4.07 
cg14789928 RBX1 -0.033 0.008 0.028 0.123 0.083 4.02 
cg10226546 NFATC2 -0.055 0.000 0.002 0.141 0.101 3.99 
cg19867899 PCDHAC2 -0.030 0.000 0.007 0.074 0.034 3.97 
cg05164185 CCND1 -0.031 0.003 0.017 0.076 0.036 3.93 
cg16310717 CCND2 -0.029 0.011 0.038 0.133 0.099 3.41 
cg09542745 SFRP5 -0.045 0.000 0.001 0.074 0.040 3.34 
cg05951646 RYK -0.018 0.017 0.050 0.070 0.038 3.23 
cg01404615 DKK2 -0.035 0.008 0.029 0.083 0.051 3.22 
cg19166347 SFRP4 -0.034 0.007 0.027 0.081 0.049 3.13 
cg06628693 PRKACB -0.036 0.004 0.020 0.115 0.084 3.06 
cg14512008 PPP2R5C -0.023 0.001 0.011 0.070 0.040 3.04 
cg22432367 ARID1B -0.045 0.000 0.001 0.074 0.046 2.84 
cg02407785 PCDH9 -0.032 0.000 0.006 0.055 0.027 2.81 
cg17976381 SMARCB1 -0.030 0.000 0.002 0.089 0.061 2.73 
cg12245996 PRKCQ -0.027 0.002 0.015 0.070 0.043 2.72 
cg19523029 TLE4 -0.043 0.000 0.007 0.096 0.070 2.59 
cg09146695 LEF1 -0.030 0.005 0.022 0.073 0.047 2.57 
cg05937453 SFRP5 -0.051 0.013 0.043 0.058 0.033 2.51 
cg26183662 NFAT5 -0.029 0.001 0.007 0.092 0.068 2.49 
cg00828602 WNT5A -0.028 0.000 0.002 0.074 0.050 2.48 
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cg03427564 EP300 -0.026 0.006 0.025 0.053 0.028 2.43 
cg22582569 PPP2R1B -0.024 0.006 0.025 0.065 0.041 2.41 
cg00888007 CCND2 -0.050 0.004 0.020 0.055 0.031 2.39 
cg09449490 ROCK1 -0.027 0.015 0.047 0.122 0.098 2.38 
cg09214920 SLC25A24 -0.027 0.008 0.029 0.063 0.039 2.38 
cg24698622 PPP2CB -0.059 0.005 0.024 0.100 0.077 2.30 
cg15839448 SFRP1 -0.061 0.003 0.019 0.076 0.054 2.23 
cg07474356 PCDH11X -0.030 0.015 0.048 0.070 0.048 2.23 
cg03133269 WNT4 -0.044 0.007 0.027 0.079 0.057 2.17 
cg27308387 CTNNBIP1 -0.027 0.000 0.006 0.052 0.031 2.13 
cg01836044 PCDH20 -0.046 0.000 0.007 0.053 0.032 2.12 
cg18333807 GSK3A -0.017 0.001 0.008 0.047 0.027 2.00 
cg00858899 CCND1 -0.025 0.001 0.010 0.069 0.049 2.00 
cg13574590 CCND2 -0.038 0.000 0.005 0.055 0.036 1.92 
cg17301902 GNA14 -0.042 0.001 0.008 0.101 0.082 1.90 
cg07786760 DCHS2 -0.020 0.003 0.018 0.050 0.032 1.84 
cg09985635 PCDH1 -0.015 0.005 0.021 0.048 0.029 1.84 
cg18795395 GNG12 -0.014 0.006 0.025 0.039 0.021 1.76 
cg15447479 SMO -0.019 0.010 0.036 0.044 0.026 1.74 
cg23779331 ARRB2 -0.025 0.002 0.016 0.055 0.038 1.72 
cg15965510 BTAF1 -0.013 0.006 0.025 0.045 0.029 1.68 
cg03029145 SMAD2 -0.021 0.001 0.009 0.039 0.022 1.67 
cg26902873 PRKX -0.022 0.000 0.003 0.034 0.018 1.60 
cg02352653 SMAD5 -0.024 0.000 0.001 0.039 0.023 1.56 
cg25425078 CCND2 -0.024 0.011 0.037 0.040 0.024 1.53 
cg22175811 TP53 -0.021 0.006 0.024 0.045 0.030 1.48 
cg21140292 SMARCA2 -0.023 0.000 0.004 0.044 0.029 1.48 
cg22764338 PCDH1 -0.034 0.001 0.009 0.050 0.036 1.46 
cg23422659 WNT9B -0.034 0.004 0.020 0.044 0.030 1.45 
cg16525692 CHD1L -0.012 0.009 0.033 0.061 0.047 1.45 
cg11490446 PSEN1 -0.016 0.003 0.016 0.034 0.020 1.43 
cg14072120 RAC2 -0.025 0.013 0.043 0.064 0.050 1.42 
cg19534879 CXXC4 -0.010 0.003 0.019 0.035 0.021 1.37 
cg26850503 DACT1 -0.017 0.000 0.004 0.036 0.023 1.33 
cg06111454 NFATC4 -0.020 0.002 0.014 0.039 0.025 1.32 
cg14665389 TCF7L2 -0.015 0.000 0.006 0.050 0.037 1.32 
cg18618964 PPP3R1 -0.014 0.001 0.013 0.037 0.024 1.31 
cg20708411 CSNK1G3 -0.012 0.000 0.007 0.030 0.017 1.29 
cg26129270 FZD5 -0.017 0.007 0.028 0.041 0.028 1.27 
cg06440646 SMAD1 -0.018 0.006 0.025 0.040 0.028 1.24 
cg20712430 KREMEN2 -0.010 0.004 0.021 0.031 0.018 1.23 
cg21599792 FZD4 -0.016 0.002 0.015 0.035 0.023 1.19 
cg03966406 ITPR2 -0.015 0.003 0.018 0.041 0.030 1.13 
cg11681073 CUL1 -0.011 0.003 0.017 0.034 0.023 1.08 
cg15508020 CSNK2A2 -0.029 0.001 0.007 0.058 0.047 1.06 
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cg00625653 WNT7A -0.012 0.016 0.049 0.045 0.035 1.05 
cg27214652 PPP2R5E -0.017 0.000 0.006 0.031 0.021 1.04 
cg06973760 NFATC1 -0.026 0.000 0.001 0.035 0.024 1.04 
cg07879727 WNT3 -0.027 0.014 0.045 0.041 0.031 1.03 
cg15879316 CELSR1 -0.020 0.000 0.001 0.074 0.064 1.03 
cg14914982 CCND2 -0.033 0.000 0.003 0.049 0.039 1.00 
cg11595245 HELLS -0.011 0.015 0.046 0.033 0.023 1.00 
cg07115558 TLE2 -0.014 0.005 0.021 0.142 0.132 1.00 
cg26910651 PPP2CB -0.015 0.000 0.003 0.025 0.016 0.96 
cg22271212 TLE2 -0.020 0.003 0.019 0.100 0.091 0.95 
cg14663065 CTNNB1 -0.025 0.000 0.002 0.036 0.027 0.94 
cg14252569 DACT1 -0.021 0.003 0.016 0.074 0.065 0.93 
cg27014642 CELSR2 -0.008 0.013 0.043 0.031 0.022 0.91 
cg13398291 SFRP1 -0.073 0.004 0.020 0.037 0.028 0.90 
cg10164137 DVL1 -0.029 0.013 0.044 0.042 0.033 0.89 
cg12411068 SMARCA4 -0.012 0.000 0.001 0.018 0.010 0.88 
cg17076921 CAMK2G -0.021 0.000 0.001 0.068 0.060 0.87 
cg27212359 FRAT2 -0.011 0.001 0.010 0.018 0.010 0.85 
cg15757271 WNT5A -0.018 0.000 0.002 0.024 0.015 0.85 
cg16211684 PCDH21 -0.023 0.007 0.026 0.058 0.050 0.85 
cg16091845 SMARCA5 -0.012 0.004 0.021 0.020 0.011 0.84 
cg23441167 GNG5 -0.011 0.001 0.007 0.039 0.031 0.84 
cg24889366 GNG13 -0.011 0.004 0.020 0.048 0.040 0.83 
cg04057053 WNT2B -0.007 0.006 0.025 0.025 0.017 0.82 
cg08149333 SLC25A24 -0.007 0.005 0.021 0.021 0.013 0.82 
cg11710000 FZD3 -0.010 0.004 0.020 0.033 0.025 0.82 
cg10806140 SFRP4 -0.018 0.000 0.002 0.040 0.032 0.80 
cg06692957 GNAQ -0.013 0.004 0.020 0.034 0.026 0.80 
cg01116966 TCF7 -0.008 0.006 0.025 0.016 0.008 0.80 
cg08400120 PRKCI -0.008 0.002 0.015 0.031 0.024 0.79 
cg13493559 PLCB3 -0.010 0.007 0.026 0.035 0.027 0.79 
cg13425637 PRKCH -0.010 0.008 0.030 0.024 0.017 0.77 
cg16250355 SMARCC1 -0.008 0.013 0.043 0.050 0.042 0.76 
cg24035370 PRKCZ -0.034 0.000 0.003 0.042 0.034 0.76 
cg10315128 SMAD4 -0.009 0.002 0.016 0.023 0.016 0.74 
cg06812033 NKD1 -0.010 0.007 0.028 0.047 0.039 0.74 
cg21572997 LRP5 -0.013 0.004 0.020 0.026 0.019 0.74 
cg05354432 LEF1 -0.028 0.000 0.002 0.036 0.029 0.73 
cg24082826 ITPR2 -0.013 0.001 0.010 0.027 0.020 0.72 
cg05013695 FRAT1 -0.010 0.001 0.008 0.016 0.009 0.71 
cg11667754 CDH1 -0.017 0.005 0.024 0.038 0.030 0.70 
cg07440414 TCF7 -0.011 0.010 0.035 0.043 0.036 0.70 
cg08261094 SFRP4 -0.065 0.004 0.020 0.086 0.079 0.68 
cg02631957 CSNK1G3 -0.009 0.000 0.003 0.028 0.021 0.67 
cg25060573 CCND1 -0.012 0.002 0.016 0.036 0.029 0.67 
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cg02569086 ITPR2 -0.007 0.002 0.014 0.022 0.015 0.65 
cg22907065 RHOA -0.010 0.014 0.046 0.022 0.016 0.64 
cg03116238 GNG8 -0.028 0.006 0.025 0.037 0.030 0.63 
cg21858376 ITPR1 -0.017 0.000 0.001 0.024 0.018 0.63 
cg02640558 PPP3CC -0.013 0.000 0.001 0.023 0.017 0.62 
cg09257092 ITPR2 -0.008 0.002 0.015 0.032 0.026 0.62 
cg07874155 CTNNA1 -0.008 0.002 0.015 0.014 0.008 0.61 
cg01322134 WNT3A -0.025 0.017 0.050 0.033 0.027 0.61 
cg25422943 PCDH9 -0.018 0.001 0.010 0.014 0.009 0.56 
cg20164558 PPP2R5D -0.010 0.003 0.018 0.042 0.037 0.55 
cg21975377 FZD6 -0.011 0.012 0.041 0.028 0.022 0.55 
cg04497885 GSK3A -0.008 0.003 0.018 0.016 0.011 0.55 
cg01663570 DVL3 -0.007 0.002 0.016 0.045 0.040 0.55 
cg18387216 HDAC2 -0.021 0.000 0.001 0.017 0.011 0.54 
cg11856093 ARID1A -0.017 0.001 0.008 0.052 0.047 0.54 
cg17886028 CCND2 -0.040 0.001 0.009 0.045 0.040 0.54 
cg16256504 WNT6 -0.003 0.015 0.047 0.028 0.024 0.48 
cg15507817 WNT7B -0.011 0.000 0.001 0.016 0.011 0.47 
cg07401901 DAAM1 -0.005 0.006 0.025 0.028 0.023 0.45 
cg18654873 MAP3K7 -0.006 0.017 0.050 0.017 0.012 0.43 
cg07288587 CSNK1G1 -0.005 0.008 0.029 0.030 0.026 0.43 
cg00318865 ACVR1B -0.009 0.004 0.020 0.020 0.016 0.42 
cg03423524 FOSL1 -0.007 0.001 0.011 0.021 0.017 0.41 
cg00240312 CDH1 -0.019 0.003 0.018 0.038 0.034 0.40 
cg10451401 RAC1 -0.015 0.002 0.013 0.041 0.038 0.38 
cg04969808 WNT7A -0.010 0.005 0.023 0.059 0.055 0.38 
cg05702737 WNT10A -0.008 0.011 0.037 0.051 0.048 0.37 
cg10740965 CTNNBIP1 -0.005 0.002 0.015 0.017 0.013 0.35 
cg00784357 RAC1 -0.008 0.001 0.009 0.023 0.019 0.35 
cg10539418 CCND1 -0.015 0.005 0.022 0.040 0.036 0.34 
cg22792432 ROCK1 -0.005 0.006 0.025 0.013 0.009 0.34 
cg08048656 SMARCE1 -0.009 0.001 0.008 0.033 0.029 0.34 
cg03384938 CXXC4 -0.006 0.002 0.016 0.026 0.022 0.32 
cg19972619 MYC -0.011 0.003 0.017 0.043 0.039 0.32 
cg04233664 CTBP2 -0.010 0.001 0.007 0.015 0.012 0.31 
cg19850348 PYGO1 -0.031 0.000 0.002 0.027 0.024 0.29 
cg27279652 ITPR2 -0.005 0.002 0.013 0.028 0.025 0.28 
cg04496615 PPP3R1 -0.008 0.008 0.028 0.011 0.008 0.27 
cg03614664 RBX1 -0.009 0.000 0.006 0.028 0.025 0.27 
cg21703138 PPP2CA -0.010 0.005 0.023 0.017 0.015 0.22 
cg14556189 SMAD3 -0.007 0.001 0.013 0.010 0.008 0.21 
cg07979577 PPP2R5A -0.015 0.002 0.016 0.023 0.021 0.20 
cg05055720 RHOA -0.012 0.002 0.016 0.021 0.019 0.19 
cg03801144 PPP6C -0.005 0.004 0.020 0.030 0.028 0.18 
cg19168631 DAAM1 -0.004 0.002 0.015 0.015 0.014 0.15 
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cg12515638 SFRP4 -0.054 0.013 0.044 0.046 0.046 0.08 
cg12116020 PRKACA -0.016 0.007 0.028 0.034 0.034 0.07 
cg02360836 SMARCD2 -0.004 0.014 0.046 0.024 0.024 0.02 
cg21104946 WNT7B -0.022 0.002 0.016 0.063 0.065 -0.22 
cg01830294 WNT2 -0.052 0.007 0.026 0.055 0.060 -0.48 
cg17108383 PCDHGC5 0.027 0.001 0.011 0.911 0.933 -2.15 
cg22174355 GNG10 0.025 0.006 0.025 0.890 0.916 -2.64 
cg22074666 C21orf7 0.069 0.005 0.024 0.538 0.594 -5.63 
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8.2.2 Further analysis of the HH Infinium HumanMethylation27 Beadchip data 
8.2.2.1 Clustering analysis 
A global analysis of the DNA methylation data was performed through hierarchical clustering 
analysis. Hierarchical clustering was performed on 86 samples including the 8 benign 
controls from 4 patients, featuring 4 DNA samples from fallopian tube and 4 DNA samples 
from benign ovarian tissue (epithelium and stroma). Interestingly for these benign samples 
the fallopian tube samples and ovarian samples clustered together (Figure 8.6A), which 
indicates that clustering is a suitable method for preliminary analysis of this methylation data. 
Following histopathological quality analysis, the arrayed site of 7 malignant tumours 
originated from omental metastasis, whereas the remaining 71 originated from the pelvic 
tumour. There did not appear to be a clustering relationship between the omental tumours 
versus the pelvic tumours.  
Hierarchical clustering was performed on the 78 malignant samples to examine for 
differential methylation in relation to clinical characteristics including surgical debulking. 
Euclidian distance determined clustering across all probes and patients appeared to cluster 
into 4 categories (Figure 8.6B). Pearson Chi-square test did not demonstrate any statistically 
significant differences between clusters and clinical characteristics including residual disease 
(0mm residual disease versus ≥1mm of residual disease) p=0.7973, stage (stage 3 versus 
stage 4 disease) p=0.717, grade p=0.4702 and age p=0.1691. 
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Figure 8.6. Hierarchical clustering analysis of all 27K array HH data generated. A, for 78 
cases and 8 controls with representation of array site. B, 78 cases with representation of 
clinical characteristics.   
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Figure 8.7. Kaplan-Meier plots for OS dependent on candidate loci methylation for complete 
macroscopically debulked patients only. A, FGF4. B, FGF21. C, ITGAE. D, MLCK. E, MYL7. 
F, MYLK2. 
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8.3 Chapter 5, Supplementary data 
 
 
Figure 8.8. Correlation between percentage of tumour nuclei on histopathology quality 
control and methylation for individual MSX1 CpG sites in HH dataset.  
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Probe ID BetaCoef* p value q value 
cg20588069 -1.047 0.002 0.007 
cg15696627 0.046 0.840 0.945 
cg26615830 -0.010 0.967 0.967 
cg15755084 0.018 0.903 0.956 
cg11930592 -0.166 0.424 0.636 
cg06677140 0.050 0.836 0.945 
cg03717979 0.056 0.713 0.945 
cg03199651 -0.131 0.765 0.945 
cg14167596 -0.418 0.305 0.498 
cg20161179 -0.632 0.154 0.277 
cg22609784 -0.668 <0.001 0.002 
cg09573795 -0.292 0.029 0.071 
cg27038439 -0.253 <0.001 0.002 
cg24840099 -0.744 <0.001 <0.001 
cg09748975 -0.423 <0.001 <0.001 
cg03843978 -0.162 0.076 0.151 
cg20891301 -0.188 0.031 0.071 
cg01785568 -0.387 0.014 0.042 
*adjusting for chip and grade 
  
Table 8.2. Repeat linear regression model for chemotherapy response with removal of stable 
disease cases in HH dataset. 
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Figure 8.9. Correlation between MSX1 and MSX2 gene expression from TCGA dataset. 
A, Probe 2055555_s_at. B, Probe 2055556_at. 
 
 
 
 
Probe id 
Beta-
coeff* p value 
  
Methylation 
cg26796283 -0.014 0.725 
  cg27096144 0.022 0.597 
  
Gene 
expression 
20555_s_at -0.003 0.968 
  205556_at -0.004 0.905 
  
      * Linear regression model adjusting chip, grade and residual disease  
 
Table 8.3. Linear regression model for differential DNA methylation and gene expression of 
MSX2 in association with chemotherapy response in TCGA dataset.   
A B 
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